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  Venous	  thrombosis	  is	  a	  major	  health	  concern,	  with	  an	  annual	  incidence	  of	  ~1	  per	  1000	   adults	   (Cushman	   2007).	   This	   includes	   deep	   vein	   thrombosis	   (DVT)	   and	  pulmonary	  embolism	  (PE),	  the	  fatal	  consequence	  of	  a	  clot	  detaching	  and	  moving	  to	   the	   lungs,	   together	   these	   diseases	   are	   termed	   venous	   thromboembolism	  (VTE).	  Current	  treatment	  options	  for	  VTE	  are	  often	  associated	  with	  serious	  side	  effects	   and	   bleeding	   complications,	   highlighting	   the	   need	   for	   more	   effective	  prophylaxis.	   This	   study	   therefore	   aimed	   to	   identify	   new	   targets	   to	   treat	   DVT,	  which	  would	  not	  have	  the	  associated	  negative	  side	  effects.	  	  	  This	  study	  shows	  the	  platelet	  receptor	  CLEC-­‐2	  (C-­‐type	  lectin	  receptor	  2)	  plays	  an	  important	  role	  in	  DVT,	  probably	  through	  interaction	  with	  podoplanin	  in	  the	  IVC	  wall,	  and	  that	  lack	  of	  CLEC-­‐2	  is	  protective	  in	  this	  disease.	  	  We	  show	  other	  immune	  cells	  may	  also	  play	  a	  role	  in	  DVT,	  and	  demonstrate	  that	  mast	  cell	  deficiency	  is	  protective	  in	  vivo.	  Furthermore,	  we	  suggest	  that	  the	  mast	  cell	   constituent	   responsible	   for	   the	   prothrombotic	   phenotype	   is	   likely	   to	   be	  histamine.	  Preliminary	  data	  also	  suggests	  that	  T-­‐cells	  may	  have	  a	  protective	  role	  in	   DVT,	   and	   that	   thrombin	   may	   be	   important	   for	   the	   release	   of	   neutrophil	  extracellular	  traps	  (NETs)	  from	  neutrophils	  inside	  a	  growing	  thrombus.	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   1	  
1.1	  Blood	  composition	  	  Blood	   has	   four	  major	   components;	   plasma,	  which	  makes	   up	   about	   55%	  of	   the	  mixture,	   the	   other	   45%	   being	   red	   blood	   cells,	   white	   blood	   cells	   and	   platelets.	  Plasma,	   the	   liquid	   component	   of	   the	  blood	   is	   important	   for	   transporting	  blood	  cells	  throughout	  the	  body	  (American	  Society	  of	  Hematology).	  It	  also	  has	  a	  crucial	  role	  in	  maintaining	  the	  body’s	  fluid	  balance	  and	  transports	  a	  complex	  mixture	  of	  solutes	   including	  clotting	  proteins,	  waste	  products,	  and	  antibodies.	  Blood	  has	  a	  number	  of	   important	   functions	   including	  the	  transport	  of	  oxygen	  and	  nutrients	  to	  the	  lungs	  and	  tissues,	  the	  transport	  of	  immune	  cells	  to	  fight	  infection,	  as	  well	  as	  forming	  clots	  to	  prevent	  excessive	  blood	  loss.	  
1.1.1	  Erythrocytes	  Erythrocytes	  or	  red	  blood	  cells	  (RBCs)	  are	  the	  most	  abundant	  cells	  in	  the	  blood	  making	   up	   ~40%	   of	   the	   volume.	   Their	   production	   is	   controlled	   by	  erythropoietin,	  a	  hormone	  produced	  in	  the	  kidneys.	  They	  originate	  as	  immature	  cells	  in	  the	  bone	  marrow	  and	  go	  through	  8	  stages	  of	  differentiation	  before	  being	  released	   into	   the	   blood	   stream	   at	   stage	   7	   of	   this	   process.	   They	   begin	   as	  pluripotent	   haematopoietic	   stem	   cells,	   before	   differentiating	   into	   common	  myeloid	   progenitor	   cells	   and	   have	   then	   become	   committed	   to	   their	  developmental	   pathway.	   Early	   erythroblasts	   form	   and	   this	   is	   where	   ribosome	  synthesis	   occurs.	   These	   cells	   further	   differentiate	   into	   late	   erythroblasts	   and	  normoblasts,	  where	  haemoglobin	  begins	  to	  accumulate.	  Finally	  the	  cell’s	  nucleus	  is	   ejected	   and	   they	   are	   released	   into	   the	   blood	   stream	   as	   reticulocytes.	   In	   the	  blood	  stream	  these	  reticulocytes	  mature	  into	  full-­‐blown	  erythrocytes.	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They	   are	   characterized	  by	   their	   biconcave	  disc	   shape	   as	   they	  have	  no	  nucleus,	  and	  are	  ~7um	   in	  diameter.	  This	   shape	  allows	  RBCs	   to	  be	  more	   flexible	   and	   fit	  through	   the	   capillaries	   of	   the	   body.	  Red	   cells	   contain	   haemoglobin,	   a	  molecule	  that	  binds	  to	  oxygen	  in	  the	  lungs	  allowing	  it	  to	  be	  transported	  around	  the	  body	  to	  metabolizing	   tissues;	   it	   also	   binds	   to	   carbon	  dioxide	   and	   returns	   this	   to	   the	  lungs	  to	  be	  exhaled.	  	  
1.1.2	  Granulocytes	  Granulocytes	   are	   types	   of	   white	   blood	   cells,	   and	   immune	   cells,	   which	   as	   their	  name	   suggests,	   contain	   small	   granules	   with	   enzymes	   that	   are	   released	   upon	  infection	   or	   during	   allergic	   reactions.	   Granulocyte	   populations	   are	   made	   of	  neutrophils,	  basophils	  and	  eosinophils.	  	  Eosinophils	   and	   basophils	   are	   the	   least	   common	   of	   the	   granulocytes,	   and	  represent	  only	  ~1-­‐5%	  and	  1%	  of	   the	  circulating	  white	  blood	  cells	  respectively.	  Basophils	  contain	  both	  heparin	  and	  histamine	  and	  are	   important	   inflammatory	  cells	   in	   response	   to	   allergic	   reactions.	   Eosinophils	   may	   also	   act	   as	   antigen	  presenting	  cells	  allowing	  them	  to	  activate	  the	  adaptive	  immune	  system,	  although	  this	  role	  is	  still	  under	  debate	  (Rothenberg	  2006).	  	  Neutrophils	   are	   the	   most	   abundant	   type	   of	   white	   blood	   cells.	   They	   are	  characterized	  by	   their	   classical	   lobed	  nucleus	  and	  are	  and	  essential	  part	  of	   the	  innate	   immune	   system.	   They	   respond	   rapidly	   to	   inflammation	   and	   also	   act	   as	  phagocytic	   cells.	   More	   recently	   a	   novel	   mechanism	   for	   neutrophils	   has	   been	  proposed	  which	  may	   potentiate	   thrombosis.	   They	   are	   able	   to	   form	   neutrophil	  extracellular	   traps	   (NETs),	   which	   are	   extracellular	   chromatin	   fibers	   bound	   to	  histones	   and	   granular	   antimicrobial	   proteins.	   Neutrophil	   death	   through	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liberation	   of	  NETs	   is	   termed	  NETosis.	   The	   concept	   of	   ‘immunothrombosis’	   has	  recently	   emerged	   and	   it	   is	   now	   known	   that	   during	   thrombus	   formation	   in	  vessels,	   neutrophils	   contribute	   to	   generating	   an	   intravascular	   scaffold,	   which	  may	   function	  both	   to	  support	   thrombus	  growth	  and	  to	   trap/destroy	  pathogens	  (Brill	  et	  al	  2012;	  Brinkmann	  et	  al	  2004;	  Engelmann	  et	  al	  2013).	  	  The	  signaling	  pathways	  that	  lead	  to	  NETosis	  have	  been	  investigated	  and	  certain	  mechanisms	  have	  been	  put	  forward,	  however	  they	  are	  still	  largely	  unknown	  and	  it	  has	  not	  yet	  been	  possible	  to	  visualize	  this	  process	  happening	  in	  real	  time.	  NETs	  are	  released	  through	  a	  cell	  death	  pathway,	  which	  is	  dependent	  on	  the	  production	  of	   Reactive	   Oxygen	   Species	   (ROS).	   ROS	   production	   causes	   delobulation	   of	   the	  nucleus	  and	  break	  down	  of	  the	  nuclear	  membrane.	  This	  allows	  the	  chromatin	  to	  mix	   with	   the	   granular	   proteins	   before	   the	   plasma	   membrane	   finally	   ruptures	  (Brinkmann	  et	  al	  2009).	  Neutrophils	  express	  high	  nuclear	   levels	  of	   the	  enzyme	  peptidylarginine	  	  deiminase	   4	   (PAD4)	   and	   this	   catalyzes	   citrullination	   of	   histones	   (replaces	  positively	  charged	  arginine	  for	  uncharged	  citrulline).	   It	   is	  hypercitrullination	  of	  histones	   by	   PAD4	   that	   mediates	   chromatin	   decondensation	   and	   further	   NET	  formation	  (Wang	  et	  al	  2012).	  It	  was	  also	  shown	  by	  Wang	  et	  al	  that	  inhibition	  of	  PAD4	  decreased	  the	  formation	  of	  NETs,	  and	  so	  histone	  citrullination	  is	  used	  as	  a	  marker	   of	   NET	   formation.	   Figure	   1.1	   below	   shows	   the	   current	   signaling	  pathways	  believed	  to	  lead	  to	  NETosis.	  	  	  	  
	  




Figure	  1.1	  –	  NETosis	  signaling	  pathway	  	  Upon	  neutrophil	   activation,	   the	  RAF-­‐MEK-­‐ERK	  pathway	   is	  necessary	   to	   lead	   to	  ROS	   production,	   this	   leads	   to	   disintegration	   of	   the	   granular	   membranes	   and	  activates	   the	   enzyme	   peptidylarginine	   deiminase	   4	   to	   citrullinate	   histone	   H3,	  further	   leading	   to	   chromatin	   decondensation.	   Following	   membrane	   rupture	  neutrophil	  extracellular	  traps	  (NETs)	  are	  then	  released.	  	  PI3K:	  Phosphoinositide	  3-­‐Kinase,	  AKT:	  Protein	  Kinase	  B,	  mTOR:	  The	  mammalian	  Target	  of	   Rapamycin,	   PKC:	   Protein	   Kinase	   C,	   RAF:	   Rapidly	   Accelerated	   Fibrosarcoma,	   MEK:	  Mitogen-­‐activated	  protein	  kinase,	  ERK:	  Extracellular	  signal-­‐regulated	  kinases.	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There	   has	   been	   controversy	   over	   whether	   the	   release	   of	   NETs	   is	   an	   active	  process	   in	   order	   to	   act	   a	   host	   defense	   mechanism,	   or	   if	   it	   is	   simply	   just	   cell	  rupture	  in	  response	  to	  trauma	  or	  infection.	  Yipp	  and	  Kubes	  (2013)	  describe	  both	  of	   these	   types	  or	  cell	  death	  as	  distinct	  pathways,	  named	  either	  vital	  or	  suicidal	  NETosis.	  	  Vital	   NETosis	   (see	   figure	   1.2	   below)	   allows	   neutrophils	   to	   maintain	   their	  conventional	   host	   defense	   functions.	   This	   form	   of	   cell	   death	   occurs	   following	  direct	  microbial	  exposure,	  NETs	  are	  then	  released	  by	  vesicles	  or	  nuclear	  budding	  which	  allows	  the	  outer	  neutrophil	  membrane	  to	  remain	  intact,	  allowing	  them	  to	  carry	   out	   their	   normal	   function.	   Gram-­‐positive	   bacteria	   activate	   neutrophils	   to	  release	   NETs	   by	   binding	   to	   complement	   receptor	   3	   (CL3)	   and	   TLR2.	  Whereas	  gram-­‐negative	   bacteria	   induce	   NET	   release	   by	   activation	   of	   TLR4	   on	   platelets	  followed	  by	  neutrophil-­‐platelet	  interaction	  via	  CD11a.	  	  In	  contrast,	  suicidal	  NETosis	  occurs	  through	  activation	  of	  PKC	  and	  the	  RAF-­‐MEK-­‐ERK	  pathway	  (see	   figure	  1.1).	  Elastase	   is	   then	   translocated	   into	   the	  nucleus	  by	  NADPH	   from	   cytosolic	   granules,	   where	   it	   breaks	   down	   the	   chromatin.	  Myloperoxidase	  (MPO)	  is	  then	  also	  involved	  in	  chromatin	  decondensation	  and	  is	  needed	  for	  nuclear	  envelope	  breakdown.	  After	  NETs	  have	  formed	  inside	  the	  cell	  the	   outer	  membrane	   entirely	   ruptures	   and	   the	   NET	   is	   released	   so	   the	   cell	   no	  longer	  remains	  functional.	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Figure	  1.2	  –	  Vital	  and	  suicidal	  NETosis	  pathways	  	  During	  suicidal	  NETosis	  NADPH	  translocates	  elastase	  into	  the	  nuclease	  where	  it	  breaks	   down	   chromatin.	   Myeloperoxidase	   (MPO)	   is	   then	   involved	   in	   nuclear	  envelope	  breakdown	  and	  finally	  the	  entire	  membrane	  ruptures	  to	  release	  NETs	  leaving	  the	  cell	  nonfunctional.	  In	  Vital	  NETosis,	  direct	  bacterial	  exposure	  leads	  to	  signaling	   via	   both	   TLR2	   and	   CR3	   (gram	   positive	   bacteria),	   or	   via	   TLR4	   on	  platelets	   followed	  by	  CD11a	  on	  neutrophils	   (gram	  negative	  bacteria).	  NETs	  are	  then	   released	   via	   nuclear	   budding	   and	   vesicles,	   leaving	   the	   cell	   intact	   and	  functional.	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Recent	   evidence	   suggests	   that	  NETs	  may	  also	  promote	   thrombosis.	   Fuchs	  et	   al	  (2010)	   showed	   that	   blood	   perfusion	   over	   NETs	   leads	   to	   platelet	   adhesion,	  aggregation	   and	   activation.	   Destruction	   of	   the	   NET	   structures	   by	   DNase	  prevented	   platelet	   accumulation.	   NETs	   are	   likely	   to	   play	   a	   role	   in	   DVT.	   In	   a	  murine	   model	   of	   DVT,	   it	   has	   been	   shown	   that	   extracellular	   chromatin	   (most	  probably	  NETs)	  is	  a	  structure	  in	  a	  venous	  thrombus,	  and	  that	  both	  this	  scaffold	  and	  the	  histones	  attached	  to	   it	  contribute	  to	  DVT	  in	  mice	  (Brill	  et	  al	  2012;	  Von	  Bruhl	  et	  al	  2012).	  	  
1.1.3	  Lymphocytes	  	  There	  are	  3	   types	  of	   lymphocytes;	  natural	  killer	   cells	   (NK	  cells),	  T-­‐cells	   and	  B-­‐cells.	  	  T	  and	  B	  cells	  are	  part	  of	   the	  acquired	  or	   ‘adaptive’	   immune	  system,	  and	  have	  a	  large	   range	   of	   receptors	   that	   are	   able	   to	   recognize	   and	   mount	   an	   immune	  response	   to	   specific	   pathogens.	   This	   adaptive	   response	   also	   creates	   an	  immunological	   memory,	   meaning	   if	   the	   same	   pathogen	   is	   encountered	   again,	  memory	  cells	  are	  able	  to	  respond	  quicker,	  providing	  long	  lasting	  immunity.	  	  T-­‐	  progenitor	  cells	  originate	  in	  the	  bone	  marrow;	  from	  there	  they	  migrate	  to	  the	  thymus	   (thymocytes)	   to	   mature	   into	   T-­‐cells.	   There	   are	   two	   types	   of	   T-­‐cells;	  cytotoxic	  T-­‐cells	  which	  express	  CD8+,	  and	  helper	  T-­‐cells	  that	  express	  CD4+.	  	  All	  cells	  express	  major	  histocompatibility	  complex	  (MHC)	  class	  I	  receptors.	  MHC	  class	  I	  receptors	  are	  used	  to	  present	  the	  foreign	  antigen	  from	  infected	  cells	  to	  the	  specific	  CD8+	  T	  cell	  receptors.	  Upon	  recognition	  of	  the	  antigen	  peptide,	  the	  T-­‐cell	  is	  activated	  and	  destroys	  the	  infected	  cell.	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T-­‐helper	  cells	  are	  able	  to	  produce	  cytokines	  to	  direct	  the	  immune	  response	  and	  act	   as	   a	   cross	   talk	  between	   the	   innate	  and	  acquired	   immune	   system.	  T-­‐	  helper	  cells	   recognize	   specific	   Antigens	   presented	   by	   antigen	   presenting	   cells	  (phagocytes,	  dendritic	  cells	  and	  macrophages)	  via	  MHC	  class	  II	  receptors.	  The	  T-­‐cells	  also	  express	  a	  CD28	  receptor,	  which	  simultaneously	  binds	  to	  CD80	  or	  CD86	  on	   the	   antigen-­‐presenting	   cell.	   	   This	   leads	   to	   activation	  of	   the	  CD4+	  T-­‐cell	   and	  causes	  differentiation	  into	  an	  effector	  cell	  (see	  figure	  1.3).	  	  These	   effector	   CD4+	   cells	   via	   their	   CD40L	   are	   able	   to	   bind	   to	   B-­‐cell	   CD40	  receptors,	   activating	   them	   into	  either	  plasma	  cells	  or	  memory	  cells.	  B	   cells	   are	  produced	   in	   the	   bone	   marrow	   but	   mature	   in	   the	   spleen.	   Once	   activated,	   they	  differentiate	   into	  plasma	  cells,	  which	  are	  able	  to	  produce	  a	  range	  of	  antibodies.	  Recognizing	  antigens	  directly	  through	  their	  own	  B-­‐cell	  receptor	  can	  also	  activate	  B-­‐	  cells.	  	  Innate	  immune	  responses	  are	  rapid,	  and	  non-­‐specific	  to	  particular	  pathogens	  in	  the	  way	  the	  adaptive	  response,	  but	  instead	  provide	  a	  generic	  response	  that	  is	  not	  long	  lasting.	  The	  innate	  leukocytes	  include	  mast	  cells,	  eosinophils	  and	  basophils,	  and	  the	   innate	  phagocytic	  cells	   include	  neutrophils,	  macrophages	  and	  dendritic	  cells.	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Figure	  1.3	  –T-­‐helper	  cell	  and	  B-­‐cell	  signaling	  	  T-­‐helper	   (CD4+)	   cells	   recognize	   antigens	   presented	   by	  MHC	   class	   II	   receptors.	  They	  also	  have	  CD28	  receptors	  that	  bind	  to	  the	  antigen	  presenting	  cells	  (APC)	  via	  CD80	  or	  D86	  on	  the	  APC.	  This	  leads	  to	  activation	  of	  CD4+	  effector	  cells,	  which	  via	  their	   CD40L	   and	   can	   bind	   to	   B-­‐cell	   CD40,	   activating	   them	   to	   become	   either	  plasma	  cells	  or	  memory	  cells.	  	  
1.1.4	  Mast	  cells	  	  Mast	  cells	  originate	  from	  the	  haematopoetic	  progenitor	  in	  bone	  marrow	  and	  also	  from	  a	  bifunctional	  basophil-­‐MC	  lineage	  progenitor	  in	  spleen.	  They	  are	  unique	  in	  that	   they	   enter	   the	   circulation	   as	   early	   progenitor	   cells	   rather	   than	   end	   stage	  cells	   (Gurish	  et	   al	  2012).	  Mast	   cells	   express	  a	   specific	   set	  of	   antigens	   including	  FcεRI	  	  (a	  receptor	  for	  immunoglobulin	  E)	  and	  Kit	  (a	  receptor	  for	  stem	  cell	  factor).	  They	   are	   the	   cells	   most	   frequently	   associated	   with	   allergy	   and	   anaphylaxis,	  however	   mast	   cells	   are	   extremely	   heterogeneous	   cells,	   they	   are	   constitutively	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present	  in	  most	  tissues,	  and	  their	  function	  will	  depend	  on	  the	  location	  in	  which	  they	  are	  found.	  A	   unique	   characteristic	   of	   Mast	   cells	   is	   they	   contain	   granules.	   These	   granules	  contain	  potent	  anticoagulants	  such	  as	  heparin	  and	  tissue	  plasminogen	  activator	  (TPA),	  endothelial	  activators	  such	  as	  histamine	  and	  TNF-­‐α,	  as	  well	  as	  a	  number	  of	  other	  enzymes	  (tryptases	  and	  chymases)	  (Moon	  et	  al	  2014).	  	  Mast	  cells	  have	  the	  ability	  to	  secrete	  their	  granule	  contents	  and	  release	  this	  vast	  array	   of	  mediators	  with	   a	   variety	   of	   biological	   functions.	   Their	   role	   in	   allergic	  inflammation	  (a	  risk	  factor	  for	  deep	  vein	  thrombosis)	  has	  been	  well	  documented	  (Majoor	  et	  al	  2013).	  Mast	  cells	  can	  be	  activated	  by	  a	  number	  of	  different	  ways,	  and	   can	   rapidly	   release	   mediators	   from	   their	   storage	   granules	   to	   induce	  inflammation.	   Allergens	   are	   able	   to	   crosslink	   with	   immunoglobulin	   E	   (IgE)	  receptors	  on	  mast	  cells,	  causing	  them	  to	  degranulate.	  This	  response	  can	  also	  be	  bought	  about	  through	  microbial	  pathogens	  and	  pattern	  recognition	  receptors	  for	  pathogen-­‐associated	   molecular	   patterns	   (PAMPs),	   or	   through	   receptors	   for	  damage-­‐associated	  molecular	  patterns	  (DAMPs)	  as	  a	  result	  of	  physical	  injury.	  	  One	   of	   the	   most	   well	   studied	   mediators	   released	   from	   mast	   cell	   granules	   is	  histamine.	   Mast	   cells	   release	   histamine	   when	   the	   body	   encounters	   a	   toxic	  substance,	   in	   response	   to	  an	  allergen	  or	  when	   they	  detect	   injury.	  Mast	  cells	  do	  not	  circulate	  in	  the	  blood,	  but	  are	  released	  from	  the	  tissues	  in	  which	  they	  reside	  to	  secrete	  histamine	  (Amin	  2012),	  this	  acts	  on	  blood	  vessels	  at	  the	  site	  of	  damage	  causing	  them	  to	  dilate	  allowing	  for	  increased	  blood	  flow	  to	  the	  area	  in	  need.	  Mast	  cells	  are	  involved	  in	  a	  number	  of	  diseases,	  including	  chronic	  inflammatory	  diseases	   such	  as	   asthma,	   as	  well	   as	   IgE	  –dependent	   allergic	   reactions.	   In	   these	  cases	  it	  is	  the	  ongoing	  mast	  cell	  activation	  and	  increased	  spontaneous	  release	  of	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histamine	   that	   is	   detrimental.	   In	   other	   cases	   however,	   mast	   cells	   have	   been	  shown	   to	  have	  a	  protective	   role,	   for	  example	   in	  a	  mouse	  model	  of	  acute	   septic	  peritonitis	  (Echtenacher	  et	  al	  1996).	  Mast	   cells	   have	   been	   shown	   to	   be	   implicated	   in	   arterial	   diseases	   such	   as	  atherosclerosis	   and	   abdominal	   aortic	   aneurysms	   (AAA).	   It	  was	   shown	   that	   the	  mast	   cell	   constituents	   responsible	   for	   increasing	   the	   incidence	   of	   abdominal	  aortic	  aneurysms	  were	  chymases	  and	  tryptases	  (Wang	  et	  al	  2012).	  Lack	  of	  mast	  cells	  was	  shown	  to	  be	  protective	   in	  AAA,	  and	  mice	   lacking	  mast	  cells	  showed	  a	  reduced	   degradation	   of	  media	   elastin	   and	   also	   decreased	  macrophages	   and	   T-­‐cells	   at	   damaged	   sites.	   Bankl	   et	   al	   (1999)	   demonstrated	   that	   there	   was	   an	  association	   between	   mast	   cells	   and	   DVT.	   This	   group	   reported	   that	   mast	   cell	  distribution	   was	   increased	   in	   veins	   of	   the	   lower	   limb	   in	   patients	   with	   DVT	  compared	  to	  in	  non-­‐thrombosed	  limbs.	  	  
1.2	  Physiological	  role	  of	  platelets	  
	  Platelets	   are	   small	   (~1-­‐3	   μm	   in	   diameter)	   anucleated	   cells	   derived	   from	  megakaryocytes	   in	   the	   bone	   marrow.	   	   In	   healthy	   individuals,	   normal	   platelet	  count	   can	   range	   from	  150,000	   –	   450,000	   per	   μL.	  Millions	   of	   new	  platelets	   are	  produced	  each	  day	  with	   the	  average	   life	   span	  of	   circulating	  platelets	  being	  5-­‐9	  days.	   	   Their	   role	   is	   to	   maintain	   hemostasis	   and	   they	   are	   recruited	   to	   sites	   of	  vessel	  damage	  to	  prevent	  bleeding.	  Platelets	  circulate	  in	  the	  vascular	  system	  in	  a	  resting	   sate,	   and	   do	   not	   interact	   with	   the	   endothelium	   unless	   it	   becomes	  damaged,	  in	  this	  case	  they	  respond	  rapidly	  to	  form	  a	  haemostatic	  plug.	  Platelets	  have	  a	  number	  of	  surface	  receptors,	  mediating	  interactions	  with	  other	  cells	  and	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proteins	   at	   sites	   of	   damage.	   Receptors	   are	   also	   necessary	   to	   activate	   platelets,	  and	  play	   a	   role	   in	   platelet	   recruitment,	   adhesion	   and	   aggregation.	   Some	  of	   the	  important	  receptors	  on	  the	  platelet	  membrane	  are	  GPIb-­‐IX-­‐V,	  GPVI,	  αIIbβ3	  and	  CLEC-­‐2	  (Figure	  1.4	  below).	  	  Platelets	   also	   contain	   a	   number	   of	   signaling	   proteins	   and	   granule	   contents.	   In	  healthy	  individuals	  platelets	  play	  an	  important	  role	  in	  forming	  vascular	  plugs	  at	  sites	  of	   injury	   in	  blood	  vessels.	  However	  platelet	  activation	  at	   sites	  of	  diseased	  endothelium	  can	   lead	   to	  a	  number	  of	   thrombotic	  disorders	   such	  as	  myocardial	  infarction,	   stroke,	   and	   atherosclerosis	   (Lindemann	   et	   al	   2001,	   Nieswandt	   et	   al	  2005).	  More	  recently	  they	  have	  also	  been	  shown	  to	  be	  important	  in	  maintaining	  vascular	   integrity	   (Gros	  et	  al	  2014)	  and	   inflammation	  (Massberg	  2013).	   	   It	  has	  been	   reported	   that	   platelets	   can	   actually	   safeguard	   developing	   lymphatics	   and	  vessels	  at	  the	  site	  of	  leukocyte	  infiltration	  in	  inflamed	  organs	  and	  in	  tumors	  (Ho-­‐Tin-­‐Noe	  et	  al	  2011).	  	  	  	  	  	  	  	  	  	  
	  	   13	  
	  	  	  	  




Figure	  1.4	  –	  major	  platelet	  receptors	  interacting	  with	  their	  specific	  ligands	  	  
	  Shows	  many	  of	  the	  major	  platelet	  receptors	  and	  which	  ligands	  they	  interact	  with	  to	  cause	  platelet	  activation	  and	  activation	  of	  further	  signaling	  pathways.	  	  1.2.1	  Platelet	  production	  There	   is	  a	  constant	  need	  for	  circulating	  platelets	  to	  remain	  at	  a	   level	  of	  around	  150-­‐450x109	   platelets	   per	   litre,	   therefore	   new	   cells	   are	   produced	   as	   they	   are	  removed	  from	  the	  circulation.	  Platelets	  arise	   from	  haematopoietic	  stem	  cells	   in	  the	  bone	  marrow,	  before	  common	  myeloid	  progenitor	  cells	   then	  commit	   to	   the	  immature	   megakaryocyte	   lineage	   (Patel	   et	   al	   2005).	   Megakaryocytes	   then	  mature	   and	   differentiate	   into	   pro-­‐platelets,	   which	   finally	   release	   platelets	   into	  the	   circulation	   (Kaushansky	  2005).	  Thrombopoietin	  plays	  a	   critical	   role	   in	   this	  megakaryocyte	  differentiation.	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1.2.2	  Platelet	  anatomy	  	  Platelets	   have	   a	   limited	   ability	   to	   synthesize	   their	   own	   proteins,	   as	   they	   are	  anucleated.	  They	  are	  able	  however	  to	  uptake	  plasma	  proteins	  such	  as	  fibrinogen.	  	  It	   has	   been	   reported	   however	   that	   despite	   being	   anucleated,	   both	  megakaryocytes	  and	  primary	  platelets	  possess	  a	   functional	   spliceosome.	  Signal	  dependent	   splicing	   is	  a	  novel	   role	  of	  platelets,	  which	   is	  highly	   complex	  despite	  the	  lack	  of	  nucleus	  (Denis	  et	  al	  2005).	  	  Platelets	  also	  possess	  an	  actin	  cytoskeleton	  and	  a	  microtubule	  network,	  allowing	  the	   cell	   to	   undergo	   marked	   structural	   changes	   during	   platelet	   spreading	  (Calaminus	  et	  al	  2008).	  They	  also	  contain	  secretory	  vesicles	  in	  the	  cytoplasm;	  α-­‐granules,	  dense	  granules	  and	  lysosomes.	  Table	  1.1	  below	  shows	  the	  contents	  of	  the	  α-­‐granules	  and	  dense	  granules	  and	  their	  functions.	  Individuals	  with	  either	  a	  low	  granular	  number	  or	   an	   inability	   to	   release	   the	   granule	   contents	   can	   suffer	  from	   mild	   to	   severe	   bleeding	   disorders	   such	   as	   grey	   platelet	   syndrome	  (Deppermann	  et	  al	  2013)	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Table	  1.1-­‐	  major	  contents	  of	  platelet	  α-­‐	  and	  dense	  granules	  	  The	  main	  contents	  of	  platelet	  α-­‐	  and	  dense	  granules	  and	  their	  functions.	  	  
α-­‐granules	   Dense	  granules	  
	  Content	   Function	   Role	   Content	   Function	   Role	  	  -­‐VWF	  -­‐Fibrinogen	  
	   Adhesion	  proteins	  
Thrombus	  formation	  and	   platelet	  aggregation	  
	  Poly-­‐p	   	  	  Activation	   of	  factor	  XII	  
	  	  Mediators	  involved	  in	  platelet	  aggregation	  and	  thrombus	  formation	  
-­‐VEGF	  -­‐EGF	  -­‐PDGF	  
	  Growth	  factors	  
Angiogenesis	  and	  wound	  repair	  
	  	  Serotonin	  ADP	  ATP	  Ca2+	  





1.3	  Platelet	  signaling	  	  
	  Platelets	  have	  a	  number	  of	  receptors,	  which	  signal	   in	  different	  ways,	   leading	  to	  Ca2+	   mobilization	   and	   secretion	   of	   granule	   contents.	   A	   number	   of	   the	   platelet	  receptors	  work	  via	  a	  feedback	  mechanism,	  either	  positive	  feedback	  or	  inhibitory,	  and	   this	   can	   lead	   to	   platelet	   activation	   and	   is	   crucial	   for	   their	   function.	   The	  receptors	  involved	  in	  this	  are	  discussed	  below.	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  A	   distinction	   has	   been	   made	   between	   two	   types	   of	   signaling;	   inside-­‐out	   and	  outside-­‐in	   signaling.	   Whilst	   ‘inside-­‐out’	   signaling	   activates	   the	   ligand	   binding	  function	   of	   the	   integrins,	   ‘outside-­‐in’	   signaling	   leads	   to	   cellular	   responses	   as	   a	  result	   of	   ligand	   binding	   to	   the	   integrin	   (Shen	   2012).	   For	   example	   inside-­‐out	  signaling	   is	   initiated	   by	   the	   binding	   of	   an	   agonist	   to	   a	   plasma	   membrane	  receptor,	   this	   could	   determine	   if	   αIIbβ3	   is	   able	   to	   find	   Von	  Willebrand	   factor	  (vWF)	  or	   fibrinogen,	  which	  would	   allow	  platelet	   aggregation	   to	   occur	   as	   these	  act	  as	  bridging	  molecules	  between	  receptors	  on	  adjacent	  platelets	  (Shattil	  1998).	  Outside-­‐in	   signaling	   refers	   to	   post-­‐ligand	  binding	   events,	   in	   platelets	   these	   are	  regulated	  by	  αIIbβ3	  and	  responsible	  for	  functions	  such	  as	  granule	  secretion	  and	  platelet	  spreading	  (Shattil	  1998).	  	  1.3.1	  -­‐	  G	  protein-­‐coupled	  receptors	  (GPCRs)	  G	  protein	  coupled	  receptors	  (GPCRs)	  are	  a	  large	  family	  of	  membrane	  receptors,	  which	  bind	  to	  a	  variety	  of	  external	  signals.	  They	  are	  sometimes	  known	  as	  ‘seven-­‐	  transmembrane	  receptors’	  as	  they	  have	  seven	  domains	  that	  span	  the	  membrane.	  They	  are	  able	  to	  enhance	  platelet	  activation	  via	  binding	  to	  a	  number	  of	  agonists	  released	  from	  platelet	  granules	  and	  from	  damaged	  endothelial	  cells,	  leading	  to	  a	  positive	  feedback	  mechanism.	  Such	  as	  the	  GPCRs	  P2Y1	  and	  P2Y12,	  which	  bind	  to	  ADP	  released	  from	  granules	  and	  damaged	  endothelial	  cells,	  and	  along	  with	  other	  receptors	  enhance	  secretion	  and	  platelet	  aggregation	  (Dawood	  et	  al	  2007).	  	  A	  subfamily	  of	  GPCRs	  are	  the	  protease-­‐activated	  receptors	  (PARs),	  unlike	  other	  GPCRs	  these	  are	  not	  activated	  via	  ligand	  binding,	  but	  instead	  by	  cleavage	  of	  part	  of	   their	   extracellular	   domain.	   Serine	   proteases	   e.g.	   thrombin	   activate	   PARs	   by	  cleaving	  the	  amino	  terminus	  of	  the	  receptor,	  exposing	  the	  N-­‐terminus	  which	  acts	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as	  a	   ‘tethered	   ligand’.	  There	  are	  4	  known	  PARs,	  PAR	  1	  and	  PAR	  4	  are	  the	  most	  important	   in	  human	  platelets,	   and	   these	  are	  activated	  by	   thrombin	   (Kahn	  et	  al	  1999)	  whilst	  PAR	  3	  and	  4	  are	  important	  in	  mouse	  platelets.	  The	  Thromboxane	  A2	  (TXA2)	   prostanoid	   receptor	   (TP)	   is	   another	   typical	   GPCR,	   which	   has	   7	  transmembrane	   segments.	   The	   effects	   of	   Thromboxane	   A2	   are	   mediated	   by	  binding	   to	   this	   TP	   receptor.	   TXA2	   is	   produced	   by	   activated	   platelets,	   and	  stimulates	  platelet	  aggregation	  by	  increasing	  the	  expression	  of	  GPIIb/IIIa	  on	  the	  platelet	  membrane,	  as	  well	  as	  vasoconstriction	  (Smyth	  EM	  2010).	  	  1.3.2-­‐	  Integrins	  Integrins	   are	   a	   family	   of	   hetrodimeric	   transmembrane	   receptors,	  which	   act	   as	  bidirectional	   signaling	   molecules.	   Platelets	   express	   both	   β1	   and	   β3	   integrins,	  which	  are	  present	   in	   a	   low-­‐affinity	   state	   in	   the	  membrane,	   and	   shift	   to	   a	  high-­‐affinity	  state	  during	  platelet	  activation	  (Nieswand	  et	  al	  2009).	  A	  highly	  expressed	  important	   receptor	   on	   the	   platelet	   surface	   is	   αIIbβ3,	   which	   mediates	   platelet	  aggregation.	   αIIbβ3	   mediates	   platelet	   aggregation	   by	   binding	   to	   plasma	  fibrinogen	   and	   also	   vWF.	   Binding	   of	   these	   ligands	   to	   the	   receptor	   results	   in	  ‘outside-­‐	   in	   signaling’	   and	   allows	  platelet	   aggregation	   to	  proceed	   as	  previously	  discussed.	  	  1.3.3	  –	  ITAM	  containing	  receptors	  	  	  Immunoreceptor	   tyrosine-­‐based	   activation	   motifs	   (ITAMs)	   are	   a	   conserved	  sequence	  of	  amino	  acids,	  Yxx(L/I)x6-­‐12Yxx(L/I)	  which	  are	  important	  for	  signal	  transduction	  in	  platelet	  and	  a	  number	  of	  other	  immune	  cell	  receptors,	  as	  well	  as	  Fc	   receptors;	   FcγRIIA	   and	   FcγRI	   (Daeron	   M	   1997).	   ITAMs	   are	   typically	  phosphorylated	  by	  Src	   family	  kinases,	  which	  enable	  recruitment	  and	  activation	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of	  Syk	  family	  kinases	  (Moicsai	  et	  al	  2010).	  The	  important	  platelet	  receptors	  that	  signal	  through	  ITAM	  receptors	  are	  described	  below.	  
	  
1.4	  Major	  Platelet	  receptors	  involved	  in	  thrombosis	  
	  1.4.1	  GPVI	  GPVI	   Is	   the	   major	   collagen	   receptor	   expressed	   only	   on	   platelets	   and	  megakaryocytes.	   It	   belongs	   to	   the	   Ig	   superfamily	   of	   surface	   receptors	   and	   has	  two	   Ig	   domains.	   There	   are	   around	   3700-­‐9300	   GPVI	   receptors	   on	   the	   platelet	  surface	   (Burkhart	   et	   al	   2012).	   Association	   of	   GPVI	   with	   the	   FcRγ	   chain	   is	  required	   for	   its	   expression.	   GPVI	   in	   its	  monomeric	   form	   has	   a	   low	   affinity	   for	  collagen	   but	   dimerization	   increases	   the	   affinity.	   GPVI	   becomes	   activated	   upon	  phosphorylation	   of	   the	   ITAM	   region	   in	   the	   FcRγ	   chain	   by	   Src	   and	   SyK	   family	  kinases,	  which	  ultimately	   leads	   to	  activation	  of	  PLCγ2	  (Watson	  et	  al	  2010).	  Src	  family	   kinases	   (SFKs)	   Fyn	   and	   Lyn	   associate	  with	   a	   poly-­‐proline	   region	   of	   the	  GPVI	   cytoplasmic	   tail	   through	   their	   SH3	   domains.	   This	   phosphorylation	   of	   the	  FcRγ	  chain	  provides	  a	  docking	  site	  for	  SH2	  domain	  of	  SyK.	  This	  binding	  further	  leads	  to	  a	  cascade	  of	  signaling	  events	  through	  adaptor	  proteins	  such	  as	  the	  linker	  for	  activation	  of	  T-­‐cells	  (LAT).	  Phosphorylation	  of	  LAT	  allows	  binding	  of	  adaptor	  proteins	   Grb2	   and	   Gads	   and	   also	   phospholipase	   C	   (PLC)γ2.	   PLCγ2	   is	   then	  activated	   by	   recruitment	   of	   SLP-­‐76	   and	   Ca2+	   is	  mobilized	   (Nieswandt,	  Watson	  2003).	  	  	  The	  role	  of	  collagen-­‐dependent	  platelet	  adhesion	  via	  GPVI	  in	  arterial	  thrombosis	  remains	  controversial.	  Using	  the	  ferric	  chloride	  injury	  model	  to	  induce	  thrombus	  formation,	   some	   groups	   have	   reported	   that	   GPVI	   is	   crucial	   for	   platelet	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recruitment	   to	   the	   injured	   arterial	  wall.	   In	   contrast	   to	  wild-­‐type	   animals,	  GPVI	  knock-­‐out	  mice	  do	  not	   show	  arterial	   occlusion	   (Massberg	  2003;	  Dubois	  2006).	  The	   authors	   conclude	   that	   sub-­‐endothelial	   collagens	   are	   the	   major	   trigger	   for	  arterial	  thrombosis	  and	  that	  GPVI	  is	  important	  for	  recruitment	  of	  platelets	  to	  the	  vessel	  wall.	  In	  contrast,	  others	  have	  shown	  that	  GPVI	  plays	  a	  less	  significant	  role.	  Using	  the	  same	  model	  to	  induce	  arterial	  thrombosis,	  Eckly	  et	  al	  (2011)	  showed	  that	   deficiency	   in	   both	   GPVI	   or	   β1	   integrin’s	   did	   not	   suppress	   thrombus	  formation.	  	  The	  role	  that	  GPVI	  may	  play	  in	  venous	  thrombosis	  is	  unknown.	  However	   it	  was	   recently	   shown	   in	   an	   in	   vivo	   ferric	   chloride	  model	   that	  whilst	  GPVI	  was	  not	   important	   for	   thrombus	   initiation,	   it	  was	   important	   for	  complete	  occlusion	   (Alshehri	   et	   al	   2015),	   with	   GPVI	   deficient	   mice	   showing	   delayed	  occlusion	  times.	  The	  authors	  show	  that	  GPIV	  is	  a	  receptor	  for	  fibrin,	  and	  it	  is	  this	  interaction	  that	  is	  important	  in	  forming	  an	  occlusive	  thrombus.	  They	  show	  that	  platelets	  are	  able	   to	  spread	  on	   fibrin,	  and	   that	   the	  ectodomin	  of	  GPVI	  can	  bind	  both	  monomeric	   and	  polymerized	   fibrin.	   It	   is	   suggested	   that	   this	   interaction	   is	  important	   for	   thrombus	   growth	   and	   stability,	   and	  may	   be	   why	   GPVI	   deficient	  mice	  show	  increased	  embolization	  in	  the	  FeCL3	  model.	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Figure	  1.5	  –	  Schematic	  of	  GPVI	  signaling	  pathway	  The	  signaling	  cascade	  that	  occurs	  after	  GPVI	  activation	  by	  collagen,	  involving	  the	  FcRγ-­‐chain,	   the	   formation	   of	   the	   LAT	   signalosome	   and	   finally	   culminating	   in	  integrin	  activation	  and	  Ca2+	  mobilization.	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1.4.2	  –	  CLEC-­‐2	  CLEC-­‐2	   is	   a	   C-­‐type	   lectin	   receptor,	   and	   type	   II	   membrane	   protein	   that	   is	  expressed	   on	   platelets	   and	   megakaryocytes.	   It	   was	   initially	   discovered	   as	   a	  receptor	  to	  the	  platelet	  activating	  snake	  venom	  rhodocytine	  (Suzuki-­‐Inoue	  et	  al	  2006).	  It	  signals	  in	  a	  similar	  way	  to	  GPVI	  but	  in	  contrast	  only	  has	  a	  single	  YxxL	  in	  its	   cytoplasmic	   tail,	   so	   is	   known	   as	   hemITAM	   (Watson	   et	   al	   2010).	   CLEC-­‐2	  mediates	   platelet	   activation	   through	   SyK	   and	   Src	   kinases.	   A	   novel	   mechanism	  was	   proposed	   whereby	   SyK	   is	   activated	   through	   cross-­‐linking	   of	   two	  phosphorylated	   CLEC-­‐2	   receptors,	   2	   SyK	   SH2	   domains	   bind	   to	   the	  phosphorylated	   YxxL	   in	   the	   cytoplasmic	   tail	   of	   CLEC-­‐2,	   which	   are	   present	   as	  dimers	  on	  the	  platelet	  surface	  (Hughes	  2010).	  	  The	   only	   known	   ligand	   to	   physiologically	   interact	   with	   CLEC-­‐2	   is	   podoplanin	  (Herzog	   et	   al	   2003),	   a	   transmembrane	   protein	   involved	   in	   lymphatic	   vessel	  formation	   as	   well	   as	   tumor	   metastasis.	   Podoplanin	   is	   not	   only	   expressed	   on	  lymphatic	   endothelial	   cells,	   but	   also	   on	   kidney	   podocytes	   and	   type	   1	   lung	  alveolar	   cells	   (Ozaki	   et	   al	   2007).	   	   Although	   podoplanin	   is	   not	   expressed	   in	  platelets	  or	  blood	  endothelial	  cells,	  some	  groups	  have	  suggested	  that	  CLEC-­‐2	   is	  an	  essential	  receptor	  in	  hemostasis	  and	  thrombosis.	  	  May	   et	   al	   (2009)	   showed	   in	   vivo	   that	   CLEC-­‐2	   deficient	   platelets	   can	   adhere	  normally	  under	  flow	  but	  are	  unable	  to	  aggregate	  properly.	  Similar	  findings	  were	  reported	   by	   Ozaki	   et	   al	   (2010),	   who	   suggest	   that	   CLEC-­‐2	   is	   required	   for	   the	  ‘platelet	  piling	  up’	  process,	  which	  eventually	  leads	  to	  stable	  thrombus	  formation.	  They	  demonstrate	  that	  single	  cell	  adhesion	  is	  normal	  on	  a	  collagen	  surface,	  but	  thrombus	   formation	   is	   severely	   impaired.	   Both	   groups	   show	   that	   arterial	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thrombus	   formation	   was	   prevented	   in	   CLEC-­‐2-­‐deficient	   mice	   using	   the	   ferric	  chloride	  injury	  model.	  May	   et	   al	   (2009)	   also	   report	   that	   the	   lack	   of	   CLEC-­‐2	   leads	   to	   increased	   tail	  bleeding	   times,	   although	   others	   have	   not	   confirmed	   this	   (Ozaki	   2010).	   Any	  evidence	  that	  CLEC-­‐2	  plays	  a	  role	  also	  in	  venous	  thrombosis	  was	  lacking.	  	  
	  
Figure	  1.6	  –	  Schematic	  of	  the	  CLEC-­‐2	  signaling	  pathway	  Upon	   binding	   to	   podoplanin,	   CLEC-­‐2	   becomes	   activated.	   This	   leads	   to	  phosphorylation	   of	   the	   HemITAM	   by	   SyK	   and	   Src	   family	   kinases	   (sfk),	   which	  further	   leads	   to	   downstream	   signaling	   and	   formation	   of	   the	   LAT	   signalosome.	  Finally	  these	  signaling	  events	  lead	  to	  integrin	  activation	  and	  Ca2+	  mobilization.	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1.4.3-­‐	  GPIbα.	  	  This	  receptor	  is	  part	  of	  the	  GPIb-­‐IX-­‐V	  complex,	  which	  also	  includes	  GPIbβ,	  GPIX	  and	  GPV.	  	  GPIbα	   is	   the	   main	   receptor	   for	   VWF	   along	   with	   integrin	   αIIbβ3.	   Whilst	   this	  integrin	  requires	  inside	  out	  signaling	  to	  become	  activated,	  GPIbα	  is	  constitutively	  active	  on	  the	  platelet	  surface	  (Bergmeier	  et	  al	  2008).	  	  The	  N-­‐terminal	  domain	  of	  GPIbα	   is	   the	  major	   ligand-­‐binding	   region;	   it	   is	   able	   to	   bind	  VWF,	   thrombin,	   P-­‐selectin	  and	  coagulation	  factors	  (Savage	  et	  al	  1998).	  Removing	  the	  extracellular	  domain	  of	  GPIbα	   abolishes	   the	   ability	   of	   platelets	   to	   adhere	   to	   sites	   of	   arterial	  damage	  (Cosemans	  et	  al	  2013).	  	  It	  has	  been	  suggested	  by	  Bergmeier	  et	  al	  (2006)	  that	  GPIbα	  is	  more	   important	  than	  its	  main	  ligand	  VWF,	  in	  arterial	  thrombosis.	  This	  group	  demonstrated	  that	  mice	   deficient	   for	   VWF	   were	   still	   able	   to	   form	   thrombi	   (although	   unlike	   wild	  type,	   VWF	   KO	   mice	   thrombi	   never	   occlude	   the	   vessel).	   In	   contrast,	   in	   GPIbα	  deficient	  mice,	  platelet-­‐vessel	  wall	  interaction	  was	  virtually	  absent	  and	  thrombi	  did	   not	   form	   at	   all.	   	   These	   findings	   suggest	   that	  GPIbα	   is	   crucial	   for	   the	   initial	  platelet	   adhesion	   to	   the	   vessel	   wall	   in	   arterial	   thrombosis.	   This	   group	   also	  reported	  that	  platelets	  lacking	  αIIbβ3,	  the	  main	  integrin	  for	  platelet	  aggregation,	  despite	   not	   being	   able	   to	   form	   thrombi	   on	   their	   own,	   can	   incorporate	   into	  growing	  WT	   thrombi	   efficiently.	   This	   implies	   that,	   at	   least	   under	   arterial	   flow,	  GPIbα	  is	  more	  important	  for	  recruitment	  and	  adhesion	  of	  platelets	  than	  αIIbβ3.	  	  The	   group	   of	   Smyth	   et	   al	   (2001)	   however	   reported	   no	   occlusion	   in	   the	  carotid	  artery	  of	  αIIbβ3	  deficient	  mice	  using	  the	  ferric	  chloride	  model	  (in	  wild-­‐type	   animals	   vessels	   occlude).	   They	   also	   showed	   that	   injection	   of	   tissue	   factor	  could	   overcome	   αIIbβ3	   deficiency	   in	   initiating	   systemic	   intravascular	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thrombosis,	  suggesting	  that	  a	  combined	  therapy	  of	  both	  anticoagulants	  and	  anti-­‐	  αIIbβ3	  agents	  may	  be	  efficacious.	  	  1.4.4-­‐	  	  αIIbβ3	  This	  is	  the	  major	  integrin	  found	  on	  the	  platelet	  surface.	  It	  is	  involved	  in	  platelet	  aggregation	   and	   therefore	   hemostasis	   and	   thrombosis.	   Its	   major	   ligands	   are	  fibrinogen,	  VWF	  and	   fibronectin	  and	   the	  activation	  of	   this	   integrin	   is	  mediated	  through	   ‘inside-­‐out	   signaling’	   (see	  1.3).	  The	  cytoplasmic	   tails	  of	  αIIb	  and	  β3	  as	  well	   as	   the	   transmembrane	   regions	   are	   in	   contact,	   keeping	   the	   integrin	   in	   its	  ‘inactive’	   state.	  When	   this	   complex	   collapses	  by	   the	  binding	  of	   cytoplasmic	   tail	  binding	  partners	  (e.g.	  talin)	  the	  integrin	  becomes	  active	  (Plow	  et	  al	  2007).	  	  Platelet	  agonists	  regulate	  αIIbβ3	  function.	  Platelets	  require	  activation	  to	  enable	  αIIbβ3	   to	   bind	   fibrinogen	   and	   VWF	   and	   cause	   platelet	   aggregation	   (Bennett	  2005).	   Fibrinogen	   binding	   to	   platelets	   via	   αIIbβ3	   is	   important	   for	   platelet	  aggregation.	  Fibrinogen	  and	  VWF	  are	   important	   for	  bringing	  adjacent	  activated	  platelets	   together	   (platelet	   cohesion)	   and	   can	   also	   promote	   stable	   aggregation	  under	  high	  shear.	  Platelet	  surface	  αIIbβ3	  can	  also	  bind	  soluble	  fibrinogen,	  which	  is	   implicated	   in	   further	   platelet	   recruitment	   to	   a	   growing	   thrombus	   (Jackson	  2003).	  	  	  
1.5	  -­‐	  Platelet	  activation	  &	  coagulation	  cascade	  When	  the	  endothelium	  becomes	  damaged,	  collagen	  is	  exposed	  and	  platelets	  are	  able	   to	   bind	   to	   it	   through	   their	   collagen	   specific	   glycoprotein	   α2β1	   surface	  receptors.	  This	  adhesion	   is	  mediated	  by	  von	  Willebrand	  Factor	   (vWF)	  released	  from	   the	   activated	   endothelium,	   and	   from	   platelets.	   vWF	   forms	   a	   crosslink	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between	   the	   collagen	   fibrils	   and	   the	   GPIb-­‐GPIX-­‐GPV	   complex.	   In	   addition	   vWF	  also	  binds	  to	  and	  stabilizes	  coagulation	  factor	  VIII.	  	  Binding	   of	   platelet	   GPVI	   to	   collagen	   then	   triggers	   a	   signaling	   cascade	   that	  activates	  platelet	  integrins.	  Activated	  platelets	  also	  release	  the	  contents	  of	  their	  stored	   granules	   including	   ADP,	   vWF,	   platelet	   activating	   factor	   (PAF),	   and	  thromboxane	  A2	  (TXA2)	  this	  in	  turn	  activates	  more	  platelets.	  	  Platelets	   themselves	   are	   also	   important	   in	   the	   activation	   of	   the	   coagulation	  cascade,	  where	  they	  provide	  an	  efficient	  surface	  for	  the	  assembly	  of	  the	  enzyme	  complexes	  of	  the	  coagulation	  system.	  	  Whilst	  the	  ‘classical’	  view	  of	  the	  coagulation	  cascade	  was	  that	  is	  divided	  into	  the	  intrinsic	   and	   extrinsic	   pathways,	   we	   now	   know	   that	   these	   are	   overlapping	  processes	  rather	  than	  alternative	  pathways.	  	  In	   the	   intrinsic	   pathway,	   all	   clotting	   factors	   are	   already	   present	   in	   the	   blood,	  starting	   with	   conversion	   of	   FXII	   to	   FXIIa	   following	   the	   secretion	   of	   platelet	  polyanions.	   The	   extrinsic	   pathway	   is	   initiated	   following	   vessel	   damage	   and	  exposure	  of	  tissue	  factor	  (TF)	  (Ajjan	  et	  al	  2005).	  Once	  TF	  is	  exposed,	  this	  is	  able	  to	  bind	  to	  factors	  VII/VIIa,	  and	  in	  the	  presence	  of	  calcium	  ions,	  forms	  a	  complex	  that	   further	  activates	   the	   ‘cascade’,	  converting	  FX	  to	  FXa,	  FIX	  to	  FIXa	  and	  FVIIa	  itself.	  This	  finally	  culminates	  in	  the	  formation	  of	  thrombin	  at	  the	  damaged	  vessel	  wall,	  which	   further	   activates	   platelets;	   followed	  by	   conversion	  of	   fibrinogen	   to	  fibrin	  that	  stabilizes	  the	  formed	  clot	  (Cimmino	  G	  et	  al	  2016).	  	  	  In	   resting	   states,	   phosphatidylserine	   (PS)	   is	   found	   in	   the	   inner	   platelet	  membrane.	   Following	   platelet	   activation	   by	   either	   exposure	   to	   collagen,	   sheer	  stress	   or	   thrombin,	   this	   phosphatidylserine	  moves	   to	   the	   outer	   surface	   of	   the	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plasma	  membrane.	  This	  leads	  to	  increased	  activation	  of	  prothrombin	  and	  factor	  X,	  as	  well	  as	  the	  appearance	  of	  high	  affinity	  binding	  sites	  for	  factors	  Va	  and	  VIIIa	  (Ahmadd	  et	  al	  1992).	  The	  transbilayer	  movement	  of	  PS	  in	  the	  platelet	  membrane	  is	   accompanied	   by	   the	   generation	   of	   phosphatidylserine-­‐rich	   microvesicles.	  Platelet	   derived	   microvesicles	   are	   localized	   to	   the	   site	   of	   vessel	   damage,	   and	  incorporated	  into	  the	  growing	  thrombus	  (Merten	  et	  al	  1999).	  The	  presence	  of	  PS	  at	   the	   phospholipid	   membrane	   facilitates	   the	   binding	   of	   FVIIa,	   FXIa,	   FXa	   and	  prothrombin	   (PT),	   this	   is	   due	   to	   an	   electrostatic	   charge	   between	   positively	  charged	  Υ-­‐	  carboxyglutamic	  acid	  (GLA)	  domains	  in	  the	  clotting	  proteins	  and	  the	  PS	  on	  the	  membrane	  (Owens	  et	  al	  2011).	  	  	  As	   well	   as	   tissue	   factor	   exposure	   following	   vessel	   wall	   injury,	   tissue	   factor	  bearing	  microparticles	  can	  also	  bind	  to	  platelets.	  A	  bridge	  is	  formed	  through	  the	  interaction	   of	   P-­‐selectin	   on	   the	   platelet	   surface	   and	   P-­‐selectin	   glycoprotein	  Ligand-­‐1	   (PSGL-­‐1).	   These	   PSGL-­‐1	   and	   TF	   rich	   microparticles	   are	   then	   able	   to	  transfer	  tissue	  factor	  to	  the	  platelet	  membrane	  (Falati	  et	  al	  2003).	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Figure	  1.7	  –	  Intrinsic	  and	  extrinsic	  coagulation	  cascades	  	  The	   coagulation	   cascade	   of	   both	   the	   contact	   activation	   pathway	   (intrinsic	  pathway)	   and	   the	   tissue	   factor	   pathway	   (extrinsic)	   both	   involve	   a	   series	   of	  downstream	   cleavage	   steps	   by	   serine	  proteases.	   Both	  pathways	   fundamentally	  culminate	  in	  the	  production	  of	  fibrin,	  which	  stabilizes	  the	  clot.	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In	   order	   to	   prevent	   platelet	   activation	   on	   an	   intact	   healthy	   endothelium,	  inhibitory	   mechanisms	   are	   in	   place.	   In	   healthy	   vessels,	   the	   endothelium	  expresses	   nitric	   oxide	   synthase	   (NOS)	   and	   cyclo-­‐oxgenase	   (COX-­‐1),	   which	  produces	  Nitric	  Oxide	   (NO)	  and	  prostacyclin	   (PGI2)	   respectively	   (Mitchell	  et	  al	  2007).	   The	   actions	   of	   NO	   and	   PGI2	   are	   synergistic	   in	   inhibiting	   platelet	  activation.	  Nitric	  Oxide	  produced	  by	  NOS	  activates	  Guanosine	  cyclase,	  which	   in	  turn	  results	  in	  the	  formation	  of	  cyclic	  guanosine	  monophosphate	  (cGMP),	  which	  then	   inhibits	   platelet	   activation	   (Feil	   at	   al	   2003).	   Release	   of	   PGI2	   from	   the	  endothelium	  also	  inhibits	  platelet	  activation;	  it	  interacts	  with	  platelet	  G	  protein-­‐coupled	   PGI2	   receptor	   coupled	   to	   Gαs,	   causing	   accumulation	   and	   activation	   of	  cAMP	  (Raslan	  &	  Naseem	  2015).	  It	  is	  through	  these	  secondary	  messengers;	  cAMP	  and	  cGMP,	  that	  platelet	  inhibition	  occurs,	  activating	  protein	  kinase	  A	  (PKA)	  and	  protein	   kinase	   G	   (PKG)	   respectively	   leading	   to	   further	   phosphorylation	   of	  targeted	  platelet	  proteins.	  	  
1.6	  Role	  of	  platelets	  in	  inflammation	  	  Inflammation	   is	   a	   complex	   set	   of	   responses	   produced	   by	   the	   innate	   immune	  system	   in	   response	   to	   a	   variety	   of	   pathological	   stimuli,	   such	   as	   microbes	   or	  damage-­‐associated	   molecular	   patterns	   (DAMPs).	   Systemic	   inflammation	   can	  however	  occur	  as	  a	  result	  of	  an	   infection,	   leading	   to	  sepsis,	  or	   in	  response	   to	  a	  substantial	   trauma	  or	  chronic	  disease.	  The	  classical	   symptoms	  of	   inflammation	  are	  redness,	  swelling,	  heat,	  pain	  and	  compromised	  function.	  The	  inflammatory	  response	  involves	  multiple	  mechanisms	  but	  an	  important	  part	  is	  the	  recruitment	  of	  immune	  cells	  e.g.	  neutrophils	  and	  monocytes	  by	  the	  vessel	  wall	   (Thomas	   et	   al	   2015).	   Platelets	   also	   play	   an	   important	   role	   in	   regulating	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inflammation,	  and	  are	  not	  only	  needed	  for	  hemostasis	  and	  thrombosis	  but	  have	  also	  been	  described	  as	  inflammatory	  cells	  (Gros	  et	  al	  2014;	  Jenne	  &	  Kubes	  2015).	  Platelets	   contain	   a	   number	   of	   inflammatory	   mediators,	   some	   of	   which	   they	  synthesize	  de	  novo,	  others	  that	  they	  store	  and	  secrete	  from	  granules	  (α-­‐granules,	  dense	   granules	   and	   lysosomes).	   The	   release	   of	   these	   substances	   upon	   platelet	  activation	  allows	  leukocytes	  to	  be	  recruited	  to	  the	  site	  of	  injury	  (Shi	  2011).	  Table	  1.2	   below	   lists	   some	   of	   these	   important	   platelet-­‐derived	   inflammatory	  mediators.	  
Table	  1.2.	  Inflammatory	  mediators	  synthesized	  by	  and	  stored	  in	  platelets	  	  	  	  
Location	   Molecule	   Family	  α-­‐	  granules	   PF4/	  CXCL4	   Chemokine	  α-­‐	  granules	   β-­‐thromboglobulin(CXCL7/NAP-­‐2)	   Chemokine	  α-­‐	  granules	   RANTES	  (CCL5)	   Chemokine	  α-­‐	  granules	   CD40L	   Cytokine	  α-­‐	  granules	   PDGF	   Growth	  factor	  α-­‐	  granules	   TGF-­‐β	   Growth	  factor	  α-­‐	  granules	   TNF-­‐α	   Cytokine	  α-­‐	  granules	   IL-­‐1α	   Cytokine	  α-­‐	  granules	   CXCL1	   Cytokine	  α-­‐	  granules	   CXCL5	   Cytokine	  α-­‐	  granules	   CXCL12	   Cytokine	  α-­‐	  granules	   CCL3	   Chemokine	  α-­‐	  granules	   CCL7	   Chemokine	  α-­‐	  granules	   CXCL7	   Chemokine	  α-­‐	  granules	   CCL17	   Chemokine	  α-­‐	  granules	   CXCL8	   Chemokine	  Dense	  granules	   ATP	   Nucleotide	  Dense	  granules	   Serotonin	   Monoamine	  Dense	  granules	   Polyphosphates	   Phosphates	  Dense	  granules	   Glutamate	   Amino	  Acid	  Synthesized	   IL-­‐1β	   Cytokine	  Synthesized	   Thromboxane	  A2	   Eicosanoid	  	  Platelet	   α-­‐granules	   contain	   many	   large	   proteins,	   the	   most	   abundant	   protein	  secreted	   by	   activated	   platelets	   is	   Platelet	   Factor	   4	   (PF4),	   which	   accounts	   for	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~25%	  of	  α-­‐granules	  content	  (Lambert	  et	  al	  2009).	  It	  has	  many	  functions	  such	  as	  acting	  as	  a	  chemoattractant	   for	  monocytes,	   it	  also	  accelerates	  atherogenesis	  by	  causing	   vascular	   inflammation	   and	   promoting	   retention	   of	   lipoproteins	   in	   the	  vascular	  wall.	  PF4	  prevents	  LDL	  interacting	  fully	  with	  its	  receptor	  and	  therefore	  results	  in	  its	  retention	  on	  the	  cell	  surface	  (Gawaz	  et	  al	  2005).	  Platelets	  also	  synthesize	  as	  well	  as	  store	  biologically	  active	  proteins;	  pro-­‐IL-­‐1β	  is	  synthesized	   as	   a	   result	   of	   thrombin	   activation.	   In	   vivo	   IL-­‐1β	   is	   shown	   to	  accumulate	  in	  thrombi	  formed	  in	  the	  ferric	  chloride	  model.	  IL-­‐1β	  from	  platelets	  causes	   up-­‐regulation	   of	   endothelial	   adhesion	   receptors	   and	   release	   of	  proinflammatory	  IL-­‐6	  and	  IL-­‐8	  from	  endothelial	  cells	  (Lindemann	  et	  al	  2001).	  Platelet	   dense	   granules	   also	   contain	   inflammatory	   mediators	   such	   as	  Polyphosphate	   (polyP).	   PolyP	   has	   been	   shown	   to	   have	   both	   procoagulant	   and	  proinflammatory	   functions	   (Muller	   et	   al	   2009).	   Upon	   platelet	   activation	   its	  release	   activates	   the	   FX11-­‐	   driven	   contact	   activation	   system,	   which	   in	   turn	  casues	   release	   of	   bradykinin	   (and	   inflammatory	   mediator)	   and	   subsequent	  accumulation	  of	  neutrophils	  and	  increased	  vascular	  permeability.	  All	  of	  these	  platelet	  inflammatory	  mediators,	  which	  are	  stored	  and	  released,	  may	  contribute	   to	  multiple	   inflammatory	  diseases	   such	   as	   rheumatoid	   arthritis	   and	  atherosclerosis,	  demonstrating	  the	  importance	  of	  platelets	  in	  inflammation.	  	  1.6.2	  Platelet	  crosstalk	  with	  endothelium	  and	  leukocytes	  	  Under	  physiological	  conditions	  (non-­‐inflammatory)	  platelets	  and	   leukocytes	  do	  not	   bind	   to	   each	   other,	   and	   endothelial	   cells	   produce	   platelet	   inhibitors	   e.g.	  prostacyclin	  to	  limit	  platelet/endothelium	  interaction	  (Arman	  et	  al	  2015).	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In	   patients	   with	   inflammatory	   diseases	   for	   example	   sepsis	   or	   cerebrovascular	  ischemia,	  activated	  platelets	  can	  be	  found	  in	  the	  blood	  (Stokes	  &	  Granger	  2012).	  Once	   activated,	   these	   platelets	   not	   only	   pose	   a	   greater	   risk	   of	   excessive	  thrombosis	  in	  these	  patients	  but	  they	  also	  stimulate	  the	  release	  of	  Weibel-­‐Palade	  body	   constituents	   leading	   to	   increased	   recruitment	   of	   leukocytes	   to	   the	   vessel	  wall	  (May	  et	  al	  2008).	  Platelet	  interaction	  with	  the	  endothelium	  leads	  to	  deposition	  of	  proinflammatory	  cytokines	   at	   the	   vessel	   wall	   such	   as	   RANTES,	   as	   well	   as	   accumulation	   of	  monocytes.	  Platelet	  binding	  to	  the	  activated	  endothelium	  is	  mediated	  through	  P-­‐selectin,	  CD40L	  and	  glycoproteins	  Ibα,	  αIIb	  and	  GPVI	  (Burger	  2003).	  Platelets	   and	   leukocytes	   can	   activate	   each	   other	   in	   a	   bi-­‐directional	   fashion.	   P-­‐selectin	   on	   activated	   platelets	   binds	   to	   PSGL-­‐1	   on	   leukocytes,	   which	  subsequently	  leads	  to	  activation	  of	  integrin’s	  on	  the	  leukocyte	  membrane	  (Mac-­‐1	  and	  LFA-­‐1)	  (Ghasemzadeh	  2013).	  Mac-­‐1	  is	  able	  to	  bind	  either	  directly	  to	  GP1bα	  on	  platelets,	  or	  bind	  α11bβ3	  through	  fibrinogen.	  Platelet	  mediated	  activation	  of	  Mac-­‐1	   on	   leukocytes	   activates	   coagulation	   Factor	   X	   and	   therefore	   thrombin	  generation,	  demonstrating	  platelet-­‐leukocyte	  interaction	  triggers	  the	  coagulation	  cascade.	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1.7	  –	  Arterial	  thrombus	  formation	  Multiple	   signaling	   events	   lead	   to	   platelet	   activation	   and	   adhesion,	   culminating	  finally	   in	   thrombus	   formation.	  At	  damaged	  sites	   in	  vessels	   collagen	   in	   the	   sub-­‐endothelial	   matrix	   is	   exposed,	   for	   example	   following	   the	   rupture	   of	  atherosclerotic	  plaques.	  Platelet	  binding	  to	  this	  collagen	  leads	  to	  further	  platelet	  recruitment.	   The	   processes	   that	   lead	   to	   thrombus	   formation	   are	   described	   in	  detail	  below	  and	  shown	  in	  figure	  6:	  
1.	  Tethering	  –	  The	  initiation	  of	  thrombus	  formation	  is	  highly	  influenced	  by	  the	  shear	   rate	   of	   blood	   flow.	   At	   low	   shear	   (0-­‐1000s-­‐1)	   such	   as	   in	   large	   veins	   and	  venules	  platelet	  aggregation	  is	  primarily	  mediated	  by	  crosslinking	  of	  fibrinogen	  with	   αIIbβ3.	   At	   higher	   shear	   rate	   (1000-­‐10000s-­‐1)	   such	   as	   in	   arterioles	   this	  association	  is	  not	  strong	  enough	  to	  maintain	  platelet	  tethering	  to	  the	  vessel	  wall.	  Instead,	   under	  high	   sheer	  VWF	  coated	  on	   collagen	   fibers	   is	  most	   important	  by	  interacting	   with	   GPIb-­‐IX-­‐V	   receptors	   on	   platelets	   (Maxwell	   et	   al	   2007).	   This	  allows	   initial	   platelet	   capture	   or	   ‘tethering’	   to	   the	   damaged	   endothelium.	   This	  initial	  capture	  has	  a	  fast	  on-­‐off	  rate	  of	  association	  and	  dissociation	  between	  the	  receptor	  and	  ligand.	  A	  stable	  adhesion	  is	  therefore	  not	  formed,	  and	  platelets	  roll	  along	  the	  endothelium	  in	  the	  direction	  of	  flow	  (Offermanns	  2006).	  
2.	   Stable	   adhesion	   -­‐	   Platelets	   become	   activated	   during	   their	   interaction	  with	  thrombogenic	   surfaces.	   	   The	   tethering	   process	   to	   vWF	   allows	   GPVI,	   the	  major	  collagen	   receptor	   to	   come	   into	   contact	  with	   the	   exposed	   collagen	   fibers	   in	   the	  vessel	  wall.	  This	  leads	  to	  integrin	  activation,	  and	  integrins	  αIIbβ3	  and	  α2β1	  form	  additional	   adhesion	  bonds	  with	  VWF	  and	   collagen	   respectively,	   promoting	   cell	  arrest	  and	  stable	  adhesion.	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3.	  Spreading-­‐	  Once	  platelets	  have	  been	  activated	  this	  stimulates	  reorganization	  of	  the	  actin	  cytoskeleton,	  and	  extension	  of	  filopodia	  and	  lamellipodia.	  This	  leads	  to	   the	   transformation	   of	   the	   biconcave	   disks	   to	   fully	   spread	   platelets	   with	   an	  increased	  surface	  area.	  This	   larger	   surface	  area	  provides	  a	   further	  more	  stable	  adhesion	  as	  the	  area	  to	  attach	  to	  exposed	  collagen	  and	  VWF	  is	  increased	  (Aslan	  	  2012).	  	  
4.Thrombus	   growth	   –	   Once	   platelet	   integrin’s	   are	   activated	   this	   leads	   to	  secretion	  of	  α	  and	  dense	  granule	  contents	  such	  as	  ADP	  and	  TxA2.	  These	  feedback	  messengers	   lead	   to	   further	   activation	   and	   aggregation	   of	   platelets	   (Watson,	  Harrison	   2007).	   Either	   the	   intrinsic	   or	   extrinsic	   coagulation	   pathways	   achieve	  the	   consolidation	  of	   a	   growing	   thrombus.	  This	   is	  by	   tissue	   factor	  expressed	  on	  the	   endothelial	   surface,	   or	   by	   the	   factor	   XII	   pathway	   driven	   by	   collagen	   and	  platelet	  polyphosphates	  (Cosemans	  et	  al	  2013).	  Tissue-­‐factor	  rich	  microparticles	  are	   also	   incorporated	   into	   the	   growing	   thrombus	   via	   a	   P-­‐selectin	   –PSGL-­‐1	  dependent	   mechanism.	   The	   platelets	   also	   provide	   a	   pro-­‐coagulant	   surface	   for	  thrombin	   generation.	   This	   thrombin	   generation	   converts	   fibrinogen	   into	   fibrin	  that	   stabilizes	   and	   consolidates	   the	   thrombus.	   The	   fibrin	   network	   can	   further	  trap	  RBCs	  and	  leukocytes	  leading	  to	  effective	  vessel	  occlusion.	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1.8	  Deep	  vein	  thrombosis	  (DVT)	  1.8.1	  DVT	  epidemiology	  Deep	   vein	   thrombosis	   is	   the	   formation	   of	   a	   thrombus	   within	   a	   deep	   vein,	  predominantly	   the	   legs.	  Pulmonary	  embolisms	  (PE)	  can	   form	  when	  clots	   in	   the	  lower	   limbs	   detach	   and	   move	   to	   the	   lungs,	   this	   is	   usually	   life	   threatening.	  Together	   deep	   vein	   thrombosis	   and	   pulmonary	   embolism	   form	   the	   serious	  disease,	  venous	  thromboembolism	  (VT).	  	  The	  incidence	  of	  venous	  thrombosis	  is	  approximately	   1	   per	   1000	   adults	   annually,	   with	   the	   incidence	   being	   slightly	  higher	   in	   men	   than	   women.	   In	   all	   cases	   of	   VT	   approximately	   70%	   of	   them	  manifest	   in	   DVT,	   with	   the	   remaining	   30%	   involving	   PE,	   with	   or	   without	   DVT	  (Cushman	  2007).	  	  Venous	  thrombosis	  is	  a	  severe	  disease,	  with	  the	  major	  outcomes	  including	  death,	  post-­‐thrombotic	  syndrome,	  recurrence	  and	  other	  bleeding	  complications.	  It	  has	  been	   reported	   that	   ~6%	   of	   people	   with	   DVT	   and	   ~10%	   of	   those	   with	   PE	   die	  within	  the	  first	  month	  of	  an	  episode,	  whilst	  the	  mortality	  rate	  of	  those	  with	  PE	  is	  estimated	  to	  be	  ~30%	  (Cushman	  2007).	  Venous	  thrombosis	  is	  a	  disease	  associated	  with	  ageing,	  with	  cases	  rising	  rapidly	  after	  45	  years	  old,	  with	  cases	  even	  higher	  in	  those	  over	  80	  years.	  In	  the	  elderly	  mortality	  tends	  to	  be	  higher	  with	  an	  increased	  incidence	  of	  PE	  compared	  to	  just	  DVT,	  and	  elderly	  people	  also	  have	  several	  other	  diseases	  and	  these	  may	  interact	  to	  predispose	  this	  population	  to	  thrombosis.	  There	  also	  seems	  to	  be	  differences	  in	   incidence	   of	   venous	   thrombosis	   among	   different	   ethnic	   groups.	   Lower	  incidences	  are	  reported	  in	  the	  US,	  Asian	  and	  Hispanic	  populations	  compared	  to	  white	  populations,	  with	  African-­‐Americans	  reportedly	  having	  a	  25%	  higher	  rate	  of	  the	  disease	  (Tsai	  et	  al	  2002).	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1.8.2	  Risk	  factors	  for	  DVT	  There	   are	   many	   risk	   factors	   for	   venous	   thrombosis,	   and	   many	   of	   them	   may	  interact,	   including	   endogenous	   patient	   characteristics	   as	   well	   as	   other	  environmental	   factors.	   These	   risk	   factors	   include	   old	   age,	   pregnancy,	   obesity,	  cancer	  and	  genetic	  factors	  affecting	  coagulation.	  As	  well	  as	  other	  external	  factors	  including	  surgery,	   trauma,	  whilst	  both	  hospitalization	  and	   long	  haul	   flights	  can	  lead	   to	   prolonged	   periods	   of	   venous	   stasis.	   Symptoms	   of	   DVT	   can	   include	  swelling	   in	   the	   affected	   area	   of	   the	   lower	   leg,	   pain	   in	   the	   leg	   often	   like	   a	  cramping,	   or	   it	   may	   occur	   without	   any	   obvious	   symptoms.	   For	   PE	   however,	  symptoms	  can	  include	  chest	  pains,	  shortness	  of	  breath,	  and	  dizziness.	  	  Currently	   advice	   given	   to	   try	   and	   prevent	   this	   disease	   is	   to	   keep	   as	   active	   as	  possible	   and	  not	   to	   have	   a	   sedentary	   life	   style.	   It	   is	   suggested	   that	   you	   should	  avoid	  sitting	  for	  long	  periods	  for	  example	  in	  bed	  post-­‐surgery	  or	  long	  haul	  flights,	  and	   should	   aim	   to	  move	   your	   lower	   limbs	   as	  much	   as	   possible.	   Other	   lifestyle	  factors	   such	   as	   quitting	   smoking	   and	   diet	   changes	   to	   prevent	   obesity	   may	   go	  some	  way	  to	  prevent	  this	  disease.	  	  1.8.3	  Current	  treatment	  options	  for	  DVT	  and	  disadvantages	  	  Current	  treatment	  options	  for	  people	  with	  the	  disease	  primarily	  aim	  to	  prevent	  the	   clot	   from	   growing,	   or	   prevent	   the	   clot	   detaching	   causing	   a	   pulmonary	  embolism.	   Secondly,	   the	   aim	   is	   then	   to	   try	   and	   prevent	   recurrence.	  Anticoagulants	  such	  as	  heparin	  or	  warfarin,	  which	  interact	  with	  clotting	  factors	  	  are	   often	  used	   as	   a	   treatment	   option,	   these	  decrease	   the	  bloods	   ability	   to	   clot,	  and	   can	   prevent	   clots	   getting	   bigger.	   Warfarin	   is	   a	   vitamin	   K	   antagonist,	   and	  produces	   its	  anticoagulant	  effect	  by	   interfering	  with	   the	  vitamin	  K	  cycle,	  which	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ultimately	   prevents	   prothrombin	   becoming	   carboxylated,	   and	   interacting	   with	  the	  phospholipid	  membrane.	   	  These	  medications	  however	   are	  often	   associated	  with	   serious	   side	   effects,	   especially	   if	   not	   taken	   exactly	   as	   instructed.	   Other	  treatment	   options	   for	   more	   serious	   cases	   of	   DVT	   or	   PE	   can	   include	   giving	  patients	   tissue	   plasminogen	   activators	   (TPA)	   to	   break	   up	   blood	   clots.	   This	   is	  however	  only	  given	  in	  extremely	  serious	  life	  threatening	  cases,	  as	  they	  can	  cause	  very	   severe	   bleeding	   complications.	   In	   order	   to	   prevent	   post-­‐thrombotic	  syndrome	  compression	  stockings	  are	  often	  given	  to	  patients	  who	  have	  had	  DVT,	  alternatively	   inferior	   vena	   cava	   filters	   can	   sometimes	   be	   fitted	   it	   patients	  who	  need	  to	  stop	  anticoagulant	  treatment.	  These	  filters	  trap	  large	  fragments	  of	  blood	  clots	  and	  prevent	  them	  detaching	  and	  causing	  a	  pulmonary	  embolism	  (NHS).	  	  This	   highlights	   that	   currently	   treatments	   either	   aim	   to	   prevent	   clots	   getting	  bigger	   or	   prevent	   the	   chance	   of	   PE	   occurring,	   but	   there	   still	   isn’t	   any	   good	  treatments	   options	   that	   tackle	   DVT	   without	   potentially	   serious	   bleeding	  complications	  as	  a	  side	  effect.	  Considering	  the	  high	  incidence	  of	  this	  disease	  and	  the	   increasing	  ageing	  population,	  better	  drug	   targets	  need	   to	  be	   identified	   that	  won’t	  have	  these	  associated	  side	  effects.	  	  1.8.4	  Mechanisms	  of	  DVT	  Virchow’s	  triad	  predicts	  that	  there	  are	  three	  main	  causes	  of	  venous	  thrombosis;	  stasis,	  changes	  in	  blood	  coaguability	  or	  changes	  in	  the	  vessel	  wall.	  Whilst	  chronic	  low	   levels	  of	   inflammation	   impact	  on	  arterial	   thrombosis,	   this	  has	   little	   impact	  on	   venous	   thrombosis,	   however	   acute	   inflammation	   can	   increase	   venous	  thrombosis	   (Esmon	   2009).	   Venous	   thrombosis	   is	   initiated	   without	   any	   visible	  injury	  to	  the	  vessel	  wall	  (expect	  for	  thrombosis	  associated	  with	  surgery).	  Venous	  thrombosis	  is	  believed	  to	  be	  initiated	  in	  the	  venous	  valvular	  sinus,	  it	  is	  in	  these	  
	  	   39	  
venous	   valve	   pockets	   that	   stasis	   occurs;	   this	   is	   also	   associated	  with	   increased	  hypoxia,	   which	   provides	   a	   hypercoagulable	   microenvironment	   (Aird	   2007).	  Hypoxia	  could	  further	  lead	  to	  up-­‐regulation	  of	  tissue	  factor	  on	  the	  endothelium	  as	  well	   increasing	  P-­‐selectin	   expression,	  which	   further	   recruits	   leukocytes	   and	  tissue	   factor	   containing	   micro	   particles,	   both	   of	   which	   are	   important	   for	  thrombus	  formation	  (Myers	  et	  al	  2003).	  	  It	  has	  previously	  been	  shown	  using	  the	  IVC	  stenosis	  model,	  where	  blood	  flow	  is	  partially	   restricted,	   that	   wild	   type	   mice	   form	   venous	   thrombi	   comparable	   to	  human	   deep	   vein	   thrombi.	   Both	   thrombi	   contain	   a	   red	   part	   rich	   in	   RBC’s	   and	  fibrin	  (Zahn	  lines),	  and	  a	  white	  part	  rich	  in	  platelets,	  suggesting	  they	  have	  similar	  mechanisms	  of	  thrombus	  formation.	  	  It	  was	  shown	  by	  Brill	  et	  al	  (2011)	  that	  von	  Willebrand	   factor	   expressed	   on	   the	   endothelium	   interacts	   with	   platelets,	   and	  plays	  and	  important	  role	  in	  the	  development	  of	  DVT.	  Mice	  deficient	  in	  VWF	  were	  protected	   from	   thrombosis	   in	   both	   the	   IVC	   stasis	   and	   stenosis	   models.	   They	  show	   that	   flow	   restriction	  by	   IVC	   ligation	   results	   in	   endothelial	   activation,	   and	  VWF	   release	   from	   Weibel-­‐Palade	   bodies	   (WPB).	   Platelets	   and	   leukocytes	   are	  then	   recruited	   and	   bind	   to	   VWF	   and	   P-­‐selectin,	   respectively,	   on	   the	   activated	  endothelium.	   Thus,	   endothelial	   activation	   and	   liberation	   of	  WPB	   is	   pivotal	   for	  DVT	  initiation.	  	  1.8.5	  Potential	  roles	  of	  immune	  cells	  in	  DVT	  It	  has	  been	  shown	  that	  T-­‐regulatory	  cells	   (T-­‐regs)	  may	  have	  a	  role	   in	  changing	  the	  functional	  status	  of	  the	  endothelium.	  This	  makes	  T-­‐regs	  important	  players	  in	  ischemic	   stroke.	   There	   is	   a	   controversy	   over	   whether	   these	   immune	   cells	  promote	  stroke	  or	  play	  a	  protective	  role.	  Some	  studies	  have	  demonstrated	  that	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adoptive	   transfer	   of	   T-­‐regs	   into	   Rag1-­‐/-­‐	   mice	   (deficient	   in	   lymphocytes)	  increased	   the	   susceptibility	   for	   brain	   ischemia	   in	   a	   model	   of	   middle	   cerebral	  artery	   occlusion	   (MCAO)	   (Kleinschnitz	   et	   al	   2013).	   In	   contrast,	   others	   have	  shown	  that	  infarct	  size	  is	  significantly	  enlarged	  when	  T-­‐regs	  are	  depleted	  (Liesz	  et	   al	   2009).	   T-­‐regs	   adhere	   to	   the	   vascular	   endothelium	   and	   it	   is	   therefore	  possible	  that	  they	  activate	  or	  downregulate	  it;	  I	  have	  therefore	  looked	  at	  if	  T-­‐regs	  have	  a	  role	  in	  DVT.	  	  Other	  immune	  cells	  may	  also	  be	  involved	  in	  DVT	  pathogenesis,	  e.g.,	  mast	  cells.	  It	  has	  been	  shown	  that	  mast	  cells	  accumulate	  in	  the	  vicinity	  of	  thrombosed	  veins	  in	  humans	   (Valent	   et	   al	   2002).	   Mast	   cells	   are	   extravascular	   and	   found	   in	   close	  proximity	   to	   capillaries	   and	   post-­‐capillary	   venules.	   They	   secrete	   a	   number	   of	  factors	   such	   as	   histamine,	   a	   WPB	   secretagogue,	   as	   well	   as	   heparin	   (an	  anticoagulant)	   and	   tissue-­‐type	   plasminogen	   activator	   (tPA),	   which	   promote	  thrombolysis.	  Thus,	  mast	  cells	  can	  potentially	  be	  implicated	  in	  thrombosis	  and	  I	  investigated	  the	  role	  mast	  cells	  play	  in	  DVT	  using	  mast	  cell	  deficient	  mice	  in	  the	  IVC	  stenosis	  model.	  	  	  	  	  	  	  	  	  	  
	  	   41	  
1.9	  -­‐	  Aims	  of	  thesis	  The	   mechanisms	   leading	   to	   venous	   thrombosis	   initiation	   have	   not	   been	   fully	  elucidated.	   The	   role	   of	   major	   platelet	   receptors	   CLEC-­‐2	   and	   GPVI	   have	   been	  extensively	  studied	   in	  arterial	   thrombosis	  but	  not	   in	  venous	   thrombosis.	  These	  platelet	  ITAM	  receptors	  participate	  in	  the	  maintenance	  of	  vascular	  integrity	  and	  endothelial	   ‘well-­‐being’	  which	  we	  know	   is	   critical	   in	  DVT	   initiation,	   therefore	   I	  aimed	   to	   understand	   their	   roles.	   I	   also	   aimed	   to	   investigate	   the	   role	   other	  immune	   cells	   may	   play	   in	   venous	   thrombosis.	   Overall,	   the	   major	   aim	   was	   to	  identify	   new	   targets	   to	   prevent	   DVT,	   which	   are	   not	   involved	   in	   normal	  hemostasis	  and	  therefore	  will	  not	  lead	  to	  bleeding	  complications	  as	  a	  side	  effect.	  The	  specific	  aims	  were:	  1. To	   investigate	   the	  role	  of	  CLEC-­‐2	  and	  GPVI	   in	  DVT,	  and	  compare	   this	   to	  their	  role	  in	  arterial	  thrombosis	  2. To	  investigate	  the	  role	  of	  mast	  cells	  in	  DVT	  3. To	  investigate	  the	  role	  of	  T-­‐cells	  in	  DVT	  4. To	  study	  the	  signaling	  pathways	  involved	  in	  NETs,	  and	  the	  role	  they	  play	  in	  thrombosis	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2.1	  Materials	  	  2.1.1	  Antibodies	  and	  Reagents	  	  
	  Details	   of	   all	   antibodies	   and	   reagents	   used	   throughout	   this	   thesis	   are	   listed	  below	  in	  the	  table.	  
Table	  2.1	  –	  Antibodies	  and	  reagents	  
Antibodies	   Source	  Anti-­‐CD3	   Abcam	  (Cambridge,	  UK)	  Anti-­‐GR1	   BD	  Bioscience	  (San	  Diego,	  USA)	  Anti-­‐CD45	   Abcam	  (Cambridge,	  UK)	  Anti-­‐CD41	   Emfret	  (Germany)	  Syrian	  hamster	  anti-­‐mouse	  PDPN	   eBioscience	  (Hatfield,	  UK)	  Mouse	  anti-­‐tubulin	   Sigma	  (Poole,	  UK)	  Anti-­‐Histone	  H3	  Ab	   Abcam	  (Cambridge,	  UK)	  Rabbit	  anti-­‐human	  VWF	   Dako	  (Denmark)	  FceR1-­‐PE	   eBioscience	  clone	  MAR-­‐1	  (Hatfield,	  UK)	  CD117	  (C-­‐Kit)-­‐APC	   eBioscience	  clone	  2B8	  (Hatfield,	  UK)	  Mouse	  anti-­‐DNP-­‐IgE	   Sigma	  (Poole,	  UK)	  DNP-­‐HAS	   Sigma	  (Poole,	  UK)	  
	   	  
Other	  Reagents	   Source	  Compound	  48/80	   Sigma	  (Poole,	  UK)	  Sodium	  cromoglycate	   Sigma	  (Poole,	  UK)	  Ketotifen	   Sigma	  (Poole,	  UK)	  Prostacyclin	  (PGI2)	   Caymen	  chemicals	  (Cambridge,	  UK)	  Histamine	   Sigma	  	  (Poole,	  UK)	  PMA	   Abcam	  (Cambridge,	  UK)	  LPS	  (from	  Escherichia	  Coli)	   Sigma	  (Poole,	  UK)	  Ionomycin	   Abcam	  (Cambridge,	  UK)	  Glucose	  Oxidase	  	  Thrombin	   Sigma	  (Poole,	  UK)	  Sigma	  (Poole,	  UK)	  	  2.1.2	  Transgenic	  mice	  All	   animal	   experiments	   were	   performed	   with	   ethical	   approval	   from	   Animal	  Welfare	   Ethical	   Review	   Body	   and	   the	   UK	   Home	   Office,	   under	   project	   licenses	  70/8286	  and	  40/3745.	  GPVI-­‐/-­‐,	  platelet	  specific	  CLEC-­‐2	  deficient	  (PF4-­‐cre	  colony)	  and	  CLEC-­‐2fl/fl	  PF4cre	  -­‐	   GPVI	   -­‐/-­‐	  (double	   deficient)	  mice	  were	   used	   in	   the	   laser	   injury	  model.	   Platelet	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factor	  4	  (PF4)	  is	  a	  megakaryocyte-­‐platelet	  lineage	  specific	  marker,	  and	  the	  CLEC-­‐2	  gene	  is	  deleted	  in	  this	  particular	  cell	  lineage	  (Tiedt	  et	  al	  2007).	  Double	  deficient	  mice	  were	  created	  by	  crossing	  GPVI	  constitutive	  KO’s,	  with	  CLEC-­‐2	  floxed	  mice	  further	  generating	  cre+	  and	  cre-­‐	  litters.	  For	   DVT	   experiments	   investigating	   the	   role	   of	   CLEC-­‐2,	   all	   mice	   were	   on	   a	  C57BL/6	   background.	   For	   conditional	   deletion	   on	   CLEC-­‐2	   expression	   from	  platelets,	   4	  week	  old	  Clec1bfl/fl	   x	  Rosa26+ERT2cre	   and	   their	   Clec1bfl/fl	  x	  Rosa26+/+	  control	  littermates	  were	  fed	  with	  a	  tamoxifen	  diet	  TAM	  400	  (400mg	  tamoxifen	  in	  citrate	   form	   per	   Kg	   of	   diet,	   Harlan,	   UK)	   for	   2	   weeks,	   followed	   by	   4	   weeks	   of	  regular	  diet.	  To	   investigate	   the	  role	  of	  podoplanin	  and	  CLEC-­‐2	   in	  DVT,	  mice	  were	  used	  with	  podoplanin	  deleted	   in	  either	  cells	  of	  hematopoietic	  or	  endothelial	  origin.	  Vav1-­‐cre	  pdpnfl/fl	  (hematopoietic	  cell-­‐specific	  knockout)	  and	  Tie2-­‐Cre	  pdpnfl/fl	  (knocks	  out	   podoplanin	   in	   cells	   of	   endothelial	   origin)	  were	   crossed	  with	   pdpnfl/fl	   mice	  with	   Vav1cre+	   and	   Tie2cre+	   mice	   respectively	   (Jackson	   Lab,	   strain	   008863).	  Podocin-­‐cre	   pdpnfl/fl	   mice	   were	   created	   in	   house	   by	   crossing	   pdpnfl/fl	   and	  podocincre+	  mice.	  For	  mast	  cell	  experiments,	  mast	  cell	  deficient	  mice	  Kitw-­‐sh	  and	  Kitw-­‐v	  on	  a	  C57Bl/6	  background	   were	   purchased	   from	   the	   Jackson	   Lab.	   These	   mice	   strains	   have	  different	  mutations	   in	   the	   C-­‐Kit	   receptor,	   leading	   to	   the	   absence	   of	  mast	   cells.	  C57BL/6	  mice	   were	   purchased	   from	   Charles	   River	   used	   for	   experiments	   with	  topical	  application	  of	  histamine	  and	  compound	  48-­‐80.	  For	   all	   experiments	   investigating	   the	   role	   of	   T-­‐cells	   in	   DVT	   both	   nude	   mice	  (absent	  T-­‐cells)	  and	  Rag1-­‐/-­‐	  mice	  (deficient	  in	  B	  and	  T	  lymphocytes)	  were	  used.	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C57Bl/6	  mice	  from	  Charles	  River	  were	  used	  for	  injection	  of	  anti-­‐CD25	  antibody	  (to	  deplete	  T-­‐regulatory	  cells).	  	  2.1.3	  Adoptive	  transfer	  of	  mast	  cells	  into	  Kitw-­‐sh	  mice	  Ten	  millions	  of	  in	  vitro	  differentiated	  MCs	  were	  injected	  into	  3-­‐4	  weeks	  old	  KitW-­‐
sh	  mice	  through	  the	  tail	  vein.	  In	  8	  –	  10	  weeks,	  mice	  were	  subjected	  to	  48	  h	  IVC	  stenosis.	  	  2.1.4	  Mast	  cell	  depletion	  in	  mice	  Mice	  were	  injected	  i.p	  every	  12	  hours	  for	  4	  days	  with	  the	  mast	  cell	  degranulator;	  compound	  48/80	  dissolved	  in	  sterile	  saline.	  Mice	  were	  injected	  with	  200μl	  of	  the	  solution	  according	  to	  the	  following	  protocol:	  day	  1-­‐	  0.6mg/kg,	  day	  2-­‐	  1.0mg/kg,	  day	  3-­‐	  1.2mg/kg	  and	  day	  4,	  2.4mg/kg.	  This	  method	  results	  in	  peritoneal	  mast	  cell	  depletion	   of	   ~84%	   (Carvalho	   M	   et	   al	   2005).	   DVT	   surgery	   (IVC	   stenosis)	   was	  performed	  24	  h	  after	  the	  mice	  received	  their	  last	  injection.	  	  2.1.5	  Mast	  cell	  membrane	  stabilization	  in	  vivo	  Sodium	  cromoglycate	  and	  Ketotifen	  inhibit	  mast	  cell	  degranulation	  by	  acting	  as	  a	  mast	   cell	  membrane	   stabilizers.	  Mice	  were	   injected	   intraperitoneally	   (i.p)	  with	  cromolyn	   (100mg/kg	  body	  weight),	   or	   i.p	  Ketotifen	   (25mg/kg	  body	  weight)	   at	  two	  time	  points;	  24	  h	  and	  30	  min	  prior	  to	  DVT	  surgery	  (IVC	  stenosis).	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2.1.6	  Treatment	  of	  mice	  with	  anti-­‐podoplanin	  antibody	  For	  deep	  vein	  thrombosis	  experiments	  (chapter	  3)	  WT	  littermates	  were	  injected	  with	   an	   anti-­‐podoplanin	   antibody	   (Syrian	   hamster	   anti-­‐mouse,	   clone	   8.1.1)	  twice:	  at	  24	  h	  and	  30	  min	  before	  surgery	  (100μg/mouse	  at	  24	  h	  and	  50μg/mouse	  respectively).	  For	  intravital	  microscopy	  experiments,	  WT	  littermates	  received	  one	  injection	  of	  the	  antibody	  (100μg/mouse)	  immediately	  before	  surgery.	  Control	  mice	  received	  the	   same	   dose	   of	   IgG.	   At	   the	   doses	   stated	   about,	   it	   has	   been	   shown	   that	   this	  antibody	  blocks	  podoplanin	  in	  mice	  for	  at	  least	  48	  hrs.	  
	  
2.2	  Blood	  collection	  2.2.1	  human	  blood	  collection	  Ethical	   approval	   for	   blood	   donation	   from	   healthy	   volunteers	   was	   granted	   by	  Birmingham	   University	   Internal	   Ethical	   Review	   (ERN_11-­‐0175).	   Healthy	  volunteers	   who	   were	   drug	   free	   consented	   to	   the	   collection	   of	   venous	   blood.	  Blood	  was	  drawn	  into	  sodium	  citrate	  (4%	  citrate	  1:9	  ratio)	  or	  into	  EDTA.	  	  	  	  2.2.2	  Mouse	  Blood	  collection	  In	  order	  to	  isolate	  platelets	  for	  transfusion	  into	  clec1bfl/fl	  PF4cre	  mice	  (chapter	  3)	   blood	  was	   collected	   from	   the	   retro-­‐orbital	   plexus	   of	  WT	   syngeneic	   C57Bl/6	  mice,	  and	  stabilized	  in	  sodium	  citrate.	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2.3	  Mouse	  platelet	  preparation	  Blood	   collected	   in	   sodium	   citrate	   was	   centrifuged	   at	   100	   g	   for	   5	   minutes	   to	  obtain	   the	   platelet	   rich	   plasma	   (PRP)	   this	  was	   performed	   in	   a	  microcentrifuge	  (ThermoScientific,	  Paisley,	  UK).	  The	  red	  blood	  cells	  (RBCs)	  were	  sedimented	  by	  centrifugation	  of	  the	  PRP	  along	  with	  the	  top	  layer	  of	  erythrocytes	  at	  100	  g	  for	  3.5	  minutes.	  The	  supernatant	  PRP	  was	  incubated	  with	  prostaglandin	  I2	  (2	  μg/ml,	  5	  min,	   37oc)	   and	   centrifuged	   at	   100	   g	   for	   5	   minutes	   (Vargas	   et	   al	   1982).	   After	  removing	  the	  supernatant	  the	  platelet	  pellet	  was	  then	  resuspended	  in	  Modified	  Tyrode’s	   buffer	   (134mM	   NaCl,	   2.9mM	   KCl,	   0.34mM	   Na2HPO4.	   12H20,	   12mM	  NaHCO3,	   20mM	   HEPES,	   1mM	   MgCl2,	   5mM	   glucose,	   pH	   7.35).	   Platelets	   from	   a	  number	   of	  mice	  were	   pooled	   together	   in	   buffer	   and	   infused	   into	   the	   recipient	  donor	  via	  injection	  into	  the	  tail	  vein.	  
	  
2.4	  Culture	  of	  murine	  bone	  marrow-­‐derived	  mast	  cells	  (BMDMCs)	  Femur	   and	   tibia	   bones	  were	   taken	   from	  mice,	   and	   these	  were	   flushed	   using	   a	  syringe	   containing	   RPMI	   to	   remove	   the	   bone	  marrow	   cells.	   The	   bone	  marrow	  cells	   were	   collected,	   centrifuged	   and	   resuspended	   in	   RPMI	   containing;	   10%	  foetal	  bovine	  serum	  (FBS),	  100U/ml	  penicillin,	  o.1	  mg/ml	  streptomycin,	  25	  mM	  HEPES,	   2	   mM	   L-­‐glutamine,	   1	   mM	   sodium	   pyruvate,	   1mM	   nonessential	  aminoacids	   and	   1	   mM	   MEM	   amino	   acids	   (all	   purchased	   from	   Sigma)	   in	   the	  presence	  of	  5ng/ml	  recombinant	  mouse	  IL_3	  (Peprotech).	  Cells	  were	  maintained	  for	  4	  weeks	  with	  continuous	  enrichment	  for	  non-­‐adherent	  fractions	  of	  mast	  cell	  precursors.	   After	   this	   time	  mast	   cells	   constituted	   over	   90%	   of	   the	   population,	  and	  this	  was	  assessed	  by	  FACS	  staining	  using	  antibodies	  against	  mouse	  FceR1-­‐PE	  (eBioscience,	   clone	   MAR-­‐1)	   and	   CD117(c-­‐Kit)-­‐APC	   (eBioscience,	   clone	   2B8).	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Mast	   cell	   functionality	   was	   checked	   by	   stimulating	   them	   to	   degranulate	   by	  sensitizing	   them	   overnight	   with	   100	   ng/ml	   mouse	   anti-­‐DNP-­‐IgE(sigma),	   they	  were	  then	  washed	  and	  stimulated	  with	  100	  ng/ml	  DNP-­‐HAS	  (sigma)	  for	  1	  h	  (fast	  release)	   or	   6	   h	   (slow	   release).	   To	   monitor	   the	   mediators	   released	   β-­‐hexosaminidase	  activity	  was	  measured	  in	  the	  mast	  cell	  releasates.	  	  	  	  
2.5	  Neutrophil	  isolation	  from	  mouse	  bone	  marrow	  The	   femur	   bones	   were	   taken	   from	   mice,	   and	   using	   a	   25	   gauge	   needle	   were	  flushed	  out	  using	  0.01%	  EDTA	   to	   collect	   the	  marrow.	  The	   cell	   suspension	  was	  then	  passed	  through	  a	  70μm	  filter,	  and	  the	  cells	  were	  then	  spun	  at	  1500	  rpm	  for	  5	  minutes.	   	   The	   supernatant	   was	   discarded	   and	   the	   cells	   resuspended	   in	   1ml	  EDTA.	   Ice-­‐cold	   water	   was	   then	   added	   (4ml)	   to	   lyse	   red	   blood	   cells,	   after	   30	  seconds	   isotonicity	  was	  restored	  by	  adding	  4	  X	  PBS	  (2ml).	  The	  cells	  were	  spun	  again	  at	  1500	  rpm	  for	  5	  minutes,	   the	  supernatant	  discarded	  and	  the	  remaining	  cell	  pellet	  resuspended	  in	  2ml	  EDTA.	  A	  percoll	  gradient	  was	  then	  set	  up	  at	  bands	  of	  72%,	  64%,	  and	  52%	  percoll,	  with	  a	  2ml	   layer	  of	   the	   cell	   suspension	  on	   top.	  The	   gradient	   was	   then	   spun	   at	   1500	   g	   for	   30	   minutes	   to	   separate	   out	   the	  neutrophils.	   The	   neutrophils	   are	   separated	   out	   as	   a	   band	   at	   the	   interface	  between	   72%	   and	   64%	   percoll.	   The	   band	   containing	   the	   neutrophils	   was	  removed	  and	  washed	  to	  remove	  any	  percoll	  by	  spinning	  at	  1500rpm	  using	  PBS.	  The	  wash	  step	  was	  repeated	  twice,	  and	  the	  neutrophil	  cell	  pellet	  resuspended	  in	  1ml	  PBS.	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2.6	  Isolation	  of	  neutrophils	  from	  human	  blood	  	  Human	   blood	   was	   collected	   in	   either	   EDTA	   or	   heparin	   (10U/ml)	   as	   an	  anticoagulant.	  A	   layer	  of	   6	  ml	  Histopaque	  1119	   (Sigma)	  was	   added	   to	   a	   falcon	  tube,	  followed	  by	  a	  layer	  of	  5	  ml	  whole	  blood	  on	  top	  of	  the	  Histopaque.	  This	  was	  then	  spun	  at	  800	  g	  for	  20	  minutes,	  and	  separates	  out	  into	  4	  bands.	  The	  top	  two	  bands	   are	   discarded	   and	   the	   lower	   ‘redish’	   band	   containing	   granulocytes	   and	  some	  erythrocytes	  were	  transferred	  to	  a	  separate	  tube.	  The	  cells	  were	  washed	  in	  PBS	  and	  centrifuged	  for	  10	  minutes	  at	  300	  g.	  A	  100%	  percoll	  solution	  was	  then	  made	  up,	  and	  using	  1x	  PBS	  a	  gradient	  of	  85%,	  80%,	  75%,	  70%	  and	  65%	  percoll	  was	   the	   prepared	   by	   layering	   2	   ml	   of	   each	   solution	   on	   top	   of	   each	   other	   in	  decreasing	   order.	   After	   spinning	   and	   resuspending	   in	   PBS,	   2	   ml	   of	   the	   cell	  solution	  was	  layered	  on	  top	  of	  the	  percoll	  gradient.	  This	  was	  then	  centrifuged	  at	  800	   g	   for	   20	   minutes.	   The	   top	   layer	   and	   most	   of	   the	   65%	   layer	   was	   then	  discarded	  and	  the	  remaining	  layers	  up	  to	  the	  85%	  interphase	  were	  collected	  into	  a	  few	  falcon	  tube.	  The	  cells	  were	  washed	  in	  PBS	  and	  centrifuged	  at	  300	  g	  for	  10	  minutes.	  The	  supernatant	  was	  then	  removed	  and	  the	  cell	  pellet	  resuspended	  in	  PBS.	  	  
2.7	  Animal	  experimentation	  –	  in	  vivo	  models	  	  2.7.1	  Laser	  injury	  model	  of	  the	  cremaster	  muscle	  Male	  mice	  were	  anesthetized	  using	  tribromethanol	  (240	  mg/kg).	  The	  mice	  were	  placed	  in	  the	  supine	  position;	  the	  carotid	  artery	  was	  isolated	  and	  cannulated.	  A	  tracheostomy	  tube	  is	  also	  inserted	  into	  the	  trachea	  to	  help	  the	  mouse	  to	  breath.	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The	   mouse’s	   testicle	   was	   then	   exteriorized	   and	   the	   connective	   tissue	  surrounding	   it	  was	   carefully	   removed	  with	  blunt	   forceps.	  Once	   an	   incision	  has	  then	   been	   made	   along	   the	   midline	   of	   the	   testicle	   the	   cremaster	   can	   then	   be	  carefully	  spread	  and	  pinned	  down	  onto	  a	  circular	  stage.	   	  The	  microvasculature	  can	  then	  be	  visualized	  on	  the	  microscope	  connected	  to	  a	  camera.	  	  	  The	  cremaster	  preparation	  was	  constantly	  kept	  wet	   throughout	   the	  procedure	  using	  a	  warm	  bicarbonate-­‐buffered	  physiological	  salt	  solution	  (PSS)	  prepared	  in	  ultrapure	  H20.	  	  The	  mouse	  was	   injected	   via	   the	   cannulated	   carotid	   artery	  with	   an	   antibody	   to	  fluorescently	   label	   platelets	   (Emfret	   analytics)	   at	   a	   dose	   of	   0.1ug/g.	   Injury	   is	  produced	  in	  both	  arteries	  and	  veins	  by	  targeting	  the	  built	  in	  laser	  to	  ‘shoot’	  at	  the	  vessel	  wall,	  thrombus	  formation	  was	  then	  visualized.	  	  2.7.2	  Intravital	  microscopy	  of	  mesenteric	  vessels	  (ferric	  chloride	  model)	  Mice	  were	  anesthetized	  with	  midazolam	  and	  hypnorm	  (200	  μl	  hypnorm,	  200	  μl	  midazolam,	  400	  μl	  water,	  given	  at	  a	  dose	  of	  10	  μl/g	  body	  weight)	  and	  an	  incision	  was	   made	   along	   the	   abdomen.	   The	   mesentery	   was	   exteriorized	   and	   carefully	  spread	  out	  flat	  so	  both	  arteries	  and	  veins	  could	  be	  visualized.	  A	  paper	  strip	  was	  saturated	   in	   a	  10%	   ferric	   chloride	   solution	  and	  placed	  across	   the	  vessels	   for	  5	  minutes.	   After	   this	   time	   point	   the	   strip	   was	   removed	   and	   observed	   down	   the	  microscope	   for	   either	   40	  min	   (maximum	   cut	   off	   time)	   or	   until	   the	   vessel	   had	  occluded.	   Time	   taken	   for	   the	   vessel	   to	   occlude	   was	   recorded.	   The	   mice	   were	  injected	   retro-­‐orbitally	   with	   a	   platelet-­‐labeling	   antibody	   (1μl	   per	   gram	   body	  weight)	  to	  visualize	  thrombus	  formation	  and	  Rhodamine	  6G	  to	  visualize	  rolling	  leukocytes.	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2.7.3	  Flow	  restriction	  in	  the	  inferior	  vena	  cava	  (IVC):	  a	  model	  of	  DVT	  in	  mice	  The	   established	   flow	   restriction	   model	   of	   DVT	   has	   been	   previously	   described	  (Brill	   et	   al	   2011).	  Mice	  were	   anesthetized	   using	   isoflurane,	   placed	   in	   a	   supine	  position,	   and	   attached	   to	   a	   mask	   with	   a	   constant	   flow	   of	   isoflurane-­‐oxygen	  mixture.	  An	   incision	  was	  made	  along	   the	  midline	  of	   the	  abdomen	  and	   the	  guts	  exteriorized.	  Saline	  was	  applied	  to	  the	  guts	  regularly	  throughout	  the	  experiment	  to	  prevent	  drying	  out.	   	  The	  Inferior	  vena	  cava	  (IVC)	  was	  gently	  separated	  from	  the	  aorta.	  Any	   side	  branches	  were	   closed	  using	  a	  7.0	  polypropylene	   suture.	  To	  achieve	   stenosis	   (partial	   flow	   restriction)	   the	   IVC	  was	   ligated	   over	   a	   30-­‐gauge	  needle	  or	  ‘spacer’.	  The	  suture	  was	  tied	  over	  the	  needle	  and	  then	  the	  needle	  was	  removed,	   this	   achieves	   ~90%	   closure	   of	   the	   vessel	   lumen	   but	   doesn’t	   cause	  endothelial	  injury.	   	  The	  peritoneum	  was	  then	  closed	  using	  a	  6.0	  suture,	  and	  the	  skin	   was	   stapled	   back	   together.	   After	   48	   hours	   the	   mice	   were	   culled	   and	   the	  thrombi,	  if	  they	  developed	  in	  the	  IVC,	  were	  taken	  for	  analysis.	  	  	  2.7.4	  Investigating	  the	  role	  of	  mast	  cells	  using	  the	  IVC	  stenosis	  model	  For	   mast	   cell	   experiments	   (chapter	   4)	   the	   mast	   cell	   degranulator	   compound	  48/80,	  or	  histamine	  was	   topically	   applied	  after	   stenosis.	  The	   IVC	  was	  partially	  closed	  as	  described	  above,	  and	  for	  these	  experiments	  a	  piece	  of	  watmann	  paper	  was	  soaked	  in	  a	  solution	  of	  compound	  48/80(1	  mg/ml),	  histamine	  (100	  mg/ml)	  or	  saline	  as	  a	  control.	  The	  strip	  was	  placed	  on	  the	  IVC	  at	  the	  place	  of	  stenosis	  for	  10	  minutes.	  After	  this,	  the	  paper	  was	  removed	  and	  the	  peritoneum	  and	  skin	  were	  then	  closed	  as	  described	  above.	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2.7.5	  Stasis	  model	  of	  DVT	  In	  order	  to	  achieve	  complete	  stasis	  of	  the	  IVC,	  back	  branches	  and	  side	  branches	  were	   all	   fully	   closed.	   	  Back	  branches	  were	   cauterized,	   and	   this	   achieved	  100%	  closure	  of	  the	  vessel	  lumen.	  The	  rodent	  stasis	  model	  of	  DVT	  has	  been	  described	  before	  elsewhere	  (Henke	  at	  al	  2001).	  Thrombus	  development	  was	  then	  checked	  in	  these	  mice	  24	  h	  post-­‐surgery.	  	  	  2.7.6	  Intravital	  microscopy	  of	  the	  IVC	  	  After	   mice	   had	   undergone	   IVC	   stenosis	   as	   described	   above	   (2.7.3)	   they	   were	  allowed	  to	  recover	  consciousness.	  6	  hours	  after	  surgery,	  they	  were	  anesthetized	  using	  tribomethanol,	  and	  syngenic	  washed	  platelets	  (2.5%	  of	  the	  total	  number	  of	  circulating	   platelets)	   labeled	  with	   calcein	  AM	  were	   injected	   intravenously.	   The	  mouse	  was	  placed	   in	  a	   supine	  position,	   the	   IVC	  exposed	  and	  a	   round	  coverslip	  was	   placed	   on	   top	   of	   the	   IVC.	   Fluorescent	   platelets	   were	   visualized	   1-­‐2	   mm	  below	  (in	  caudal	  direction)	  the	  ligation	  site	  using	  3i	  VIVO-­‐SDC	  confocal	  system,	  with	  Yokogawa	  CSU-­‐10	  and	  Photometrics	  Evolve	  EMCCD	  camera,	  on	  an	  Olympus	  BX61WI	   upright	   microscope.	   The	   air	   objective	   x10	   was	   used,	   and	   focus	   was	  adjusted	  to	  the	  upper	  focal	  plane.	   	  Flow	  was	  recorded	  for	  at	  least	  1-­‐minute	  and	  Fiji/ImageJ	   was	   used	   to	   quantify	   areas	   of	   adhered	   platelets.	   Median-­‐based	  intensity	   projection	   from	   10	   randomly	   chosen	   consecutive	   acquired	   images	  (corresponding	  to	  1	  s)	  was	  employed	  to	  generate	  a	  single	  projected	  image.	  After	  automatic	  set	  of	  threshold,	  total	  area	  of	  adhered	  platelets	  was	  measured	  by	  a	  Fiji	  incorporated	  function	  ‘analyze	  particles’	  using	  image	  J	  software	  (NIH,	  USA).	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2.8	  Immunohistochemistry	  DVT	   thrombi,	   and	  also	   thrombi	   still	   in	   the	   intact	   IVC	  were	  collected	   from	  mice	  and	   fixed	   in	   formalin.	   The	   tissue	   was	   frozen	   in	   OCT	   blocks,	   and	   cryosections	  10μm	   thick	   were	   cut	   and	   mounted	   onto	   polylysine	   adhesion	   slides	  (ThermoScientific	  Paisley,	  UK)	  for	  staining	  and	  stored	  at	  -­‐80oc.	  	  Fluorescent	  staining	  of	  thrombi	  cyrosections	  For	   staining	   for	   podoplanin	   (chapter	   3)	   slides	   were	   removed	   from	   -­‐80oc	   and	  immersed	  in	  ice-­‐cold	  acetone	  for	  10	  minutes.	  After	  leaving	  them	  to	  air	  dry	  for	  15	  minutes,	  they	  were	  blocked	  with	  1%	  BSA,	  5%	  goat	  serum	  in	  0.1%	  Tween	  for	  1h	  at	  room	  temperature	  (RT)	  without	  permeabilization.	  They	  were	  stained	  with	  the	  primary	   antibody:	   hamster	   anti-­‐mouse	   PDPN	   (eBioscience),	   rabbit	   anti-­‐human	  VWF	   (DAKO)	   overnight	   at	   4oC.	   After	   washing,	   Alexa-­‐Fluor	   labeled	   secondary	  antibodies	   (molecular	   probes)	  were	   added	   for	   45	  min	   at	   RT.	   Nuclei	  were	   also	  stained	  using	  ToPro3.	  Staining	   for	  T-­‐cells	  and	  neutrophils	   in	   thrombi	   (chapter	  5)	  was	  performed	   in	  a	  similar	  way	  described	  above.	  But	  slides	  were	  permeabilized	  using	  0.3%	  Triton	  in	  blocking	  buffer	  (3%	  BSA	  in	  PBS),	  washed	  and	  incubated	  in	  blocking	  buffer	  for	  1	  h	  at	  RT.	  Primary	  antibodies	  anti-­‐CD3	  and	  anti-­‐Gr-­‐1	  were	  used	  to	  stain	   for	  T-­‐cells	  and	  neutrophils	  respectively,	  whilst	  anti-­‐CD45	  and	  anti-­‐CD41	  were	  used	  to	  stain	  for	   leukocytes	   and	   platelets	   (Overnight	   at	   4oc).	   The	   next	   day	   secondary	  antibodies	  were	  added	  and	  ToPro3	  was	  used	  to	  stain	  nuclei.	  After	  staining	  images	  were	  taken	  on	  the	  Leica	  confocal	  microscope.	  Scanning	  of	  the	  whole	   thrombus	  was	  performed	  using	  Axio	  Scan.Z1	   (Zeiss)	  and	   the	   images	  were	  analyzed	  using	  Fiji/imageJ.	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2.9	  Western	  blotting	  Thrombi	  were	   taken	   from	  mice	   following	  DVT	  surgery	   (IVC	   stenosis),	   the	   IVCs	  were	  also	   taken	  separately	   from	  control	  and	  operated	  mice,	  and	  these	  were	  all	  lysed.	   50	   μg	   of	   total	   protein	  was	   loaded	   per	   lane	   and	   separated	   in	   SDS-­‐PAGE.	  Protein	   gels	   were	   blotted	   to	   PVC	   membranes	   in	   Turbo	   Blot	   Transfer	   system.	  They	  were	  blocked	  with	  3%	  BSA	  and	  developed	  using	   the	  primary	   antibodies:	  hamster	   anti-­‐mouse	   PDPN	   (eBioscience,	   clone	   8.1.1)	   and	   mouse	   anti-­‐tubulin	  (Sigma).	  Densitometry	  of	  bands	  was	  performed	  and	  results	  were	  normalized	  to	  the	  density	  of	  the	  corresponding	  tubulin	  band.	  	  
	  
2.10	  Measuring	  soluble	  P-­‐selectin	  The	  content	  of	  soluble	  P-­‐selectin	  (sP-­‐selectin)	  in	  plasma	  samples	  (chapter	  3)	  was	  measured	   using	   an	   ELISA	   kit	   (R&D	   systems)	   in	   accordance	   to	   manufacturer’s	  instructions.	  	  	  
2.11	  Activating	  neutrophils	  for	  NET	  formation	  A	  24	  –well	  cell	  culture	  plate	  was	  prepared	  by	  placing	  a	  13mm	  round	  glass	  cover	  slip	   into	   each	   well,	   or	   wells	   were	   coated	   in	   Poly-­‐lysine	   (Sigma).	   2x105	  	  neutrophils	   in	   RPMI	   were	   seeded	   into	   each	   well	   and	   allowed	   to	   settle	   in	   an	  incubator	   at	   37oC	   for	   1	   h.	   In	   order	   to	   activate	   the	   neutrophils	   to	   produce	  neutrophil	  extracellular	  traps	  (NETs)	  they	  were	  treated	  with	  the	  following;	  PMA	  (100	  nM),	  LPS	  (100	  μg/ml),	   ionomycin	  (20	  μM)	  or	  glucose	  oxidase	  (10	  mU/ml)	  and	  were	  incubated	  at	  37oC	  for	  3	  h.	  After	  3	  h	  incubation,	  the	  cells	  were	  stained	  with	  DNA	  dye	  DAPI,	  fixed	  in	  2%	  formalin	  and	  NET	  formation	  was	  analyzed	  using	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a	  fluorescent	  microscope.	  In	  some	  wells,	  cells	  were	  also	  stained	  for	  citrullinated	  histone	  H3	  using	  an	  anti-­‐Histone	  H3	  antibody	  (Abcam)	  	  2.11.1	  Quantitative	  analysis	  of	  NET	  formation	  The	   extracellular	   chromatin	   was	   stained	   with	   DAPI	   and	   the	   area	   covered	   by	  NETs	   was	   quantified	   by	   the	   ImageJ	   software.	   The	   result	   was	   expressed	   as	   a	  percentage	  of	  the	  area	  covered	  by	  NETs	  to	  the	  total	  area	  of	  each	  view	  field.	  	  	  
2.12	  Statistics	  The	   sample	   size	   estimation	   was	   performed	   using	   G*Power	   3.1.9.2	   (Faul	   et	   al	  2007)	   Based	   on	   our	   current	   experience	   with	   the	   model	   at	   the	   University	   of	  Birmingham,	   thrombi	  prevalence	   in	  control	  mice	  after	  48	  h	   IVC	  stenosis	  varies	  between	  60	  –	  100%.	  Therefore,	  we	  assumed	  the	  expected	  difference	  (effect	  size)	  between	  experimental	  groups	  to	  be	  at	  least	  0.8,	  error	  probability	  of	  0.1	  and	  the	  desired	   power	   value	   of	   0.80.	   The	   calculated	   sample	   size	   for	   DVT	   experiments	  was	  15	  animals	  per	  group.	  In	  cases	  when	  statistical	  significance	  was	  achieved	  we	  used	  lower	  numbers	  of	  animals.	  	  Non-­‐parametric	   results	   (e.g.,	   length	  and	  weight	  of	   thrombi)	  were	   compared	  by	  the	  Mann-­‐Whitney	  test.	  Parametric	  data	  (e.g.,	  area	  covered	  by	  adhered	  platelets)	  were	  compared	  using	  two-­‐tailed	  unpaired	  Student’s	  t-­‐test	  or	  (in	  case	  of	  multiple	  comparisons)	   ANOVA.	   Thrombosis	   prevalence	   was	   compared	   using	   a	  contingency	   table	   followed	   by	   the	   Fisher’s	   exact	   square	   method.	   Difference	  between	  experimental	  groups	  was	  considered	  significant	  at	  p<0.05	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Chapter	  3	  
	  
The	  role	  of	  GPVI	  and	  CLEC-­‐2	  in	  deep	  
vein	  thrombosis	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3.1	  Introduction	   	  Platelets	   are	   critical	   in	   hemostasis,	   and	   upon	   vascular	   injury	   are	   the	   first	   cells	  arriving	  at	   the	  site	  of	  damage.	  They	  are	  able	   to	  adhere	   to	   the	  vascular	  wall	  via	  exposed	  subendothelial	  proteins	  such	  as	  collagen,	  and	  after	  capture	  of	  VWF	  they	  become	   activated	   and	   develop	   a	   preliminary	   clot,	   sealing	   the	   damaged	   area	   in	  the	  vessel	  wall.	  Platelets	  become	  activated	  by	  the	  binding	  of	  various	  stimulatory	  ligands	  such	  as	  collagen	   and	   ADP,	   which	   triggers	   a	   signaling	   cascade,	   ultimately	   leading	   to	   a	  conformational	  change	   in	  αIIβb3	  (known	  as	   inside	  out	  signaling).	  This	   leads	   to	  platelet	   aggregation	   and	   formation	   of	   the	   primary	   clot.	   Thrombin	   then	   acts	   to	  converts	  fibrinogen	  into	  fibrin;	  this	  polymerized	  fibrin	  along	  with	  platelets	  forms	  a	   hemostatic	   plug.	   Clot	   retraction,	   or	   ‘shrinking’	   then	   usually	   occurs	   over	   a	  period	  of	  days	  as	  a	  result	  of	  fibrin	  capturing	  coagulation	  factors	  from	  platelets.	  	  	  One	   such	   mechanism	   of	   platelet	   activation	   is	   implemented	   through	   receptors	  containing	  an	  ITAM	  or	  structurally	  similar	  (hem)ITAM	  domains.	  Murine	  platelets	  express	  the	  receptors	  GPVI	  and	  CLEC-­‐2,	  which	  are	  ITAM	  and	  (hem)ITAM	  bearing	  receptors	  respectively.	  In	  contrast	  human	  platelet	  also	  have	  an	  additional	  ITAM-­‐containing	  protein	   FcΥRIIA	   (Bergmeier	   2006).	   	   GPVI	   binds	   collagen	   and	   fibrin,	  whereas	  CLEC-­‐2	  is	  a	  receptor	  for	  podoplanin.	  Until	  now,	  podoplanin	  expression	  has	   been	   detected	   in	   various	   cell	   types,	   such	   as	   lymphatic	   endothelium	   and	  tumor	  cells,	  but	  not	   in	   the	  blood	  vasculature	  (Suzuki-­‐Inoue	  2010;	  Leyre	  2013),	  with	  the	  exception	  of	  recent	  findings	  by	  Hitchcock	  et	  al	  (2015).	  The	  physiological	  role	  of	  podoplanin	  (PDPN)	  that	  has	  been	  most	  well	  researched	  is	   its	   interaction	   with	   CLEC-­‐2	   on	   platelets	   leading	   to	   their	   aggregation	   and	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activation	   (Astarita	   2012).	   Podoplanin	   is	   also	   known	   to	   play	   a	   critical	   role	   in	  development	   of	   organs	   such	   as	   the	   heart	   and	   lungs,	   as	   well	   as	   the	   lymphatic	  system,	   demonstrated	   in	   studies	   using	   podoplanin-­‐deficient	  mice.	  Much	   of	   the	  understanding	  of	  podoplanin	  and	  its	  mechanisms	  has	  come	  from	  studying	  tumor	  cells,	   which	   upregulate	   PDPN	   expression	   during	   epithelial-­‐mesenchymal	  transition,	  this	  up-­‐regulation	  is	  linked	  to	  increased	  metastasis	  (Astarita	  2012).	  	  We	   already	   know	   that	   podoplanin	   plays	   a	   critical	   role	   in	   development.	   It	   is	  expressed	  in	  the	  developing	  mouse	  embryo	  on	  day	  E9,	  but	  over	  time	  is	  restricted	  to	  certain	  cells	  such	  as	  alveolar	  type	  1	  and	  lymphoid	  cells	  by	  adult	  stage,	  and	  is	  critical	   in	   the	   development	   of	   these	   organs	   (Astarita	   2012).	   Deficiency	   in	  podoplanin	   in	  mice	  embryos	   is	   lethal,	   and	   they	  often	  die	   in	  utero,	  or	  ones	   that	  survive	   die	   within	   a	   few	   days	   after	   birth	   (Mahtab	   et	   al	   2008).	   Recent	   critical	  findings	  were	  that	  podoplanin	  and	  CLEC-­‐2	  drive	  cerebrovascular	  patterning,	  and	  are	  important	  in	  vascular	  integrity	  maintenance	  during	  development	  (Lowe	  et	  al	  2014).	   Lowe	   et	   al	   found	   that	   podoplanin	   expression	   on	   the	   neuro-­‐epithelium	  (epithelium	   of	   the	   neural	   tube)	   was	   important	   in	   interacting	   with	   CLEC-­‐2	   on	  platelets.	  This	  interaction	  mediated	  platelet	  adhesion,	  aggregation	  and	  secretion,	  which	  ultimately	  guided	  the	  maturation	  of	  the	  developing	  vasculature,	  supported	  vascular	   integrity	   and	   prevented	   hemorrhage.	   They	   showed	   that	   constitutive	  deletion	  of	  CLEC-­‐2	  or	  podoplanin	  led	  to	  a	  similar	  pattern	  of	  hemorrhaging	  from	  E11.5,	  this	  was	  associated	  with	  defective	  angiogenesis	  of	  cerebral	  blood	  vessels.	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Both	   CLEC-­‐2	   and	   GPVI	   receptors	   play	   a	   role	   in	   platelet	   activation	   and	   arterial	  thrombosis.	  Platelet	  activation	  by	  diesel	  exhaust	  particles	  has	  been	  shown	  to	  be	  dependent	  on	  both	  receptors	  (Alshehri	  2015).	  CLEC-­‐2	  has	  been	  reported	  to	  play	  a	  role	  in	  ferric	  chloride-­‐	  and	  photochemically	  induced	   thrombosis	   in	   mesenteric	   arterioles	   (May	   2009;	   Suzuki-­‐Inoue	   2010).	  May	   et	   al	   showed	   that	   whilst	   CLEC-­‐2	   deficient	   platelets	   displayed	   normal	  adhesion	   under	   flow,	   subsequent	   aggregate	   formation	   was	   dramatically	  defective	  in	  both	  vivo	  and	  in	  vitro.	  They	  report	  that	  CLEC-­‐2	  deficient	  mice	  have	  increased	   tail-­‐bleeding	   times,	   and	   increased	   protection	   from	   occlusive	   arterial	  thrombus	   formation.	   Demonstrating	   an	   essential	   role	   of	   CLEC-­‐2	   in	   hemostasis	  and	   thrombosis.	   Similar	   findings	   were	   reported	   by	   Ozaki	   et	   al	   (2010).	   They	  suggest	   that	   CLEC-­‐2	   is	   required	   for	   the	   ‘platelet	   piling	   up’	   process,	   which	  eventually	  leads	  to	  stable	  thrombus	  formation.	  They	  demonstrate	  that	  single	  cell	  adhesion	  appeared	  to	  be	  normal	  on	  a	  collagen	  surface,	  but	  thrombus	  formation	  was	  severely	  impaired.	  Both	  groups	  show	  that	  arterial	  thrombus	  formation	  was	  prevented	  in	  CLEC-­‐2	  knock	  out	  mice,	  with	  Nieswandt	  et	  al	  (2009)	  also	  reporting	  this	  leads	  to	  increased	  tail	  bleeding	  times,	  although	  this	  increase	  in	  bleeding	  time	  is	  unlikely	  as	  many	  others	  have	  not	  confirmed	  this	  (Watson	  2010,	  Bender	  2013).	  However,	  any	  evidence	   that	  CLEC-­‐2	  may	  also	  play	  a	   role	   in	  venous	   thrombosis	  has	  been	  lacking.	  Massberg	   et	   al.	   used	   a	   ferric	   chloride	   injury	  model	   to	   demonstrate	   that	   GPVI-­‐deficient	   mice	   have	   longer	   time	   to	   occlusion	   with	   some	   mice	   showing	   no	  occlusion	   at	   all	   (Massberg	   2003).	   Bender	   et	   al.	   (2013)	   and	   Alshehri	   (2015)	  reported	   impaired	   thrombus	   stability	   after	   ferric	   chloride	   application	   in	   mice	  after	  GPVI-­‐depletion	  or	  in	  GPVI-­‐deficient	  mice.	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Recently,	  it	  was	  found	  that	  GPVI	  can	  bind	  fibrin	  and	  mediate	  via	  this	  mechanism	  various	   platelet	   activation	   events	   (Mammadova-­‐Bach	   2015;	   Alshehri	   2015).	  Kalia	   and	   co-­‐authors	   reported	   severely	   impaired	   thrombus	   development	   in	  FcRg-­‐deficient	   mice	   that	   don’t	   express	   GPVI	   (Kalia	   2008).	   In	   contrast,	   others	  have	  shown	  that	  GPVI	  plays	  a	   less	  significant	  role.	  Eckly	  et	  al	   (2011)	  using	   the	  same	  laser	  injury	  model	  to	  induce	  arterial	  thrombosis,	  showed	  that	  deficiency	  in	  both	  GPVI	  and	  β1	  integrin’s	  did	  not	  suppress	  thrombus	  formation.	  	  The	  role	  that	  GPVI	  may	  play	  in	  venous	  thrombosis	  had	  not	  previously	  been	  reported.	  	  The	   ITAM	  and	  (hem)ITAM	  receptors	  seem	  to	  play	  only	  minimal	  role	   in	  normal	  hemostasis.	   One	   report	   demonstrated	   that	   CLEC-­‐2	   deficiency	   prolonged	   tail-­‐bleeding	   time	   (May	   2009),	   whereas	   others	   found	   an	   insignificant	   trend	   or	   no	  increased	  blood	  loss	  (Suzuki-­‐Inoue	  2010;	  Moroi,	  Watson;	  Hughes	  2010;	  Bender	  2013).	  Lack	  of	  GPVI	  did	  not	  result	  in	  impaired	  hemostasis	  in	  one	  study	  (Lockyer	  et	   al	   2006)	   and	   led	   to	   a	   moderately	   prolonged	   bleeding	   time	   in	   another	   one	  (Nieswandt	   2001).	   However,	   deficiency	   in	   both	   CLEC-­‐2	   and	   GPVI,	   results	   in	  severely	  impaired	  both	  hemostasis	  and	  thrombosis	  (Bender	  2013).	  	  In	   addition	   to	   their	   hemostatic	   roles,	   platelets	   play	   a	   role	   in	   a	   number	  of	   non-­‐hemostatic	  processes.	  Platelets	  have	  been	  shown	  to	  maintain	  vascular	   integrity	  and	  prevent	  hemorrhage	  under	  inflammatory	  conditions	  (Goerge	  2008;	  Gros	  et	  al	  2014;	  Lee	  et	  al	  2016).	  Recent	  studies	  demonstrated	  the	  critical	  role	  of	  platelet	  (hem)ITAM	  receptors	  in	  this	  process	  (Boulaftali	  2013).	  They	  demonstrated	  that	  inhibition	   of	   GPVI,	   or	   deficiency	   in	   CLEC-­‐2,	   partially	   reduced	   the	   ability	   of	  platelets	  to	  maintain	  vascular	  integrity	  in	  both	  LPS	  induced	  inflammation	  in	  the	  lung,	   and	   immune-­‐complex	   induced	   inflammation	   in	   the	   skin.	   Hillgruber	   et	   al	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found	  that	  neutrophil	  diapedesis	  across	  the	  endothelial	  barrier	  was	  the	  primary	  cause	  of	  hemorrhage	  under	  thrombocytopenic	  conditions.	  	  GPVI	  and	  CLEC-­‐2	  are	  critical	   in	   prevention	   of	   this	   inflammatory	   induced	  hemorrhage.	   	   Thus	   platelet	  ITAM	   and	   hem(ITAM)	   receptors	   modulate	   the	   functional	   state	   of	   the	  endothelium	  in	  inflammation.	  	  Deep	  vein	  thrombosis	  (DVT)	  and	  pulmonary	  embolism,	  the	  fatal	  consequence	  of	  clots	   detaching	   and	   moving	   to	   the	   lungs	   are	   designated	   together	   as	   venous	  thromboembolism	  (VTE).	  This	  disease	  poses	  a	  disastrous	  health	  problem,	  with	  around	  1	  per	  1000	  adults	  developing	  the	  disease	  annually	  (Cushman	  2007).	  	  The	  prevalence	  of	  VTE	  has	  not	  significantly	  decreased	  over	  the	  past	  2.5	  decades	  (Heit	  	  2008;	  Heit	  2006)	  despite	  new	  prophylactic	  methods,	  suggesting	  new	  therapeutic	  targets	  are	  needed	  for	  this	  disease.	  	  	  Although	  the	  mechanisms	  of	  venous	  thrombosis	  are	  not	  completely	  understood,	  we	  know	  it	  occurs	  without	  endothelial	  denudation	  (Sevitte	  1974).	  In	  contrast	  to	  arterial	   thrombosis,	   which	   is	   based	   on	   platelet	   accumulation	   at	   the	   site	   of	  ruptured	   atherosclerotic	   plaques.	   One	   of	   the	   main	   causes	   of	   DVT,	   with	   the	  exception	  of	  cancer	  or	  trauma	  related	  DVT,	  is	  stagnant	  blood	  flow	  in	  the	  venous	  valves,	   a	   component	   of	   the	   Virchow’s	   triad	   (Esmon	   2009).	   As	   a	   result	   of	   flow	  distortion,	  local	  hypoxia	  may	  develop	  and	  result	  in	  an	  even	  more	  pro-­‐thrombotic	  environment.	  At	  static	  conditions,	  blood	  which	  pools	  inside	  valvular	  pockets	  has	  been	   shown	   to	   become	   rapidly	   hypoxic,	   with	   pO2	   returning	   back	   to	   normal	  levels	   when	   flow	   is	   restored	   and	   blood	   exchange	   in	   pockets	   become	   quicker	  again	   (Hamer	   et	   al	   1981).	   	   We	   know	   that	   hypoxia	   can	   induce	   the	   release	   of	  Weibel-­‐Palade	  bodies	  (WPB),	  which	  are	  the	  storage	  granules	  of	  endothelial	  cells,	  containing	   P-­‐selectin	   and	   VWF,	   implemented	   in	   inflammation	   (Pinsky	   et	   al	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1996).	   	   Brill	   et	   al	   (2011)	   recently	   showed	   that	   the	   release	   of	   WPB’s	   and	   cell	  recruitment	  to	  the	  vessel	  wall	  are	  critical	  in	  a	  murine	  model	  of	  DVT.	  	  Thus,	   DVT	   develops	   in	   a	   similar	   way	   to	   sterile	   inflammation,	   with	   initiation	  depending	  on	   the	   recruitment	  of	   immune	  cells	  and	  platelets	   to	   the	  vessel	  wall.	  Because	   of	   this,	   DVT	   can	   be	   described	   as	   a	   thromboinflammatory	   disease	   or	  ‘immunothrombosis’	   (Engelmann	   &	   Massberg	   2013),	   as	   venous	   thrombosis	   is	  closely	  linked	  with	  inflammatory	  mechanisms.	  We	  therefore	  hypothesized	  that	  the	  platelet	  receptors	  responsible	  for	  regulating	  the	  functional	  properties	  of	  the	  vessel	  wall	  during	  inflammation	  could	  also	  play	  a	  role	  in	  DVT.	  	  In	   this	   chapter,	   we	   used	   both	   the	   laser	   injury	  model	   and	   the	   well-­‐established	  model	   of	   IVC	   stenosis	   (which	  mimics	   the	   flow	   distortion	   in	   venous	   valves),	   to	  investigate	  the	  roles	  of	  GPVI	  and	  CLEC-­‐2	  in	  venous	  and	  arterial	  thrombosis	  in	  a	  comparative	   aspect.	   The	  main	   aims	   of	   this	   chapter	   are	   (i)	   to	   investigate	   if	   the	  absence	   of	   GPVI	   affects	   thrombosis	   (ii)	   to	   investigate	   the	   role	   of	   CLEC-­‐2	   in	  thrombosis,	   and	   (iii)	   to	   determine	   if	   podoplanin	   expression	   in	   the	   vessel	   wall	  correlates	  with	  the	  degree	  of	  thrombosis.	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3.2	  Results	  	  3.2.1	  CLEC-­‐2	  plays	  a	  critical	  role	  in	  DVT	  formation	  in	  mice	  
	  To	  investigate	  the	  role	  of	  CLEC-­‐2	  in	  venous	  thrombosis	  (DVT)	  we	  used	  the	  well-­‐established	  model	   of	   IVC	   stenosis,	   described	   in	   methods	   2.7.3.	   48	   hours	   after	  mice	  underwent	  DVT	  surgery	  (stenosis	  application),	  mice	  with	  an	  inducible	  loss	  of	   CLEC-­‐2	   (methods)	   were	   protected	   from	   developing	   DVT	   in	   100%	   of	   cases,	  compared	  to	  60%	  of	  the	  mice	  in	  the	  littermate	  control	  group,	  which	  did	  produce	  a	  thrombus	  (P	  <	  0.03	  figure	  3.1	  A).	   	  The	  frequency	  of	  thrombosis	  in	  the	  control	  group	   was	   similar	   to	   what	   is	   normally	   seen	   in	   C57BL6	   mice	   using	   this	   same	  model,	  where	  it	  can	  range	  from	  60	  to	  100%.	  No	  phenotype	  was	  observed	  in	  the	  stasis	  model	  (data	  not	  shown).	  In	  order	  to	  test	  if	  this	  role	  was	  specific	  to	  CLEC-­‐2	  found	  of	  platelets,	  we	  used	  the	  same	  model	  on	  platelet-­‐specific	  knock	  out	  mice	  `and	   their	   littermate	   controls.	   In	   the	   control	   group,	   81%	   of	   mice	   produced	   a	  thrombus	  post	  stenosis,	  compared	  to	  38%	  in	  the	  knockout	  mice	  (p<0.05,	  figure	  3.1B).	   We	   then	   aimed	   to	   investigate	   if	   this	   response	   could	   be	   reversed.	   We	  transfused	   the	  knockout	  mice	  with	  WT	  platelets	   (to	  around	  50%	  of	   circulating	  platelets)	  and	  thrombosis	  was	  restored	  in	  these	  mice	  (as	  shown	  in	  figure	  3.1B),	  further	  supporting	  the	  role	  of	  platelet	  specific	  CLEC-­‐2	  in	  DVT.	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Figure	  3.1	  -­‐	  CLEC-­‐2	  exacerbates	  DVT	  
	  Panels	   i,	   ii	   and	   iii	   show	   thrombus	   weight,	   thrombus	   length	   and	   thrombosis	  prevalence	  respectively.	  Each	  dot	  represents	  one	  mouse,	  with	  the	  horizontal	  line	  representing	   the	   median	   A)	   Thrombus	   prevalence	   after	   48	   hour	   IVC	   stenosis	  application	   in	  clec1bfl/fl	  xRosa26+/creERT2	   (n=10)	  and	  Clec1bfl/fl	   littermates	  (n=9).	  B)	  Thrombus	  prevalence	  48	  hours	  after	   IVC	  stenosis	   in	  Clec1bfl/fl	  PF4-­‐Cre	  mice	  (n=13)	   that	   received	   a	   transfusion	   of	   WT	   platelets	   (8	   x	   108)	   and	   control	  littermates	   (n=11).	   Of	   importance	   is	   the	   restoration	   of	   thrombus	   after	  transfusion	  of	  WT	  platelets.	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3.2.2	  GPVI	  is	  not	  critical	  for	  DVT	  formation	  in	  mice	  	  
	  To	  investigate	  if	  GPVI	  also	  played	  a	  critical	  role	  in	  venous	  thrombosis	  similarly	  to	  CLEC-­‐2,	  we	  again	  used	  the	  IVC	  stenosis	  model	  to	  replicate	  DVT	  in	  GPVI	  KO	  mice.	  After	  48	  hours	  stenosis,	  30%	  of	  GPVI	  deficient	  mice	  produced	  a	  thrombus	  compared	  to	  69%	  of	  control	  mice	  (p	  =	  0.07,	  figure	  3.2).	  Whilst	  this	  data	  suggests	  that	  GPVI	  may	  play	  some	  role,	  it	  does	  not	  appear	  to	  be	  significant	  in	  leading	  to	  DVT.	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3.2.3	  Mice	  without	  CLEC-­‐2	  have	  a	  reduced	  recruitment	  of	  platelets	  to	  the	  vessel	  wall	  	  It	  had	  previously	  been	  reported	  that	  endothelial	  activation,	  secretion	  of	  Weibel-­‐Palade	   bodies	   and	   the	   resulting	   accumulation	   of	   platelets	   and	   immune	   cells	   at	  the	   vessel	  wall	   are	   critical	   events	   in	   the	  development	  of	  DVT	   (Brill	   et	   al	   2011,	  Von	  Bruhl	  et	  al	  2012).	  	  We	  therefore	  used	  intravital	  microscopy	  to	  assess	  platelet	  recruitment	  to	  the	  vessel	  wall	  in	  CLEC-­‐2	  deficient	  and	  WT	  mice.	  Mice	  underwent	  stenosis	   of	   the	   IVC	   as	   previously	   described,	   6h	   post	   stenosis	   application	  mice	  were	  then	  opened	  and	  intravital	  microscopy	  was	  performed	  (methods	  2.7.5).	  	  In	  WT	  controls,	  a	  large	  proportion	  of	  platelets	  were	  adhered	  to	  the	  vessel	  wall	  and	  remained	   fixed	  during	  the	  period	  of	  observation	  (supplementary	  videos	  can	  be	  observed	  on	  request).	  	  The	  average	  area	  covered	  by	  adhered	  platelets	  was	  7.8	  ±	  0.7%	  of	  the	  view	  field	  (Figure	  3.3	  A).	  In	  contrast,	  in	  CLEC-­‐2	  deficient	  mice	  most	  platelets	   rapidly	   flowed	   away	   in	   the	   direction	   of	   the	   blood	   flow	   and	   did	   not	  firmly	  attach	  to	  the	  IVC	  wall.	   	  The	  average	  area	  covered	  by	  adhered	  platelets	  in	  mice	  lacking	  CLEC-­‐2	  was	  1.3	  ±	  0.4%	  (Figure	  3B,	  P	  <	  0.003).	  This	  implies	  that	  the	  release	   of	   platelet-­‐recruiting	   molecules	   from	   the	   endothelium	   is	   strongly	  reduced	  in	  the	  absence	  of	  CLEC-­‐2.	  	  We	  then	  further	  investigated	  if	  podoplanin,	  the	  ligand	  for	  CLEC-­‐2,	  was	  involved	  in	  this	  process.	  A	  specific	  neutralizing	  antibody	  was	  used	  to	  inhibit	  podoplanin.	  In	  these	  mice,	  a	  similar	  phenotype	  was	  observed	  to	  that	  in	  the	  CLEC-­‐2	  deficient	  mice.	   The	   area	   covered	   by	   adhered	   platelets	   in	   IgG	   controls	   was	   6.5 ± 1.3%,	  compared	   to	   an	   area	   of	   2.6	   ± 0.4%	   after	   antibody	   administration;	   this	   was	  significant	  at	  P<	  0.03	  (Figure	  3.3	  C	  &	  D).	  Together	  these	  results	  suggest	  that	  both	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CLEC-­‐2	  and	  podoplanin	  expression	  are	  required	   for	  platelet	   recruitment	   to	   the	  vessel	  wall,	  potentially	  through	  direct	  binding.	  	  
	  
	  
Figure	  3.3-­‐	  Stenosis-­‐induced	  platelet	  recruitment	  is	  reduced	  in	  the	  absence	  
of	  CLEC-­‐2	  and	  inhibition	  of	  podoplanin	  
	  Clec1bfl/flxRosa26+/creERT2	  and	  their	  Clec1bfl/fl	  littermates	  underwent	  IVC	  stenosis	  for	  6h.	  Intravital	  microscopy	  was	  then	  used	  to	  visualize	  the	  deposition	  of	  infused	  fluorescently	   labeled	   syngeneic	   platelets	   on	   the	   IVC	   wall.	   A)	   Representative	  image	   of	   adhered	   platelets	   (in	   white)	   B)	   The	   percent	   of	   area	   covered	   by	  immobilized	  platelets.	  This	  was	  significantly	  different	  at	  p<0.003	  (n=4,	  data	  are	  presented	  as	  mean	  ±	  SEM).	  	  C)	  WT	  mice	   administered	   an	   podoplanin	   neutralizing	   antibody	   (100μg/mouse,	  I.V)	  or	  an	  IgG	  control	  prior	  to	  surgery.	  D)	  Shows	  the	  percent	  of	  area	  covered	  by	  recruited	  platelets	  	  (n=	  4	  for	  both	  group)	  this	  was	  significant	  at	  p<	  0.03.	  	  
(Performed	  in	  collaboration	  with	  A.Brill)	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p < 0.003  





























α-PDPN IgG α-PDPN IgG 
C D p < 0.03  p  .   
p < 0. 03  
WT	  100μm	  
100μm	  
	  	   68	  
3.2.4	  Podoplanin	  is	  expressed	  in	  the	  IVC	  vessel	  wall	  	  As	  both	  CLEC-­‐2	  and	  podoplanin	  deficient	  mice	  produced	  a	  similar	  phenotype	  in	  terms	   of	   platelet	   recruitment	   to	   the	   vessel	  wall	   during	   stenosis,	  we	  wanted	   to	  investigate	   this	  role	   that	   they	  may	  both	  play	   in	  venous	   thrombosis	   further.	  We	  tested	   to	   see	   if	   podoplanin	   was	   expressed	   in	   the	   IVC	   wall.	   Immunostaining	  showed	  that	  there	  was	  a	  low,	  but	  definative	  level	  of	  podoplanin	  expression	  in	  the	  vessel	  wall	   of	   sham-­‐operated	   IVC’s	   (Figure	  3.4	  Ai).	   Podoplanin	   expression	  was	  substantially	   increased	   in	   IVCs	   after	   thrombosis	   development,	   shown	   by	   the	  staining	   in	   Fig	   3.4	   ii.	   	   Podoplanin	   was	   expressed	   exclusively	   under	   the	  endothelium	  of	   the	  vessel	   (abluminal	   side)	  but	  not	   in	   the	   thrombus	   itself.	   	  The	  endothelium	  of	  the	  vessel	  wall	  was	  distinguished	  by	  positive	  staining	  for	  PECAM-­‐1	  (CD31)	   	   (Figure	  3.4	  Ci)	  and	   the	   thrombus	  was	  observed	  by	  staining	   for	  VWF	  (Figure	  3.4	  Cii).	  During	  DVT,	  platelets	  can	  penetrate	  the	  vessel	  wall	  and	  they	  may	  then	   come	   into	   contact	   with	   sub	   endothelial	   matrix	   components,	   potentially	  podoplanin	  (Figure	  3.4	  D).	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Figure	  3.4	  -­‐	  	  IVC	  wall	  expresses	  podoplanin	  
	  
Ai)	   shows	   the	   low	   level	  of	   staining	   for	  podoplanin	   (green)	   in	   a	   sham-­‐operated	  IVC,	   compared	   to	   in	   Aii)	   where	   staining	   for	   podoplanin	   is	   much	   higher	   in	   a	  thrombosed	   IVC.	   ‘L’	   designates	   lumen,	   ‘T’	   designates	   thrombus.	   	  B)	   Shows	   the	  whole	  thrombus	  after	  48	  h	  of	  stenosis	  inside	  the	  IVC	  
Ci	  &	  Cii)	  Show	  that	  podoplnain	  expression	  is	   localized	  to	  the	  abluminal	  side	  of	  the	  endothelium	  and	  not	   in	   the	   thrombus	   itself,	  by	   staining	   for	  PECAM-­‐1	   (red)	  and	  VWF	  respectively	  (red).	  	  
D)	  Shows	  staining	  of	  IVC	  with	  a	  thrombus	  after	  48	  h	  stenosis.	  Arrowheads	  show	  where	  platelets	  area	  able	  to	  penetrate	  the	  vessel	  wall	  and	  localize	  in	  the	  vicinity	  to	  podoplanin.	  	  A,	  scale	  bar	  is	  50μm;	  B,	  Scale	  bar	  is	  500μm;	  C	  scale	  bar	  is	  100μm,	  D	  scale	  bar	  is	  10μm.	  Representative	  images	  are	  taken	  n	  =	  3	  with	  10-­‐15	  images	  from	  each	  IVC.	  (Performed	  in	  collaboration	  with	  T.Ponomaryov)	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  3.2.5	  Podoplanin	  expression	  in	  the	  IVC	  wall	  increases	  with	  thrombosis	  
	  To	   confirm	   the	   presence	   of	   podoplanin	   in	   the	   vascular	   wall	   further,	   we	  performed	  western	  blotting	  (methods	  2.9).	  	  Podoplanin	  was	  not	  found	  in	  4	  out	  of	  the	  5	  thrombi	  tested	  as	  shown	  in	  Figure	  3.5A,	  with	  only	  very	  small	  trace	  amounts	  found	   in	   the	   fifth	   thrombus,	   but	   this	   can	   probably	   be	   attributed	   to	   the	   fact	  remnants	  of	  the	  vessel	  wall	  may	  have	  contaminated	  the	  sample.	  Podoplanin	  was	  detected	   in	   the	   intact	   IVC	   (sham-­‐operated)	   that	   had	   not	   undergone	   stenosis,	  suggesting	  it	   is	  constitutively	  expressed.	  This	   is	  shown	  in	  Fig	  3.5	  B	  in	  the	  three	  left	  lanes.	  After	  48	  h	  stenosis,	  leading	  to	  thrombosis,	  this	  resulted	  in	  an	  increased	  podoplanin	  expression	  in	  the	  IVC	  wall	  compared	  to	  non-­‐thrombosed	  IVC’s.	  This	  was	   measured	   by	   band	   densitometry	   and	   normalized	   corresponding	   to	   the	  control	  (tubulin)	  shown	  in	  Figure	  3.5	  B.	   	  Podoplanin	  expression	  increased	  from	  3.6	  ±	  1.3	  arbitrary	  units	  in	  the	  sham	  operated	  IVC,	  to	  33.4	  ±	  8.3	  arbitrary	  units	  in	  the	  IVC	  with	  a	  thrombus	  post	  stenosis.	  Furthermore,	  we	  also	  measured	  podoplanin	  expression	  in	  the	  vessel	  wall	  of	  IVC’s	  that	  underwent	  stenosis	  for	  the	  same	  time	  period,	  but	  did	  not	  result	  in	  thrombus	  formation.	  We	   found	  that	  podoplanin	  expression	  demonstrated	  an	   insignificant	  trend	  to	  increase	  in	  the	  intact	  IVC,	  but	  to	  a	  lesser	  extent	  that	  in	  those	  IVCs	  that	  resulted	  in	  thrombosis	  after	  stenosis.	  Podoplanin	  expression	  in	  the	  stenosed	  IVC	  without	   a	   thrombus	   increased	   to	   14.3	   	   ±	   4.7	   a.u	   compared	   to	   the	   intact	   IVC	  (p=0.053	  Figure	  3.5	  C).	   	  Therefore,	  podoplanin	  expression	   in	   the	   IVC	  wall	  does	  increase	   as	   a	   result	   of	   flow	   restriction,	   but	   the	   magnitude	   of	   this	   increase	  corresponds	  to	  the	  event	  of	  thrombosis.	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Figure	  3.5	  –	  Podoplanin	  expression	  in	  the	  IVC	  wall	  increases	  with	  
thrombosis	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3.2.6	  Testing	  of	  anti-­‐podoplanin	  antibody	  
	  To	  test	  the	  specificity	  of	  the	  anti-­‐podoplanin	  antibody,	  and	  therefore	  to	  allow	  us	  to	  be	  confident	  that	  the	  results	  described	  below	  (3.2.7)	  were	  due	  to	  podoplanin	  deletion,	   staining	   was	   performed.	   Specificity	   of	   the	   antibody	  was	   proven	   by	   a	  high	   amount	   of	   staining	   in	   the	   kidneys	   of	   WT	   mice	   (Podoplanin	   staining	   in	  green).	   	   No	   staining	   in	  mice	   with	   tissue-­‐specific	   podoplanin	   deficiency	   (figure	  3.6).	  
Figure	  3.6	  Testing	  of	  the	  anti-­‐podoplanin	  antibody	  
	  Shows	  positive	  staining	  for	  podoplanin	  (green)	  in	  the	  kidneys	  of	  WT	  mice	  but	  no	  staining	   in	   the	   tissue	   specific	   podoplanin	   deficient	   mice.	   (Performed	   in	  
collaboration	  with	  T.Ponomaryov)	  	  	  	  
	  
WT Podocin-cre pdpnfl/fl 
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3.2.7	  Anti-­‐podoplanin	  antibody	  decreases	  size	  of	  thrombi	  in	  murine	  DVT	  
	  In	   order	   to	   determine	   the	   role	   podoplanin	   plays	   in	  DVT	  we	   treated	  mice	  with	  anti-­‐podoplanin	   blocking	   antibody	   (clone	  8.1.1)	   as	   described	   in	  methods	  2.1.6.	  There	   was	   no	   significant	   difference	   in	   thrombosis	   prevalence	   between	   IgG	  treated	   littermate	   control	   mice	   and	   antibody-­‐treated	   mice,	   at	   82%	   and	   90%	  respectively	  (shown	  in	   figure	  3.6	   iii).	   	  As	  no	  significant	  difference	  was	   found	  in	  thrombosis	   prevalence	   we	   could	   then	   compare	   thrombus	   size	   using	   a	   non-­‐parametric	   Mann-­‐Whitney	   test.	   Mice	   treated	   with	   the	   podoplanin-­‐blocking	  antibody	  had	  significantly	  lower	  weight,	  and	  length	  of	  thrombi	  compared	  to	  IgG	  treated	   mice	   (p<0.02	   shown	   in	   figure	   3.6	   i	   &	   ii).	   This	   result	   suggests	   that	  podoplanin	  is	  also	  involved	  in	  DVT,	  affecting	  thrombus	  propagation	  rather	  than	  thrombus	  initiation.	  
Figure	   3.7	   –	   lack	   of	   podoplanin	   results	   in	   decreased	   thrombus	   size	   in	  
































































Figure 5. Anti-podoplanin antibody decreases size of thrombi in murine DVT. 
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blocking	   antibody	   (clone	   8.1.1)	   had	   a	   decreased	   thrombus	   size	   and	   weight	  compared	  to	  mice	  that	  received	  and	  IgG	  control	  (p	  <	  0.02).	  Lines	  in	  the	  dot	  plots	  represent	  median.	  N=10	  (IgG),	  N=11	  (antibody)	  iii)	  Shows	  that	  there	  was	  no	  significant	  difference	  in	  thrombosis	  prevalence.	  	  
(Performed	  in	  collaboration	  with	  A.Brill)	  
	  	  	  3.2.8	  -­‐	  Deletion	  of	  podoplanin	  in	  hematopoietic	  or	  endothelial	  cells	  does	  not	  prevent	  DVT	  	  We	  have	  shown	  that	  podoplanin	  is	  expressed	  in	  the	  IVC	  wall	  and	  that	  this	  is	  up-­‐	  regulated	   during	   DVT,	   with	   increased	   expression	   correlating	   to	   the	   degree	   of	  thrombosis.	   The	   source	   of	   this	   podoplanin	   is	   however	   yet	   to	   be	   identified.	  We	  next	   aimed	   to	   check	   whether	   the	   source	   of	   this	   podoplanin	   could	   be	  hematopoietic	   or	   endothelial	   cells.	   	   We	   therefore	   used	   mice	   with	   podoplanin	  specifically	  knocked	  out	  on	   these	   cells.	  Vav1cre+pdpnfl/fl	   is	   a	  hematopoietic	   cell-­‐specific	   knockout,	   while	   Tie2Cre+pdpnfl/fl	  mice	   have	   podoplanin	   knocked	   out	   in	  cells	   of	   endothelial	   origin	   (mice	   described	   in	   methods	   2.1.2).	   Both	   strains	  showed	  no	  phenotype	  in	  the	  DVT	  stenosis	  model,	  with	  thrombosis	  prevalence	  48	  h	  after	  IVC	  stenosis	  application,	  being	  comparable	  to	  normal	  WTs	  (Figure	  3.8.1).	  Furthermore,	   mice	   lacking	   podoplanin	   in	   these	   cells	   still	   retained	   podoplanin	  expression	  in	  the	  vessel	  wall,	  as	  shown	  in	  Figure	  3.8.2	  Suggesting	  that	  these	  cells	  are	  not	  the	  source.	  The	  ubiquitous	  podoplanin	  staining	  in	  the	  IVCs	  of	  these	  mice	  also	   showed	   a	   ‘layer-­‐like’	   pattern	   and	   rules	   out	   lymphatic	   vessels	   and	   lymph	  nodes	  as	  a	  potential	  source.	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Figure	   3.8.1	   -­‐	   DVT	   is	   not	   prevented	   after	   podoplanin	   deletion	   in	  
hematopoietic	  or	  endothelial	  cells	  




































































Supplemental Figure 3. Deletion of podoplanin in haematopoietic or endothelial cells does not 
prevent DVT.  
A, Vav1cre+ pdpnfl/fl and B, Tie2cre+ pdpnfl/fl mic  were subjected to 48 h IVC stenosis n parallel 
with their cre- littermates. i, thrombus weight; ii, thrombus length; iii, thrombosis prevalence. Line 
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Supplemental Figure 2. Deletion of podoplanin in haematopoietic or endothelial cells does not 
prevent its expression in the IVC. 
IVCs with thrombi after 48 h stenosis were stained for PECAM-1 (red) and podoplanin (green). 
Nuclei are in blue. Representative stainings from A, Vav1cre+ pdpnfl/fl and B, Tie2cre+ pdpnfl/fl mice. 





















Figure	  3.8.2	  -­‐	  Deletion	  of	  podoplanin	  in	  hematopoietic	  or	  endothelial	  cells	  
does	  not	  prevent	  its	  expression	  in	  the	  IVC	  
	  IVCs	   with	   thrombi	   after	   48	   h	   stenosis	   were	   stained	   for	   PECAM-­‐1	   (red)	   and	  podoplanin	   (green).	  Representative	   images	   taken	   from	  N=3.	  Nuclei	  are	   in	  blue.	  Representative	  staining’s	   from	  A,	  pdpnfl/flVav1cre+	   	  and	  B,	  pdpnfl/flTie2cre+	  shows	  podoplanin	   staining	   (Green)	   in	   the	   vessel	   walls	   of	  mice	   lacking	   podoplanin	   in	  hematopoietic	   cells,	   and	   endothelial	   cells.	   (Performed	   in	   collaboration	   with	  
T.Ponomaryov)	  	  
	  3.2.9	  Lack	  of	  GPVI	  but	  not	  CLEC-­‐2	  impairs	  thrombus	  formation	  after	  laser	  injury	  	  
	  
	  To	  study	  whether	  the	  differential	  roles	  of	  CLEC-­‐2	  and	  GPVI	  in	  DVT	  are	  specific	  to	  venous	  thrombosis	  or	  may	  be	  expanded	  to	  other	  endothelial	  activation-­‐triggered	  thrombosis	  models,	  we	  next	  used	  the	  model	  of	  laser	  stimulation	  of	  arterioles	  in	  the	   cremaster	   muscle.	   Despite	   different	   thrombus	   composition	   (platelets	  constitute	   major	   component	   of	   a	   thrombus	   after	   laser	   injury	   (Celi	   2002),	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whereas	   in	  DVT,	   thrombi	   largely	   consist	   of	   red	   blood	   cells	   and	   fibrin),	   in	   both	  models,	   endothelial	   activation	   rather	   than	   denudation	   and	   injury,	   initiates	  thrombus	   development	   (Furie	   2015).	   Different	   patterns	   of	   thrombus	  development	  are	  depicted	  in	  Figure	  3.9	  (graphs	  on	  the	  right	  side)	  as	  a	  function	  of	  integral	   fluorescence	   intensity	   of	   time.	   In	   control	   mice,	   despite	   some	   natural	  variability	   in	   size,	   thrombi	   developed	   within	   1-­‐2	   min	   and	   were	   always	   3-­‐dimentional	  (Figure	  3.9).	  Similar	  thrombi	  were	  observed	  in	  mice	  lacking	  CLEC-­‐2.	  Animals,	  deficient	  for	  GPVI,	  demonstrated	  a	  phenotype,	  when	  thrombi	  started	  to	  develop	   but	   were	   unstable	   and	   constantly	   embolized.	   The	   resulting	   thrombus	  remained	  two-­‐dimensional	  with	  a	  layer	  of	  platelets	  adhered	  to	  the	  site	  of	  injury	  but	   no	   thrombus	   propagation	   was	   observed.	   Combined	   deficiency	   of	   both	  receptors	  gave	  a	  phenotype	  similar	  to	  deficiency	  of	  GPVI	  only	  (movies	  available	  on	   request).	   Thus,	   absence	   of	   CLEC-­‐2	   is	   dispensable	   for	   laser-­‐induced	  thrombosis,	  whereas	  GPVI	  is	  required	  for	  thrombus	  stability	  in	  this	  model.	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Figure	   3.9	   –	   lack	   of	   GPVI,	   but	   not	   CLEC-­‐2	   impairs	   thrombus	   formation	   in	  
mice	  following	  laser	  injury	  	  	  	  Fluorescent	   platelet-­‐labeling	   antibody	   (green)	   was	   infused	   intravenously	   and	  thrombosis	  was	  induced	  by	  laser	  impulse	  in	  cremaster	  muscle	  arterioles	  of	  mice	  deficient	   for	   CLEC-­‐2,	   GPVI,	   both	   receptors	   or	   WT	   controls.	   Thrombus	  development	  was	   recorded;	   integral	   fluorescence	   intensity	  was	   calculated	   and	  presented	   as	   a	   function	   of	   time	   (graphs).	   Representative	   images	   demonstrate	  thrombi	   at	   different	   time	   points	   (above).	   DKO	   stands	   for	   double	   knockouts.	  White	  lines	  delineate	  the	  vessel.	  Note	  the	  difference	  in	  the	  pattern	  of	  thrombus	  development	  between	  WT/CLEC-­‐2-­‐deficient	  and	  GPVI/double-­‐deficient	  mice.	  
Figure 5. Lack of GPVI but not CLEC-2 impairs thrombosis after laser injury 
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3.3	  Discussion	  	  This	  study	  demonstrates	   the	  differential	   roles	   that	   ITAM	  receptors	  CLEC-­‐2	  and	  GPVI	   play	   in	   thrombosis.	   We	   show	   that	   mice	   deficient	   in	   GPVI	   had	   only	   an	  insignificant	   trend	   towards	   decreased	   DVT	   prevalence.	   	  Whereas	  mice	   lacking	  CLEC-­‐2	  were	  protected	  against	  DVT,	  whilst	  this	  resulted	  in	  complete	  protection	  in	   CLEC-­‐2	   knockouts,	   those	   mice	   with	   a	   specific	   platelet	   CLEC-­‐2	   knocked	   out	  showed	  a	  partial,	  but	  a	  significant	  protection	  from	  DVT	  development.	  	  This	   dramatic	   effect	   of	   CLEC-­‐2	   deficiency	   is	   unlikely	   to	   be	   related	   to	   impaired	  platelet-­‐platelet	   interactions	   because	   laser-­‐induced	   thrombosis	   in	   these	   mice	  was	   intact.	   Laser-­‐initiated	   thrombosis	   absolutely	   depends	   on	   platelet	  aggregation	   because	   platelet	   accumulation	   can	   be	   prevented	   by	   a	   GPIIb-­‐IIIa	  inhibitor	  eptifibatide	  (Atkinson	  et	  al	  2010).	  Neutrophils	   have	   also	   been	   suggested	   to	   express	   CLEC-­‐2	   in	   some	   studies,	  however	   others	   have	   reported	   this	   is	   not	   the	   case,	   and	   remains	   controversial	  (Kerrigan	  et	  al	  2009;	  Lowe	  et	  al	  2015).	  Our	  results	  showing	  that	  platelet-­‐specific	  knockout	  mice	  have	  reduced	  thrombosis	  prevalence,	  suggests	  that	  platelet	  CLEC-­‐2	  plays	  a	  role	  in	  DVT	  initiation.	  As	  can	  be	  seen	  in	  the	  results,	  the	  median	  thrombus	  size	  in	  the	  WT	  littermates	  of	  the	  Clec1bfl/fl	  	  x	  Rosa26+/-­‐	  and	  the	  Clec1bfl/fl	  Pf4	  cre+	  varies	  slightly.	  The	  reason	  for	  this	  is	  unclear	  but	  could	  be	  attributed	  to	  a	  number	  of	  factors	  such	  as	  treatment	  with	  tamoxifen,	  or	  that	  the	  mice	  carry	  different	  transgenes.	  	  It	   may	   seem	   reasonable	   to	   hypothesize	   that	   because	   the	   platelet	   specific	  knockout	  mice	   present	  with	   blood-­‐lymphatic	  mixing,	   that	   this	   could	   somehow	  contribute	   to	   the	   fact	   they	   show	   reduced	   thrombosis.	   However,	   we	   show	   that	  thrombosis	  is	  restored	  in	  the	  Clec1bfl/fl	  Pf4	  cre+	  mice	  following	  transfusion	  of	  WT	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platelets;	  despite	   the	   fact	   they	  still	  show	  blood-­‐lymphatic	  mixing.	  Furthermore,	  the	  Clec1bfl/fl	  	  x	  Rosa26+/-­‐	  inducible	  knockouts	   show	  an	  even	  greater	  phenotype	  than	   the	   platelet	   specific	   knockouts,	   and	   these	  mice	   do	   not	   have	   the	   defect	   in	  blood-­‐lymphatic	  mixing.	  	  It	  had	  been	  previously	  shown	  that	  a	  shift	  in	  the	  state	  of	  the	  endothelium	  (one	  of	  the	  factors	  in	  Virchow’s	  triad)	  to	  a	  proinflammatory	  state,	  and	  the	  consequential	  release	  of	  WPB	  and	  recruitment	  of	  platelets	  and	  leukocytes	  to	  the	  vessel	  wall	  is	  a	  crucial	  step	  in	  the	  formation	  of	  deep	  vein	  thrombosis	  (Brill	  et	  al	  2011).	  Meaning	  that	   the	  mechanisms	  of	  DVT	   initiation	  and	  development	  are	  similar	   to	   those	   in	  sterile	  inflammation.	  We	  know	  that	  platelets	  are	  predominately	  recruited	  to	  the	  vessel	  wall	  in	  DVT	  as	  a	   result	   of	   VWF	   secretion	   by	   WPB’s.	   A	   deficiency	   in	   CLEC-­‐2	   prevented	   this	  platelet	   accumulation	   at	   the	   IVC	   wall	   after	   stenosis,	   at	   the	   stage	   preceding	  thrombus	   development	   (shown	   in	   figure	   3.3A).	   This	   observation	   suggests	   that	  the	  endothelium	  may	  remain	  quiescent	  under	  the	  conditions	  normally	  triggering	  thrombosis	   in	   the	   presence	   of	   CLEC-­‐2	   i.e.	   endothelial	   activation	   is	   suppressed.	  This	   suggests	   that	   platelets,	   in	   a	   CLEC-­‐2	   –	   dependent	   fashion,	   either	   directly	  interact	  with	  the	  vessel	  wall	  modifying	   its	   functional	  properties,	  or	  secrete	  and	  agent	  mediating	  this	  effect.	  It	  is	  likely	  that	  this	  direct	  interaction	  between	  CLEC-­‐2	  and	  the	  vessel	  wall	  is	  crucial	  for	  platelet	  recruitment	  and	  thrombosis	  initiation.	  	  This	  direct	  interaction	  between	  CLEC-­‐2	  and	  the	  vessel	  wall	  may	  occur	  not	  only	  at	  the	   endothelial	   surface,	   but	   also	   at	   sites	   of	   endothelial	   junctions.	   As	   platelets	  penetrate	   the	   vessel	  wall	   during	   thrombosis,	   they	  might	   also	   interact	  with	   cell	  types	  other	  than	  the	  endothelium.	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Stenosis	  of	  the	  IVC	  results	  in	  the	  formation	  of	  a	  ‘bulb’	  where	  the	  vessel	  has	  been	  compressed,	   in	  which	   there	  will	   be	   a	   low	   flow	   rate	  with	  highly	   distorted	   flow.	  Blood	  pressure	   is	   also	   increased	   in	   this	   region.	  This	   could	   cause	   local	  hypoxia,	  and	  potentially	  up	  regulate	  podoplanin	  expression	  in	  the	  vessel	  wall,	  as	  has	  been	  demonstrated	   previously	   in	   other	   tissues	   (Kolenda	   et	   al	   2011).	   These	   factors	  described	   above,	   along	   with	   local	   hypoxia,	   could	   result	   in	   the	   loosening	   of	  endothelial	   cell-­‐cell	   junctions	   allowing	   platelet	   CLEC-­‐2	   to	   interact	   with	  podoplanin,	  or	  another	  possible	   ligand.	  Podoplanin	  up-­‐regulation	  may	  not	  only	  be	   a	   cause	   of	   thrombosis,	   but	   it	   could	   also	   occur	   as	   a	   result	   of	   thrombus	  formation,	  while	   it	   is	  possible	   that	   they	  both	  processes	  work	   in	   tandem	  and	   in	  fact	  form	  a	  positive	  feedback	  loop.	  This	  anti-­‐thrombotic	  phenotype	  we	  observed	  in	  the	  stenosis	  model,	  was	  not	  seen	  when	  we	  repeated	  the	  same	  method	  using	  the	  complete	  stasis	  model.	  This	  could	  be	  attributed	  to	  the	  fact	  that	  thrombosis	  in	  the	  stasis	  model	  is	  a	  result	  of	  tissue	  factor	   driven	   blood	   coagulation	   (Day	   et	   al	   2005),	   and	   the	   change	   in	   the	   pro-­‐inflammatory	   state	   of	   the	   endothelium,	   which	   appears	   to	   be	   so	   crucial	   after	  partial	  occlusion,	  is	  less	  important	  in	  this	  model.	  	  	  It	   has	  been	   reported	   that	  CLEC-­‐2	  and	  GPVI	  play	  a	   role	   in	  maintaining	  vascular	  integrity	  under	  inflammatory	  conditions	  (Goerge	  et	  al	  2008).	  And	  it	  was	  shown	  that	  platelets	  lacking	  these	  ITAM	  receptors	  were	  unable	  to	  prevent	  hemorrhage	  (Bergmeier	  2006).	   Therefore	   ITAM	   receptors,	   in	  particular	  CLEC-­‐2,	   are	   able	   to	  modify	   the	   properties	   of	   the	   endothelium,	   which	   has	   a	   central	   role	   in	   DVT	  development.	   Although	   the	   mechanism,	   through	   which	   platelet	   (hem)ITAM	  receptors	   implement	   this	   function,	   is	   still	   unclear,	   it	   might	   be	   involved	   in	   the	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decreased	  endothelial	  ability	  to	  recruit	  cells	  and	  protection	  against	  DVT	  in	  CLEC-­‐2-­‐deficient	  mice.	  A	   similar	  niche	   role	  of	  CLEC-­‐2,	  which	   is	   again	   independent	  of	  GPVI,	  has	  been	  shown	  in	  Salmonella	  infection-­‐induced	  thrombosis	  (Hitchcock	  et	  al	   2015).	   They	   demonstrate	   a	   link	   between	   infection,	   inflammation	   and	  thrombosis,	   following	   bacterial	   infection	   in	   the	   liver,	   podoplanin	   expressing	  monocyte-­‐lineage	  cells	  accumulate.	  As	  a	  result	  of	  bacteremia	  and	  inflammation,	  vascular	   endothelial	   cells	   become	   damaged,	   exposing	   platelets	   to	   these	  podoplanin-­‐expressing	  cells,	  leading	  to	  a	  thrombotic	  response	  (Hitchcock	  2015).	  	  Given	   that	   DVT	   may	   be	   considered	   a	   thromboinflammatory	   disease,	   the	  prothrombotic	   effect	   we	   have	   shown	   for	   CLEC-­‐2	   may	   be	   mediated	   by	  neutrophils.	   It	   has	   been	   shown	   that	   flow	   restriction	   in	   the	   IVC,	   which	   results	  from	  stenosis,	   can	   lead	   to	   increased	  expression	  of	  CCL2	  and	  CXCL1,	   trafficking	  agents	   which	   attract	   and	   activate	   neutrophils	   (Von	   Bruhl	   et	   al	   2012).	   It	   has	  recently	   been	   discovered	   that	   platelets	   protect	   the	   vessel	   wall	   from	  inflammatory	  bleeding,	  part	  of	  the	  mechanism	  for	  this	  includes	  the	  prevention	  of	  deleterious	   neutrophil	   diapedesis	   (Goerge	   et	   al	   2008).	   It	   has	   also	   been	  demonstrated	  that	  CLEC-­‐2	  and	  podoplanin	  are	  able	  to	  secure	  the	  vessel	  wall	   in	  high	   endothelial	   venules	   during	   lymphocyte	   transmigration	   in	   lymph	   nodes	  (Herzog	   et	   al	   2013).	   Platelets	   are	   therefore	   known	   to	   support	   leukocyte	  recruitment	  to	  the	  vascular	  wall	  through	  various	  mechanisms,	  such	  as	  releasing	  chemoattractants	   or	   acting	   as	   a	   bridge	   between	   activated	   endothelium	   and	  leukocytes.	  Platelets	  potentiate	  the	  recruitment	  of	   leukocytes	  to	  the	  vessel	  wall	  during	  early	  stages	  of	  DVT	  development.	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Leukocytes	  not	  only	  modulate	  physiological	  properties	  of	  the	  vascular	  wall,	  but	  they	   also	   play	   a	   role	   in	   the	   pathogenesis	   of	   venous	   thrombosis	   through	   the	  release	  of	  Neutrophil	  Extracellular	  Traps	  (NETs)	  (Brill	  2012,	  Fuchs	  et	  al	  2012).	  NETs	   act	   as	   a	   scaffold	   to	   stabilize	   the	   thrombus	   and	   provide	   a	   surface	   for	   the	  activation	  of	  coagulation	  factors	  (Massberg	  2017).	  	  The	  decreased	  attachment	  of	  platelets	  at	  the	  IVC	  wall	  following	  stenosis	  in	  CLEC-­‐2	  deficient	  mice	  could	  impair	  leukocyte	   recruitment,	   and	  could	  be	  a	   factor	   contributing	   to	  protection	  against	  DVT	  in	  these	  mice.	  	  As	   previously	   stated,	   DVT	   can	   be	   considered	   a	   thromboinflammatory	   disease.	  Other	   studies	   have	   supported	   the	   role	   of	   CLEC-­‐2	   in	   thromboinflammatory	  settings.	   It	   was	   shown	   that	   after	   infection	   with	   salmonella,	   a	   high	   level	   of	  thrombosis	   develops	   in	   the	   liver	   of	   control	   mice,	   but	   markedly	   decreased	   in	  CLEC-­‐2	  deficient	  mice	  (Hitchcock	  et	  al	  2015).	  Thrombosis	  induced	  by	  salmonella	  was	   dependent	   entirely	   on	   CLEC-­‐2	   and	   similarly	   in	   our	   experiments,	   GPVI	   did	  not	   contribute	   to	   DVT	   with	   mice	   lacking	   this	   receptor	   only	   showing	   an	  insignificant	  trend	  towards	  decreased	  DVT	  prevalence.	  	  These	  results	  align	  with	  our	  results,	  and	  assume	  that	  CLEC-­‐2	  plays	  an	  important	  role	  in	  venous	  thrombosis	  under	  septic	  or	  aseptic	  inflammatory	  conditions,	  and	  GPVI	  plays	  a	  less	  important	  role.	  	  Currently,	  the	  only	  known	  natural	   ligand	  for	  CLEC-­‐2	  is	  podoplanin,	  but	  this	  has	  not	   previously	   been	   shown	   to	   be	   expressed	   in	   the	   vascular	   wall.	   It	   is	   already	  known	  podoplanin	  is	  expressed	  in	  the	  lymphatic	  endothelium,	  kidney	  podocytes	  and	  type	  1	  alveolar	  lung	  cells	  (Suzuki	  et	  al	  2010).	  Recently,	  it	  was	  shown	  to	  be	  up	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regulated	  in	  the	  tissues	  next	  to	  the	  blood	  vasculature	  after	  salmonella	  infection	  (Hitchcock	  et	  al	  2015).	  Our	   results	  demonstrate	   that	  podoplanin	   is	   expressed	   in	   the	   IVC	  wall,	   staining	  shows	  that	  it	  is	  located	  in	  the	  vicinity	  immediately	  below	  the	  endothelium,	  which	  is	   similar	   to	   the	   salmonella-­‐induced	   pattern.	   We	   show	   that	   podoplanin	   is	  constitutively	  expressed	  in	  the	  intact	  IVC	  vessel	  wall,	  whilst	  it	  is	  dramatically	  up	  regulated	   following	   IVC	   stenosis.	   Furthermore,	   podoplanin	   expression	   was	  further	   increased	   if	   stenosis	   of	   the	   IVC	   resulted	   in	   thrombosis,	   and	  was	  much	  higher	  than	  in	  those	  IVCs	  post	  stenosis	  where	  thrombi	  did	  not	  develop.	  It	  is	  not	  clear	   whether	   increased	   podoplanin	   is	   a	   cause	   or	   consequence	   of	   thrombosis,	  although	  this	  result	  indirectly	  suggests	  that	  podoplanin	  in	  the	  IVC	  wall	  is	  related	  to	  DVT.	  We	  can	  speculate	   that	  platelets	  accumulate	  at	   the	   IVC	  vessel	  wall	  as	  a	  result	  of	  their	   exposure	   to	   podoplanin,	   which	   would	   in	   turn	   result	   in	   further	   platelet	  recruitment	  and	  activation,	  leading	  to	  further	  increased	  podoplanin	  expression.	  	  We	   performed	   further	   experiments	   to	   verify	   a	   causal	   relationship	   between	  podoplanin	   expression	   in	   the	   vessel	   wall	   and	   DVT,	   using	   an	   anti-­‐podoplanin	  inhibitory	   antibody.	   	   While	   it	   is	   not	   clear	   how	   to	   antibody	   penetrates	   the	  endothelial	  monolayer,	   to	  get	  to	  podoplanin	  found	  on	  the	  abluminal	  side	  of	   the	  endothelium	   we	   can	   make	   a	   suggestion.	   It	   is	   plausible	   that	   increased	   blood	  pressure	  allows	  the	  vessel	  wall	  to	  stretch,	  which	  in	  turn	  allows	  endothelial	  gaps	  to	   widen	   allowing	   the	   antibody	   to	   make	   contact	   with	   the	   podoplanin	   in	   the	  vessel	  wall.	  	  Administration	   of	   the	   anti-­‐podoplanin	   antibody	   resulted	   in	   smaller	   size	   of	  thrombi,	  while	  thrombosis	  prevalence	  remained	  the	  same	  as	  in	  control	  mice.	  The	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fact	   that	   IgG	   control	   mice	   and	   the	   mice	   administered	   the	   antibody	   had	  comparable	   thrombosis	   prevalence,	   implies	   that	   podoplanin	   is	   implicated	   in	  thrombus	  propagation	  rather	  than	  its	  initiation.	  Because	  absence	  of	  CLEC-­‐2	  and	  absence	   of	   podoplanin	   produce	   different	   (though	   both	   antithrombotic)	  phenotypes,	  we	  cannot	  say	  categorically	  that	  they	  work	  together	  as	  a	  receptor-­‐ligand	  couple	  in	  this	  process.	  Other	  mechanisms	   cannot	  be	   excluded.	   For	   example,	   it	   is	   possible	   that	  CLEC-­‐2	  binds	   to	   another	   unidentified	   ligand,	   not	   podoplanin.	   And	   that	   platelets	   still	  interact	  will	   the	  vessel	  wall	  via	  this	  alternative	  mechanism	  when	  podoplanin	   is	  neutralized	  with	  the	  antibody,	  but	  platelet	  activation	  is	  impaired	  which	  results	  in	  reduced	  thrombus	  growth.	  Alternatively,	  we	  cannot	  exclude	  the	  possibility	  that	  the	  antibody	  may	  not	  100%	  block	  podoplanin	  in	  vivo.	  	  The	   question	   still	   remains	   as	   to	   what	   is	   the	   source	   of	   podoplanin	   in	   the	   IVC	  vessel	   wall.	   We	   have	   however	   been	   able	   to	   rule	   out	   a	   number	   of	   potential	  options.	   We	   have	   shown	   that	   it	   is	   unlikely	   to	   be	   from	   hematopoietic	   or	  endothelial	   cell	   origin,	   since	  mice	  with	   podoplanin	   knocked	   out	   specifically	   on	  these	  cells	   still	   retained	  podoplanin	  expression	   in	   the	  vessel	  wall	   (figure	  3.8.2)	  and	  DVT	  formation	  in	  these	  mice	  was	  normal.	  Another	   potential	   source	   of	   podoplanin	   in	   the	   vessel	   wall	   could	   be	   from	  fibroblastic	   cells.	   It	   has	   previously	   been	   shown	   that	   fibroblastic	   reticular	   cells	  surrounding	  high	  endothelial	  venules	  highly	  expressed	  podoplanin	  (Herzog	  et	  al	  Nature	  2013).	   It	  has	  also	  been	  shown	  to	  be	  expressed	  on	  myofibroblasts	  of	  the	  prostate	  and	  in	  cancer-­‐associated	  fibroblasts	  (Schacht	  et	  al	  2005).	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Whilst	   a	   less	   likely	   option,	   as	   the	   venous	   wall	   only	   contains	   small	   amounts,	  vascular	   smooth	   muscle	   cells	   (VSMC)	   cannot	   be	   ruled	   out	   as	   a	   potential	  contributor	   to	   venous	   thrombosis.	   In	   addition	   to	   podoplanin,	   VSMCs	   express	  another	   potential	   CLEC-­‐2	   ligand,	   S100A13	   (Inoue	   et	   al	   2015).	   This	   ligand	  becomes	   highly	   expressed	   of	   VSMC	   that	   are	   exposed	   to	   oxidative	   stress.	   This	  could	   potentially	   happen	   in	   the	   IVC	   during	   stenosis	   as	   a	   result	   of	   the	   local	  hypoxia.	  	  Our	   results	   show	   that	   lack	   of	   another	   ITAM	   receptor,	   GPVI	   did	   not	   lead	   to	  protection	   against	   DVT.	   	   However	   GPVI	   deficient	  mice	   showed	   poor	   thrombus	  stability	   in	   the	   laser	   injury	   model	   (figure	   9),	   which	   is	   consistent	   with	   other	  group’s	  findings,	  where	  GPVI	  has	  been	  shown	  to	  play	  a	  role	  in	  a	  photochemical	  injury	   model	   (Marjoram	   et	   al	   2014).	   Interestingly,	   mice	   lacking	   both	   ITAM	  receptors,	  GPVI	  and	  CLEC-­‐2,	  have	  shown	  a	  sever	  defect	  in	  both	  thrombosis	  and	  hemostasis	  (Nieswandt	  2009),	  which	  indicates	  that	  combined	  inhibition	  of	  both	  receptors	  is	  not	  a	  beneficial	  anti-­‐thrombotic	  strategy.	  Several	  groups	  have	  not	  observed	  this	  same	  anti-­‐thrombotic	  phenotype	  in	  GPVI	  deficient	   mice.	   The	   group	   of	   Dubois	   et	   al	   (2006)	   did	   not	   report	   impaired	  thrombus	   development	   in	   the	   laser	   injury	   model.	   This	   discrepancy	   could	  however	  be	  attributed	  to	  the	  fact	  that	  we	  used	  different	  mouse	  strains.	  Dubois	  et	  al	  used	  FcR-­‐γ	  null	  mice,	  which	  lack	  platelet	  surface	  GPVI,	  whereas	  we	  used	  GPVI	  knockouts,	  and	  these	  receptors	  have	  previously	  been	  shown	  to	  produce	  different	  results	   in	   various	   models.	   For	   example	   lack	   of	   GPVI	   affects	   carotid	   artery	  occlusion,	  but	  absence	  of	  FcRγ	  does	  not	   (Marjoram	  et	  al	  2014).	  Whilst	  another	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group	  reported	  a	  strong	  antithrombotic	  phenotype	  in	  FcRγ-­‐	  deficient	  mice	  (Kalia	  et	  al	  2008)	  It	  has	  recently	  been	   identified	   that	  GPVI	  not	  only	  binds	   to	  collagen,	  but	  also	   to	  fibrinogen,	  leading	  to	  platelet	  activation	  (Alshehri	  et	  al	  2015,	  Mammadova-­‐Bach	  et	  al	  2015).	  This	  has	  implications	  in	  ferric	  chloride	  induced	  thrombosis	   in	  vivo.	  Without	  GPVI-­‐fibrinogen	  binding,	  platelet	  αIIbβ3	  cannot	  be	   fully	  activated,	  and	  cannot	   efficiently	   bind	   to	   fibrinogen.	   This	   prevents	   firm	   platelet-­‐platelet	  interactions	   and	   therefore	   thrombus	   growth.	   This	   reduced	   platelet	   cohesion	  could	  explain	  the	  unstable	  thrombus	  formation	  we	  see	  in	  our	  model	  (figure	  3.9)	  and	  the	  partial	  protection	  we	  see	  against	  DVT	  in	  the	  GPVI-­‐deficient	  mice.	  	  	  In	  conclusion,	  we	  have	  answered	  the	  main	  aims	  of	  this	  chapter.	  We	  have	  shown	  that	   both	   CLEC-­‐2	   and	   podoplanin	   have	   a	   significant	   impact	   in	   DVT.	   Complete	  deficiency	   in	  CLEC-­‐2	  protects	  mice	   totally	   from	  DVT,	  with	  mice	   lacking	  CLEC-­‐2	  only	   on	   platelets	   showing	   a	   smaller,	   but	   still	   significant	   protection	   from	   DVT.	  GPVI	  deficiency	   showed	  only	  a	   trend	   towards	  DVT	  protection	  but	   this	  was	  not	  significant.	  The	   IVC	  wall	   expresses	  podoplanin	  and	   this	   is	   important	   in	  venous	  thrombosis.	   Although	   further	   studies	   are	   required	   to	   ascertain	   to	  what	   extent	  podoplanin	   mediates	   the	   prothrombotic	   effect	   of	   CLEC-­‐2.	   As	   CLEC-­‐2	   deficient	  mice	   only	   show	   a	   minor	   impairment	   in	   normal	   hemostasis,	   this	   could	   be	   a	  potential	  target	  for	  DVT	  treatment	  in	  the	  future.	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4.1	  Introduction	  	  Deep	   vein	   thrombosis	   (DVT),	   and	   its	   associated	   complication	   pulmonary	  embolism	  (PE),	  as	  previously	  discussed	  in	  chapter	  3,	  is	  a	  serious	  health	  problem	  in	  the	  western	  world.	  With	  DVT	  being	  responsible	  for	  over	  100,000	  deaths	  in	  the	  US	  annually,	  as	  reported	  by	  the	  American	  Surgeon	  General	  (centers	   for	  disease	  control	  and	  prevention),	  and	  affecting	  1	  in	  every	  1,000	  people	  in	  the	  UK	  (NHS).	  Despite	   this	   disease	   being	   a	   major	   heath	   concern,	   the	   mechanisms	   leading	   to	  venous	   thrombosis	   have	   still	   not	   been	   fully	   elucidated,	   and	   the	   reported	   cases	  are	   not	   declining	   annually.	   In	   fact,	   even	   after	   development	   of	   efficient	   current	  treatment	  options,	  patients	  are	  still	  presenting	  with	  post	   thrombotic	  syndrome	  and	   chronic	   thromboembolic	   pulmonary	   hypertension	   from	   DVT	   and	   PE	  respectively	   (Ashrani	   et	   al	   2009).	   This	   usually	   requires	   prolonged	   periods	   of	  anticoagulation	   therapy	   and	   general	   poor	   quality	   of	   life,	   not	   to	   mention	   the	  additional	  cost	  and	  medical	  attention	  as	  a	  result.	  Therefore	  there	  is	  a	  great	  need	  for	  a	  better	  understanding	  of	  the	  mechanisms	  of	  DVT	  and	  alternative	  treatment	  options	   as	   current	   anticoagulant	   treatments	   such	   as	  Warfarin	   and	   Clexane	   are	  efficient,	   but	   associated	   with	   bleeding	   complications.	   	   The	   paradigm	   of	   our	  approach	  is	  to	  identify	  new	  targets	  to	  tackle	  DVT	  through	  a	  ‘backdoor	  approach’	  this	  is	  not	  involved	  in	  normal	  hemostasis.	  One	  such	  target	  is	  the	  immune	  system.	  	  	  As	   described	   in	   chapter	   1,	   we	   know	   that	   thrombosis	   in	   veins	   develops	   in	   a	  different	  manner	  to	  that	  in	  arteries.	  In	  veins	  thrombi	  develop	  without	  any	  sign	  of	  endothelial	   denudation,	   whereas	   thrombus	   formation	   in	   arteries	   occurs	   as	   a	  result	  of	  exposure	  of	  the	  subendothelial	  adhesion	  proteins	  after	  atherosclerotic	  plaque	  rupture.	   In	  venous	  valves,	  blood	  flow	  can	  become	  stagnant	  and	  stasis,	  a	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component	  of	  Virchow’s	  triad	  (Bovill	  et	  al	  2011),	  can	  lead	  to	  local	  hypoxia,	  and	  prolonged	  period	  of	  blood	  exchange	  in	  valves	  increases	  thrombogenicity	  (Hamer	  et	  al	  1981).	  	  	  A	  common	  cause	  of	  this	  ‘blood	  pooling’	  in	  valves	  and	  stagnant	  flow	  is	  a	  result	  of	  prolonged	  periods	  of	  inactivity	  such	  as	  during	  long-­‐haul	  flights,	  or	  post-­‐surgery	  when	  patients	  are	  in	  bed-­‐ridden	  positions	  with	  limited	  mobility.	  It	  has	  previously	  been	  demonstrated	   (refer	   to	  chapter	  3)	   that	  an	   inflammatory	  component	  plays	  a	  role	  in	  DVT	  initiation.	  We	  know	  that	  local	  hypoxia	  caused	  as	  a	  result	  of	   stagnancy	   in	   the	  venous	  valves,	  may	   lead	   to	   release	  of	  P-­‐selectin,	   and	  WVF	   from	   WPB’s.	   This	   in	   turn	   leads	   to	   the	   recruitment	   of	   platelets	   and	  leukocytes.	  While	  we	  know	  the	  importance	  of	  platelets	  in	  thrombosis	  initiation,	  as	   they	   provide	   a	   surface	   for	   clotting	   factors,	   other	   cells	  may	   also	   play	   a	   role.	  Neutrophils	   have	  been	   shown	   to	   support	  DVT	  propagation	  by	  producing	  NETs	  (Brill	   et	   al	   2012;	  Von	  Bruhl	   et	   al	   2012).	  We	   sought	   to	   investigate	   if	  mast	   cells,	  which	  have	  previously	  been	   associated	  with	  other	   cardiovascular	  diseases,	   are	  implicated	  in	  DVT.	  	  	  Mast	   cells	   (MC)	   are	   part	   of	   the	   innate	   immune	   system.	   Their	   development	   is	  different	   to	   other	   myeloid-­‐derived	   cells,	   in	   that	   mast	   cells	   originate	   from	   the	  hematopoietic	   progenitor	   in	   the	   bone	   marrow,	   but	   they	   leave	   and	   enter	   the	  circulation	  as	  early	  progenitors	  rather	   than	  end-­‐stage	  cells	   (Gurish	  et	  al	  2012).	  Once	   mast	   cells	   have	   moved	   to	   the	   tissues	   and	   matured,	   they	   can	   be	  distinguished	  as	  they	  express	  a	  specific	  set	  of	  antigens;	  the	  receptor	  FcεRI	  which	  has	  a	  high	  affinity	  for	  immunoglobulin	  E	  (IgE),	  and	  Kit	  (stem	  cell	  factor	  receptor).	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  Mast	  cells	  do	  not	  circulate	  permanently	  in	  the	  blood	  but	  reside	  in	  the	  connective	  tissue	  (Amin	  2012).	   	  Mast	  cells	  are	  constitutively	  present	  in	  most	  tissues,	  there	  are	  different	  subsets	   including	  peritoneal,	  mucosal	  and	  connective	  tissues	  mast	  cells.	  They	  are	  functionally	  heterogeneous	  cells	  depending	  on	  which	  tissue	  they	  mature	  in.	  A	  specific	  subset	  of	  mast	  cells	  which	  highly	  express	  FcεRI	  II	  and	  MHC	  II	   can	   act	   as	   antigen	   presenting	   cells	   (Theoharies	   et	   al	   2012).	   Although	   their	  most	  well	   documented	   role	   is	   as	   effector	   cells	   in	   allergic	   diseases,	   they	  have	   a	  number	  of	  other	  roles	  such	  as	  in	  homeostatic	  responses	  and	  immunoregulation	  (Moon	  et	  al	  2014).	  Allergic	  inflammation	  has	  been	  shown	  to	  be	  a	  risk	  factor	  for	  DVT	   and	   PE	   (Lippi	   et	   al	   2016).	   Mast	   cells	   are	   located	   in	   the	   vicinity	   of	   blood	  vessels	  as	  well	  being	  observed	  at	  the	  site	  of	  human	  DVT	  (Bankl	  et	  al	  1999).	  	  	  Another	  distinctive	  feature	  of	  mast	  cells	  is	  that	  they	  contain	  granules.	  They	  have	  the	  ability	  to	  secrete	  their	  granular	  contents	  and	  release	  a	  variety	  of	   important	  mediators	   with	   a	   diverse	   range	   of	   biological	   activities.	   These	   include	   Amines;	  (histamine	  and	  polyamines),	  proteoglycans,	  proteases	  (tryptases	  and	  chymases),	  lysosomal	  enzymes	  and	  cytokines	  (Moon	  et	  al	  2014).	  	  	  It	  is	  known	  that	  mast	  cells	  play	  a	  role	  in	  allergic	  inflammation;	  one	  of	  the	  most	  well	   studied	  mediators	   released	   from	  MC	   granules	   involved	   in	   this	   process	   is	  histamine.	   Histamine	   is	   released	   from	   mast	   cells	   when	   they	   detect	   injury,	   or	  when	  the	  body	  encounters	  a	  toxic	  substance	  (Amin	  2012).	  Histamine	  acts	  on	  the	  nearby	  blood	  vessels	  at	   the	  site	  of	   toxicity	  or	  damage	  to	  cause	  blood	  vessels	   to	  dilate,	  allowing	  more	  blood	  to	  flow	  to	  the	  infected	  area.	  Histamine	  also	  acts	  upon	  endothelial	  cell	  WPB’s	  causing	  them	  to	  exocytose	  and	  release	  VWF	  (Conte	  2015).	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  Asthma	  is	  considered	  to	  be	  a	  chronic	  inflammatory	  disease,	  and	  this	  is	  associated	  with	  ongoing	  mast	  cell	  activation.	  	  In	  the	  bronchoalveolar	  lavage	  of	  asthmatics	  it	  has	  been	  shown	  to	  contain	  an	  increase	  in	  spontaneous	  release	  of	  histamine	  from	  mast	   cells,	   compared	   to	   that	  of	  non-­‐asthmatics	   (Amin	  2012).	   	  While	  mast	   cells	  play	  a	  detrimental	  role	  in	  IgE-­‐dependent	  allergic	  reactions,	  they	  may	  also	  have	  a	  protective	   role	   in	   other	   diseases.	   Some	   reports	   have	   shown	   mast	   cells	   to	   be	  protective	   in	  bacterial	   infections,	   for	  example	   in	  a	  mouse	  model	  of	  acute	  septic	  peritonitis	   (Echtenacher	   et	   al	   1996).	   Using	   the	   caecum	   ligation	   and	   puncture	  (CLP)	   method,	   mice	   that	   were	   deficient	   in	   mast	   cells	   showed	   an	   increased	  mortality	   compared	   to	  mice	  with	  mast	   cells.	   If	   these	   deficient	  mice	  were	   then	  reconstituted	  with	  cultured	  mast	  cells	  this	  protected	  them	  from	  the	  lethal	  effects	  of	   CLP.	   Demonstrating	   a	   protective	   role	   of	   mast	   cells	   in	   bacterial	   peritonitis	  (Echtenacher	   at	   al	   1996).	   Another	   group	   also	   showed	   that	   mast	   cells	   had	   a	  protective	   role	   against	   enterobacterial	   infection,	   they	   show	  mast	   cells	   exerted	  this	   effect	  by	   releasing	   inflammatory	   cytokines	   and	   recruiting	  neutrophils,	   and	  this	  recognition	  of	  enterobacteria	  was	  mediated	  TLR4	  on	  mast	  cells	  (Supajatura	  et	  al	  2001).	  	  Mast	  cells	  have	  also	  been	  shown	  to	  play	  an	  important	  role	  in	  the	  pathogenesis	  of	  other	   diseases	   such	   as	   atherosclerosis	   and	   abdominal	   aortic	   aneurysm.	  Abdominal	   aortic	   aneurysm	   (AAA)	   is	   an	   inflammatory	   arterial	   disease.	   The	  number	   of	   medial	   and	   adventitial	   MC’s	   (particularly	   those	   that	   have	  degranulated)	   is	   significantly	   increased	   in	   atherosclerotic	   aortas	   compared	   to	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non-­‐	  diseased	  aortas.	  This	  number	  is	  further	  increased	  in	  AAA	  (Swedenborg	  et	  al	  2011).	  	  The	  role	  of	  mast	  cells	  in	  AAA	  has	  been	  well	  studied	  using	  various	  mouse	  models,	  and	   it	  was	   shown	   that	  Kit	  W-­‐sh/W-­‐sh	  ,	  which	   lack	  MC’s	  were	  protected	   from	  AAA.	  Lack	  of	  mast	   cells	   in	   these	  mice	  was	   associated	  with	   a	   significant	   reduction	   in	  media	  elastin	  degradation	  and	  adventitial	  angiogenesis,	  along	  with	  a	  reduction	  in	  macrophages	  and	  T-­‐cells	  at	  lesion	  sites	  (Swedenborg	  et	  al	  2011).	  	  This	  phenotype	  could	  be	  reversed,	  by	  adoptive	  transfer	  of	  exogenous	  mast	  cells	  from	   WT	   mice	   (Wang	   et	   al	   2012).	   Furthermore	   if	   mice	   were	   treated	   with	  compound	   40/80,	   which	   stimulates	   mast	   cell	   degranulation,	   abdominal	   aortic	  aneurysms	   were	   larger	   compared	   to	   mice	   treated	   with	   a	   vehicle,	   and	   also	  showed	  an	  increase	  in	  elastin	  degradation	  and	  lesion	  inflammation.	  All	  of	  these	  effects	   could	   be	   partially	   suppressed	   by	   administering	  mice	  with	   the	  mast	   cell	  stabilizing	  agent,	  cromolyn	  (Wang	  et	  al	  2012).	  	  Further	  studies	  were	  performed	  to	  elucidate	  which	  components	  of	  the	  mast	  cell	  granules	  were	  responsible	   for	   this.	  Chymase	  and	  tryptase	  are	  mast	  cell	  specific	  proteases	  and	  account	  for	  over	  25%	  of	  the	  total	  cellular	  proteins	  (Schwartz	  et	  al	  1987)	  they	  are	  commonly	  used	  to	  detect	  mast	  cells.	  	  Pharmacological	   inhibition	   of	   chymase	   or	   tryptase	   decreased	   AAA	   formation,	  along	   with	   reducing	   other	   associated	   pathologies	   (Wang	   et	   al	   2012),	  demonstrating	   the	   important	   role	   these	   mast	   cell	   constituents	   play	   in	   AAA	  development.	  This	  study	  demonstrated	  the	   importance	  of	  mast	  cells,	  at	   least	   in	  an	  arterial	  inflammatory	  setting.	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An	  association	  has	  previously	  been	  made	  between	  mast	  cells	  and	  DVT.	  Bankl	  et	  al	   (1999)	   performed	   a	   study	   comparing	   the	   number	   and	   distribution	   of	   mast	  cells	   in	   the	   deep	   veins	   of	   the	   lower	   limb	   in	   patients	   with	   and	   without	   DVT.	  Giemsa	   staining	   and	   immunohistochemistry,	   using	   antibodies	   against	  mast	   cell	  granule	  constituents	  (e.g.	  Tryptase	  and	  chymase)	  showed	  an	  increase	  in	  number	  of	  mast	  cells	  in	  DVT	  compared	  to	  nonthrombosed	  limb	  veins	  (Bankl	  et	  al	  1999).	  Overall	  we	  know	  that	  mast	  cells	  contain	  both	  anticoagulants	  (heparin,	  tPA)	  and	  pro-­‐inflammatory	  mediators	  (histamine,	  TNF-­‐α)	  and	  therefore	  could	  potentially	  have	   either	   a	   pro-­‐thrombotic	   or	   anti-­‐thrombotic	   phenotype	   in	   DVT.	   In	   this	  chapter	  we	  aimed	  to	  investigate	  this.	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4.2	  Results	  
	  4.2.1	  Mast	  cell	  deficient	  mice	  are	  protected	  against	  DVT	  	  To	   investigate	   if	  mast	   cells	   play	   a	   role	   in	   DVT,	  we	   performed	   IVC	   stenosis	   (as	  described	   methods	   2.7.3)	   to	   KitW-­‐sh	   mice	   that	   lack	   mast	   cells	   vs.	   their	   WT	  littermates	   and	   looked	   for	   thrombosis	  prevalence	   at	   two	  different	   time	  points;	  24	  hours	  and	  48	  hours	  after	  stenosis	  application.	  Whilst	  in	  the	  WT	  group	  75%	  of	  the	   mice	   produced	   a	   thrombus	   after	   24	   h	   stenosis,	   and	   90%	   produced	   a	  thrombus	  after	  48	  h,	  none	  of	  the	  mast	  cell	  deficient	  mice	  developed	  a	  thrombus	  at	   either	   time	   point	   (Figure	   4.2	   a,b).	   To	   further	   confirm	   this	   phenotype,	   we	  performed	  the	  same	  experiment	  with	  a	  different	  strain	  of	  Kit	  mutant	  mice	  KitW-­‐v	  and	  their	  littermate	  controls.	  As	  can	  be	  seen	  in	  figure	  4.2C,	  the	  same	  phenotype	  was	   observed,	   after	   48	   h	   stenosis,	   89%	   of	   control	  mice	   produced	   a	   thrombus	  compared	  to	  none	  of	  the	  mutant	  mice.	  	  	  Because	   the	   Kit	   mutation	   could	   potentially	   mediate	   other	   abnormalities	   apart	  from	   lack	  of	  mast	  cells,	   such	  as	   impaired	  germ	  cell	  development,	  altered	  blood	  count,	   or	   abnormal	   vascular	   permeability,	   we	   wanted	   to	   rule	   these	   out	   as	  potential	  causes	  or	  mechanisms	  for	  the	  affected	  thrombosis	  phenotype	  observed.	  	  We	  therefore	  cultured	  murine	  bone	  marrow-­‐derived	  mast	  cells,	  and	  performed	  adoptive	  transfer	  of	  these	  in	  vitro-­‐differentiated	  MCs	  into	  Kit	  W-­‐sh	  mice	  to	  restore	  their	  pool	  of	  mast	  cells,	  and	  see	  if	  the	  phenotype	  could	  be	  reversed.	  We	  cultured	  murine	   bone	   marrow-­‐derived	   mast	   cells	   (BMDMC)	   using	   methods	   that	   have	  previously	   been	   described	   in	   the	   literature	   (methods	   2.4).	   The	   in	   vitro	  differentiated	  cells	  were	  assessed	  by	  FACS	  staining	  for	  c-­‐Kit	  and	  FcεR	  and	  its	  was	  shown	  they	  were	  around	  >	  90%	  mature	  after	  about	  4	  weeks.	  The	  functionality	  of	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these	  mast	  cells	  was	  confirmed	  by	  their	  ability	  to	  release	  β-­‐hexaminidase	  upon	  stimulation	  (figure	  4.1).	  	  In	  vitro	  differentiated	  mast	  cells	  (10	  X	  106	  )	  were	  injected	  into	  the	  tail	  vein	  of	  3-­‐4	  week	   old	  KitW-­‐sh	  mice.	   8-­‐10	  weeks	   after	   the	   adoptive	   transfer	   these	  mice	  were	  subjected	  to	  48	  h	  IVC	  stenosis.	  As	  can	  be	  seen	  in	  figure	  4.2b,	  67%	  of	  the	  mice	  that	  received	  these	  mast	  cells	  produced	  a	  thrombus.	  This	  is	  significantly	  higher	  than	  the	   KitW-­‐sh	   mice	   without	   the	   adoptive	   transfer,	   and	   it	   is	   also	   comparable	   to	  thrombosis	  prevalence	   in	  WT	  controls.	  This	  confirms	  that	   it	   is	   the	   lack	  of	  mast	  cells	  that	  protects	  mice	  against	  DVT.	  	  4.2.2	  –	  Evaluating	  the	  purity	  and	  functionality	  of	  in-­‐vitro	  differentiated	  mast	  cells	  	  We	   performed	   further	   experiments	   to	   make	   sure	   that	   the	   mast	   cells	   we	   had	  cultured,	   and	   were	   going	   to	   adoptively	   transfer	   into	   the	   Kit-­‐W-­‐sh	   mice	   were	  functional.	  In	  order	  to	  assess	  if	  the	  mast	  cells	  were	  mature	  we	  performed	  FACS	  staining	  (figure	  4.1	  a).	  Staining	  with	  antibodies	  against	  mouse	  FcεR1	  and	  CD117,	  showed	   that	   more	   than	   90%	   of	   the	   mast	   cells	   expressed	   both	   receptors,	   and	  were	   therefore	   classed	   as	   mature.	   The	   mast	   cell	   functionality	   was	   tested,	   by	  testing	  their	  ability	  to	  secrete	  their	  granule	  contents	  when	  stimulated.	  In	   order	   to	   assess	   the	   efficiency	   of	   the	  mast	   cells	   to	   release	   the	  mediators,	   β-­‐hexaminidase	  activity	  was	  measured	  in	  the	  supernatants	  (figure	  4.1	  b).	  The	  two	  batches	  of	  mast	  cells,	  which	  were	  used	  for	  the	  adoptive	  transfer	  experiments,	  are	  shown	  below	  (figure	  4.1a	  -­‐	  MC#3	  and	  MC#4).	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Figure	   4.1	   -­‐	   Evaluation	   of	   purity	   and	   functionality	   of	   the	   in	   vitro	  
differentiated	  Mast	  cells	  
(A)	  To	  assess	  maturity	  of	  mast	  cells	  FACS	  staining	  was	  performed	  for	  FCεRI	  and	  CD117.	  Over	  90%	  of	  cells	  expressed	  both	  receptors.	  Two	  MC	  batches	  used	  in	  the	  adoptive	   transfer	   experiments	   are	   presented	   (MC#3	   and	   MC#4)	   (B)	   β-­‐hexaminidase	  activity	  was	  measured	   in	   the	  mast	  cell	   supernatant	   to	  assess	   the	  cells	   functionality	   and	   ability	   to	   secrete	   their	   granular	   contents.	   (Performed	   in	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Figure	  4.2	  	  -­‐	  	  KitW-­‐sh	  and	  KitW-­‐v	  mice	  are	  protected	  against	  DVT,	  and	  mast	  cell	  
repopulation	  restores	  thrombosis	  
	  Stenosis	  of	   the	  IVC	  was	  performed	  in	  KitW-­‐sh	  mice	  (lacking	  mast	  cells)	  and	  their	  WT	   littermates.	   Thrombosis	   prevalence	  was	  measured	   at	   either	   (a)	   24	   h	   after	  stenosis	   or	   (b)	   48	   h	   after	   stenosis.	   Another	   group	   of	   KitW-­‐sh	   	   	  mice	   underwent	  adoptive	  transfer	  (AT)	  of	  10	  x106	   in	  vitro-­‐differentiated	  mast	  cells,	  8-­‐10	  weeks	  prior	  to	  stenosis.	  Thrombus	  weight,	  length	  and	  prevalence	  were	  measured.	  	  (a)	  WT	  n=	  8,	  KitW-­‐sh	  	  n=	  6;	  (b)	  WT	  n=	  10,	  KitW-­‐sh	  	  n=	  14,	  KitW-­‐sh	  	  following	  adoptive	  transfer	  n=	  9.	  Note	  that	  mice	  without	  mast	  cells	  were	  protected	  against	  DVT	  and	  thrombosis	  was	  restored	  after	  adoptive	  transfer	  of	  mast	  cells.	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Figure	  4.2	  continued	  -­‐	  	  KitW-­‐sh	  and	  KitW-­‐v	  mice	  are	  protected	  against	  DVT,	  
and	  mast	  cell	  repopulation	  restores	  thrombosis	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  4.2.3	  Objectively	  assessing	  the	  presence	  or	  absence	  of	  thrombi	  in	  WT	  and	  KitW-­‐sh	  mice	  	  In	   order	   to	   provide	   further	   evidence	   with	   an	   objective	   verification	   of	   the	  presence	  of	   thrombi	   in	   either	  WT	  or	  KitW-­‐sh	  mice,	  we	  used	  ultrasound	  Doppler	  (figure	  4.3).	  	  	  	  
	  	  	  	  
Figure	  4.3	  Presence	  of	  thrombi	  in	  WT	  but	  not	  in	  KitW-­‐sh	  mice	  detected	  by	  
ultrasound	  Doppler	  	  Ultrasound	  Doppler	  was	  performed	  on	  WT	  and	  KitW-­‐sh	  mice	  (n=4	  mice	  per	  group)	  48	   h	   after	   IVC	   stenosis.	   No	   blood	   flow	   was	   detected	   in	   the	   IVC	   of	   WT	   mice,	  suggesting	   the	   presence	   of	   a	   thrombus.	   In	   KitW-­‐sh	   mice	   blood	   flow	   could	   be	  detected,	   showing	   that	   a	   thrombus	   did	   not	   form	   in	   the	   IVCs	   of	   these	   mice.	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Figure	  4.4	  Granule-­‐containing	  MCs	  are	  present	  in	  the	  IVC	  wall	  and	  decrease	  
in	  number	  with	  thrombosis.	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  4.2.5	  Mast	  cell	  granule	  depletion	  prevents	  DVT	  	  Having	  observed	  that	  the	  that	  absence	  of	  mast	  cells	   is	  protective	  from	  DVT,	  we	  next	  wanted	   to	   investigate	   if	   pharmacological	   depletion	   of	  mast	   cells	   granules	  gave	  the	  same	  result.	  	  Mice	  were	  given	  an	  i.p.	  Injection	  of	  the	  mast	  cell	  degranulator	  compound	  48/80	  in	   sterile	   saline	   consecutively	   for	  4	  days	  prior	   to	   surgery	   (methods	  2.1.4).	  The	  mice	   were	   then	   subjected	   to	   IVC	   stenosis	   24	   h	   after	   the	   last	   injection	   of	   the	  compound.	  This	  treatment	  regime	  should	  have	  depleted	  mast	  cells	  by	  ~84%.	  	  IVC	  stenosis	  was	  performed	  for	  48	  h	  as	  described	  in	  methods	  2.7.3,	  thrombosis	  prevalence,	  thrombus	  length	  and	  weight	  were	  then	  measured.	  None	  of	  the	  mice	  administered	  the	  compound	  48/80	  developed	  a	  thrombus,	  compared	  to	  86%	  of	  the	   control	  mice	   that	   received	   and	   injection	   of	   sterile	   saline	   (figure	   4.5).	   This	  result	   phenocopied	   what	   we	   previously	   saw	   in	   mast	   cell	   deficient	   mice,	  suggesting	   that	   functional	   mast	   cells	   and	   their	   granules	   are	   critical	   in	   venous	  thrombosis.	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Figure	  4.5-­‐	  Mast	  cell	  granule	  depletion	  prevents	  DVT.	  	  	  Mice	  either	  received	  consecutive	  daily	  injections	  of	  sterile	  saline,	  or	  the	  mast	  cell	  degranulator	   compound	   48/80	   (n=	   7	   in	   both	   groups).	   After	   48	   h	   stenosis	  thrombus	  weight	  (a),	  length	  (b)	  and	  thrombosis	  prevalence	  (c)	  were	  measured.	  86%	   of	   control	   mice	   produced	   a	   thrombus	   compared	   to	   none	   of	   the	   48/80	  treated	  mice.	  (Performed	  in	  collaboration	  with	  A.Brill)	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As	  we	   also	   know	   that	   cell	   recruitment	   is	   a	   prerequisite	   for	   DVT	   development,	  and	  that	  stenosis	  of	  the	  IVC	  promotes	  this	  recruitment.	  We	  sought	  to	  investigate	  if	  this	  cell	  recruitment	  process	  is	  modified	  in	  the	  absence	  of	  mast	  cells.	  	  Mice	   were	   subjected	   to	   IVC	   stenosis	   for	   6	   h,	   and	   mice	   that	   had	   not	   already	  produced	  thrombi	  at	  this	  time	  point	  were	  used	  in	  the	  further	  experiments.	  These	  mice	   were	   then	   injected	   with	   washed	   platelets	   labeled	   with	   calcein	   AM,	   and	  intravital	  microscopy	  of	  the	  IVC	  was	  performed	  (as	  described	  in	  methods	  2.7.5).	  As	  can	  be	  seen	   in	   figure	  4.6	  b	  &	  c,	   after	   stenosis	   in	  WT	  mice	  multiple	  platelets	  stay	  adhered	  to	  the	  IVC	  vessel	  wall,	  compared	  to	  in	  Kitw-­‐sh	  mice,	  where	  platelets	  did	  not	   stay	   attached	  or	  make	   contact	  with	   the	   endothelium,	   but	   instead	  were	  carried	   away	   in	   the	   direction	   of	   the	   blood	   flow.	   Only	   single	   platelets	   were	  adhered	  to	  the	  vessel	  wall	  (videos	  available	  upon	  request).	  	  This	   was	   then	   quantified	   using	   10	   randomly	   chosen	   consecutive	   images	  (corresponding	   to	   1s	   recording)	   and	   the	   total	   area	   of	   adhered	   platelets	   was	  measured	   (methods	   2.7.5).	   Figure	   4.6	   c)	   shows	   that	   in	   the	  WT	  mice,	   the	   total	  area	  covered	  by	  adhered	  platelets	  was	  6.9	  ±	  0.73%.	  Compared	  to	  2.4	  ±	  0.54%	  in	  KitW-­‐sh	  mice	  (p<0.003).	  This	  result	  could	  suggest	   that	  mast	  cells	  are	   involved	   in	  endothelial	  activation	  critical	  for	  DVT	  initiation.	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Figure	   4.6	   -­‐	   Mast	   cells	   regulate	   plasma	   levels	   of	   VWF	   and	   platelet	  
recruitment	  to	  the	  stenosed	  IVC	  wall.	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  4.2.7	  Mast	  cell	  involvement	  in	  activation	  of	  the	  endothelium	  	  




























Figure	  4.7	  -­‐	  MC	  releasate	  induces	  ICAM-­‐1	  expression	  on	  HUVEC	  in	  vitro	  

















Figure	  4.8-­‐	  Plasma	  sP-­‐selectin	  levels	  are	  elevated	  during	  DVT	  in	  WT	  mice	  
but	  not	  MC-­‐deficient	  mice.	  
	  Blood	  samples	  were	  taken	  from	  both	  WT	  and	  KitW-­‐sh	  mice	  prior	  to	  surgery	  and	  6	  h	  post	  stenosis	  (n=	  5	  to	  9).	  Plasma	  sP-­‐selectin	  levels	  were	  measured	  using	  a	  commercial	  ELISA	  kit.	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Figure	  4.9	  -­‐	  Inhibition	  of	  MC	  degranulation	  by	  membrane	  stabilization	  
protects	  against	  DVT.	  	  	  (a-­‐c)	  WT	  mice	  were	  administered	  either	  sterile	  saline	  or	  cromolyn	  (100mg/kg)	  at	  24	  h	  and	  30	  min	  prior	  to	  IVC	  stenosis.	  (n=16	  for	  both	  groups).	  	  (d-­‐f)	  WT	  mice	  were	   administered	   either	   sterile	   saline	   or	   Ketotifen	   (25mg/kg).	  Saline	  n=	  10,	  Ketotifen	  n=7.	  	  Thrombus	  formation	  was	  checked	  in	  all	  groups	  48	  h	  after	  stenosis.	  Thrombus	  weight,	   length	  and	   thrombosis	  prevalence	  are	  shown,	  with	  the	  horizontal	  bar	  representing	  the	  median.	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  4.2.9	  	  Topical	  application	  of	  either	  compound	  48/80	  or	  histamine	  increases	  thrombosis	  in	  WT	  mice,	  and	  induces	  DVT	  in	  KitW-­‐sh	  mice.	  
	  
	  In	  order	  in	  investigate	  further	  how	  mast	  cells	  and	  their	  granule	  contents	  play	  a	  role	   in	   the	   development	   of	   DVT,	   we	   performed	   topical	   application	   of	   the	  secretogogues,	   compound	   48/80,	   or	   histamine,	   onto	   the	   IVCs	   of	   mice	   during	  stenosis.	  After	  stenosis	  application	  a	  strip	  of	  Whatman	  paper	  was	  soaked	  in	  a	  solution	  of	  either	  compound	  48/80	  (1mg/ml),	  histamine	  (100mg/ml)	  or	  saline.	  The	  paper	  strip	  was	  placed	  on	  the	  IVC	  for	  10	  minutes	  immediately	  after	  stenosis	  induction.	  6	   h	   post	   surgery	   the	   mice	   were	   opened	   to	   investigate	   the	   development	   of	  thrombi.	  	  WT	  mice	   were	   used	   for	   topical	   application	   of	   compound	   48/80,	   histamine	   or	  saline.	  KitW-­‐sh	  mice	  were	  used	  for	  topical	  application	  of	  histamine	  or	  saline	  only.	  Figure	   4.10	   shows	   that	   in	   WT	   control	   mice,	   thrombosis	   prevalence	   was	   25%	  after	   IVC	   stenosis.	   When	   WT	   mice	   were	   treated	   with	   compound	   48/80-­‐thrombosis	   prevalence	   increased	   to	   80%	   (p<0.03),	   whilst	   when	   treated	   with	  histamine,	  mice	  produced	  a	  thrombus	  in	  87.5%	  of	  cases	  (p<0.02	  Vs.	  saline).	  None	   of	   the	   KitW-­‐sh	   treated	   with	   saline	   produced	   a	   thrombus,	   but	   when	   these	  mice	   received	   topical	   application	   of	   histamine,	   thrombosis	   prevalence	  dramatically	   increased	  to	  100%.	  Demonstration	  that	  histamine	  can	  induce	  DVT	  in	  mast	  cell	  deficient	  mice,	  mimicking	  thus	  the	  effect	  of	  mast	  cells,	  suggesting	  the	  effect	  is	  probably	  mediated	  by	  histamine	  release.	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Figure	   4.10	   -­‐Topical	   application	   of	   compound	   48-­‐80	   or	   histamine	  
potentiates	  thrombosis	  in	  WT	  and	  histamine	  induces	  DVT	  in	  KitW-­‐sh	  mice.	  	  
	  The	  groups	  shown	  above;	  1)	  WT	  +	  saline,	  2)	  WT	  +	  48-­‐80,	  3)	  WT	  +	  Histamine,	  4)	  KitW-­‐sh	  +	  saline,	  5)	  KitW-­‐sh	  +	  Histamine.	  WT	   and	   KitW-­‐sh	   mice	   underwent	   IVC	   stenosis	   for	   6	   hours.	   Immediately	   after	  stenosis	   application	   a	   strip	   of	   paper	   soaked	   in	   either	   compound	   48/80	  (1mg/ml),	  histamine	  (100mg/ml)	  or	  saline	  was	  applied	   to	   the	   IVCs	  of	  mice	   for	  10	  min.	  After	  6	  h	  thrombus	  formation,	  weight	  and	  length	  were	  tested.	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  4.2.10	  No	  difference	  is	  seen	  in	  arterial	  thrombosis	  or	  normal	  hemostasis	  between	  WT	  and	  KitW-­‐sh	  mice	  	  We	  wanted	  to	   investigate	   if	   the	  prothrombotic	  effect	  of	  mast	  cells	   is	  specific	   to	  DVT	  or	   if	   they	  also	  exacerbate	  arterial	   thrombosis.	  We	  used	   the	   ferric	   chloride	  model	   of	   thrombosis,	   which	   induces	   thrombus	   formation	   as	   a	   result	   of	  denudation	  of	  the	  endothelium.	  As	  can	  be	  seen	  in	  figure	  4.11a,	  no	  difference	  was	  observed	  between	  WT	  and	  KitW-­‐sh	  mice	  in	  time	  to	  occlusion	  in	  the	  ferric	  chloride	  model.	  This	   further	   suggests	   that	   the	  endothelium	   is	   required	   for	  mast	   cells	   to	  exert	  their	  prothrombotic	  activity,	  and	  that	  the	  effect	  of	  mast	  cells	  is	  specific	  to	  venous	  thrombosis.	  In	  order	  to	  rule	  out	  any	  other	  factors,	  which	  could	  be	  causing	  the	  anti-­‐thrombotic	  phenotype	   in	  KitW-­‐sh	  mice,	  we	  then	  compared	  normal	  hemostasis	  parameters	   in	  WT	  and	  KitW-­‐sh	  mice.	  Tail	  bleeding	  times	  were	  taken	  by	  cutting	  the	  tail	  at	  3mm,	  and	   monitoring	   the	   time	   until	   bleeding	   arrest.	   No	   difference	   was	   seen	   in	   tail	  bleeding	  times	  between	  WT	  and	  KitW-­‐sh	  mice	  (figure	  4.11	  b).	  We	  also	  performed	  coagulation	   tests,	   looking	   at	   Prothrombin	   time	   (PT)	   and	   activated	   partial	  thromboplastin	  time	  (aPTT).	  In	  both	  of	  these	  coagulation	  tests,	  no	  difference	  was	  seen	  between	  WT	  and	  KitW-­‐sh	  mice.	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Figure	  4.11	  -­‐	  No	  difference	  in	  normal	  hemostasis	  and	  arterial	  thrombosis	  
between	  WT	  and	  KitW-­‐sh	  mice.	  	  a)	  Fluorescent	  platelets	  were	  infused	  into	  WT	  and	  KitW-­‐sh	  mice	  (n=	  5)	  and	  a	  strip	  soaked	   in	   10%	   ferric	   chloride	  was	   applied	   to	   their	  mesentery	   for	   5	  mins.	   The	  time	  to	  vessel	  occlusion	  was	  recorded.	  b)	  The	  tip	  of	   the	  tail	  was	  cut	  at	  3mm	  in	  both	  WT	  and	  KitW-­‐sh	  mice	  and	  time	  to	  bleeding	  arrest	  was	  measured	  (n=	  6	  to	  8).	  C)	  PT	  and	  d)	  aPTT	  test	  were	  performed	  using	  a	  coagulometer	  (n=	  5).	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4.3	  Discussion	  	  Current	  options	  for	  DVT	  prophylaxis	  are	  associated	  with	  bleeding	  complications,	  because	   they	  mostly	   target	   clotting	   factors,	  which	   are	   essential	   components	   of	  both	   pathological	   thrombosis	   and	   normal	   hemostasis.	   Therefore	   the	   existing	  drugs	   used	   to	   prevent	   DVT	   also	   impact	   on	   normal	   hemostasis	   and	   bleeding	  arrest.	  Throughout	  this	  chapter	  we	  have	  demonstrated	  that	  mast	  cells	  play	  a	  role	  in	  DVT,	  and	  are	  involved	  in	  DVT	  initiation.	  Also	  we	  have	  shown	  that	  a	  potential	  treatment	  option	  for	  venous	  thrombosis	  could	  be	  to	  inhibit	  mast	  cells,	  which	  are	  not	   directly	   involved	   in	   hemostasis,	   and	   therefore	   this	   is	   unlikely	   to	   result	   in	  bleeding	  complications	  as	  a	  side	  effect.	  	  Venous	  thrombosis	  occurs	  as	  a	  result	  of	  blood	  pooling,	  and	  flow	  distortion.	  These	  lead	  to	  local	  hypoxia,	  endothelial	  activation,	  subsequent	  release	  of	  WPB	  contents,	  and	  recruitment	  of	  immune	  cells	  and	  platelets,	  which	  is	  essential	  in	  thrombosis	  initiation	  (Von	  Bruhl	  et	  al	  2012).	  P-­‐selectin	  deficient	  mice,	  in	  which	  immune	  cells	  cannot	   be	   recruited,	   are	   protected	   from	   DVT.	   Therefore	   mechanisms	   of	   DVT	  appear	  not	   only	   to	   involve	  blood	   coagulation,	   but	   also	  have	  parallels	   to	   sterile	  inflammation.	   DVT	   can	   therefore	   be	   considered	   an	   immunothrombosis	  (Engelmann	   et	   al	   2013)	   as	   inflammatory	   components	   are	   involved	   in	   its	  formation.	  	  Mast	   cells	   were	   initially	   considered	   as	   good	   candidates	   for	   a	   potential	   role	   in	  DVT,	   but	   weather	   this	   role	   was	   to	   be	   protective	   or	   prothrombotic	   was	   to	   be	  investigated.	   	   This	   is	   because	   mast	   cell	   granules	   contain	   some	   inhibitors	   of	  coagulation	  such	  as	  heparin	  and	  tPA,	  and	  may	  therefore	  inhibit	  thrombosis,	  but	  also	   contain	   pro-­‐inflammatory	   mediators	   such	   as	   histamine	   and	   TNF-­‐α,	   and	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given	   that	   inflammatory	   components	   play	   a	   role	   in	   DVT	   mast	   cells	   could	  potentially	  be	  prothrombotic.	  	  	  In	  this	  chapter	  we	  have	  shown	  that	  two	  strains	  of	  mast	  cell	  deficient	  mice;	  KitW-­‐sh	  and	  KitW-­‐v	  are	  completely	  protected	  against	  DVT,	  using	   the	   IVC	  stenosis	  model.	  This	   phenotype	  was	   striking,	  with	  0%	  of	  mice	  producing	   a	   thrombus	   in	   either	  strain.	  This	  result	  suggests	  that	  of	  mast	  cells	  exacerbate	  venous	  thrombosis,	  and	  the	  mast	  cells	  contain	  a	  pro-­‐thrombotic	  components/s,	  whose	  role	  in	  thrombus	  formation	   outweighs	   that	   of	   the	   other	   anti-­‐coagulant	   components	   such	   a	  heparin.	  A	   potential	   reason	   why	   mast	   cell	   prothrombotic	   components	   play	   a	   more	  important	   role	   in	   DVT	   that	   the	   anti-­‐thrombotic	   components,	   could	   be	   due	   to	  their	   location	   in	   the	   vessel	   wall.	   As	   mast	   cells	   are	   found	   in	   the	   tissues	  surrounding	   the	   IVC,	   they	  have	   the	  ability	   to	  secrete	   their	  granules	  contents	   to	  the	   abluminal	   side	   of	   the	   endothelium.	   Here	   the	   inflammatory	  mediators	  may	  activate	   the	  endothelium,	  but	   the	  anticoagulant	   components	   (heparin	  and	   tPA)	  cannot	  actually	  reach	  the	  blood	  steam	  to	  mediate	  their	  effect.	  	  However	  we	  cannot	  categorically	  state	  this	  is	  the	  only	  process	  leading	  to	  DVT,	  as	  a	   small	  number	  of	  WT	  mice	  do	  not	  produce	  a	   thrombus	   in	   the	   stenosis	  model.	  Therefore	   mast	   cells	   may	   not	   be	   prothrombotic	   in	   some	   cases,	   and	   other	  processes	   may	   be	   involved.	   It	   should	   also	   be	   noted	   these	   results	   have	   been	  obtained	   in	   mouse	   models,	   and	   further	   translational	   studies	   are	   needed	   in	  patients	  to	  verify	  their	  validity	  in	  humans.	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Mast	  cell	  deficient	  mice	  we	  used	  in	  these	  experiments,	  carrying	  mutations	  in	  the	  c-­‐Kit	   receptor	   (CD117)	   are	   known	   to	   have	   other	   abnormalities.	  We	  wanted	   to	  rule	   out	   any	   of	   these	   other	   abnormalities	   as	   potential	   causes	   of	   the	  antithrombotic	  phenotype	  shown	  in	  the	  Kit	  mutant	  mice,	  and	  prove	  it	  is	  indeed	  the	  lack	  of	  mast	  cells	  that	  specifically	  cause	  this	  effect.	  	  It	  has	  been	  reported	  that	  KitW-­‐sh	  mice	  also	  have	  abnormal	  vascular	  permeability,	  and	   that	  KitW-­‐v	  mice	   have	  macrocytic	   anemia,	   both	   stains	   of	  mast	   cell	   deficient	  mice	  may	  also	  have	  other	  not	  yet	  known	  defects	  as	  a	  result	  of	  the	  Kit	  mutation.	  	  To	   rule	   these	   possibilities	   out,	   we	   performed	   adoptive	   transfer	   of	   in	   vitro	  differentiated	  mast	  cells	  into	  the	  KitW-­‐sh	  mice;	  it	  has	  been	  previously	  shown	  that	  this	  approach	  restores	  tissue	  pools	  of	  mast	  cells	  within	  2-­‐3	  months	  (Wolters	  et	  al	  2005).	  Adoptive	  transfer	  restored	  thrombosis	  in	  mast	  cell	  deficient	  mice,	  further	  supporting	  the	  fact	  that	  lack	  of	  mast	  cells	  is	  responsible	  for	  the	  anti-­‐thrombotic	  phenotype,	  not	  any	  other	  defects	  caused	  by	  the	  c-­‐Kit	  mutation.	  Although	  it	  is	  not	  known	   if	  engraftment	  of	   transferred	  mast	  cells	   is	   the	  same	  as	   the	  normal	  mast	  cell	   distribution	   pattern,	   this	   would	   be	   a	   likely	   explanation	   however	   if	   the	  phenotype	  was	  not	  restored	  following	  mast	  cell	  infusion.	  	  	  We	  knew	  that	  mast	  cells	  were	  found	  near	  blood	  vessels	  (Metcalfe	  et	  al	  1997),	  but	  we	   wanted	   to	   further	   investigate	   if	   they	   are	   found	   in	   the	   IVC.	   Staining	   with	  toluidine	   blue	   showed	   that	   mast	   cells	   were	   located	   the	   IVC	   wall,	   close	   to	   the	  abluminal	   part	   of	   the	   endothelium.	   Staining	   showed	   that	   there	   were	   fewer	  granule	   containing	   mast	   cells	   in	   ICVs	   after	   stenosis	   where	   a	   thrombus	   had	  formed.	  Whereas,	  if	  a	  thrombus	  did	  not	  form,	  there	  was	  no	  significant	  change	  in	  mast	  cell	  number	  between	  WT	  and	  IVCs	  which	  underwent	  stenosis.	  This	  result	  
	  	   118	  
suggests	   that	   there	   is	   a	   link	  between	   functional	  mast	   cells	   and	  DVT	   formation,	  and	  the	  fact	  that	  less	  mast	  cells	  are	  found	  in	  IVCs	  where	  a	  thrombus	  has	  formed,	  suggests	  their	  released	  granule	  contents	  might	  be	   linked	  to	  DVT.	  We	  cannot	  be	  sure	  however	  if	  mast	  cells	  become	  fully	  degranulated	  which	  is	  why	  they	  do	  not	  stain	   with	   toluidine	   blue,	   or	   if	   they	   migrate	   out	   of	   the	   IVC	   wall.	   However	  disappearance	  of	  mast	  cells	  in	  thrombosed	  IVCs	  does	  suggest	  that	  their	  released	  cargo	  triggers	  DVT.	  	  	  We	  wanted	  to	  next	  investigate	  if	  mast	  cells	  could	  be	  targeted	  pharmacologically,	  which	   would	   probably	   be	   more	   clinically	   relevant,	   as	   well	   as	   showing	   this	  phenotype	   in	   mice	   with	   genetic	   mutations.	   Many	   drugs	   are	   already	   on	   the	  market	  which	  inhibit	  mast	  cell	  degranulation	  such	  as	  anti-­‐histamines,	  which	  are	  used	   in	   allergies.	   We	   firstly	   used	   a	   mast	   cell	   secretagogue	   48-­‐80	   and	  administered	  it	  over	  a	  period	  of	  4	  days	  to	  mice	  in	  order	  to	  degranulate	  mast	  cells.	  This	  appeared	  to	  be	  protective	  in	  DVT,	  and	  none	  of	  the	  mice	  administered	  40-­‐80	  developed	  a	  thrombus.	  	  	  We	   then	   performed	   a	   similar	   experiment,	   using	   the	   mast	   cell	   membrane	  stabilizers	  sodium	  cromoglycate	  and	  Ketotifen.	  This	  produces	  a	  similar	  effect	  but	  instead	  of	  depleting	  the	  granules	  contents,	  prevents	  the	  mast	  cell	  secreting	  their	  contents.	   Both	   membrane	   stabilizers	   also	   protected	   mice	   from	   DVT	  development.	  When	  used	  as	  a	  mast	  cell	  stabilizers	  these	  compounds	  do	  not	  have	  an	  anti-­‐platelet	  effect	  as	  shown	  by	  Platelet	  Function	  Analyzer-­‐100,	  therefore	  we	  know	  this	  effect	  is	  not	  attributed	  to	  platelet	  inhibition.	  The	  anti-­‐thrombotic	  effect	  seen	   after	   chronic	   administration	   of	   40-­‐80	   could	   be	   attributed	   to	   the	   down	  
	  	   119	  
regulation	  of	   coagulation	   factor	  VII	   (Chu	  et	  al	  2000),	   and	   therefore	   it	  may	  also	  inhibit	  the	  coagulation	  cascade,	  as	  well	  as	  deplete	  mast	  cell	  granules.	  	  We	  further	  explored	  this	  by	  investigating	  if	  topical	  application	  of	  the	  mast	  cells	  secretagogue,	   compound	   48-­‐80	   could	   potentiate	   thrombosis.	   A	   dramatic	  increase	   in	   thrombosis	   prevalence	   was	   seen	   in	   WT	   mice	   treated	   with	   this	  compound	   compared	   to	   controls.	   This	   suggested	   it	   is	   a	   mast	   cell	   granule	  constituent	   responsible	   for	   this	   phenotype.	   A	   likely	   candidate	   was	   histamine,	  seeing	  as	  is	  a	  small	  molecule	  and	  can	  stimulate	  the	  endothelium	  causing	  WPB	  to	  be	  released.	  We	  therefore	  performed	  local	  topical	  application	  of	  histamine	  to	  the	  IVCs	  of	  WT	  and	  Kit	  mice.	  Histamine	  potentiated	  thrombosis	  in	  the	  WT	  mice,	  and	  was	   able	   to	   induce	  DVT	   in	  mast	   cell	   deficient	  mice.	   These	   results	   suggest	   that	  histamine	   is	   the	   likely	   candidate	   in	  mast	   cells	   that	   is	   responsible	   for	   the	   pro-­‐thrombotic	  effect.	  	  We	   also	   performed	   intravital	   microscopy	   to	   investigate	   how	   mast	   cells	   may	  effect	  platelet	  recruitment	  to	  the	  vessel	  wall	  post	  stenosis.	  In	  mast	  cell	  deficient	  mice	  only	  single	  platelets	  firmly	  adhered	  to	  the	  vessel	  wall	  with	  the	  majority	  of	  them	   being	   carried	   away	   in	   the	   direction	   of	   the	   blood	   flow.	  We	   know	   platelet	  recruitment	   is	   vital	   for	   DVT	   formation,	   and	   that	   this	   process	   is	   dependent	   on	  WPBs	  releasing	  WVF.	   	  We	  measured	  plasma	  levels	  of	  WVF	  and	  show	  that	  these	  are	   reduced	   in	   KitW-­‐sh	  mice	   compared	   to	   WTs.	   Therefore	   mast	   cells	   somehow	  maintain	   VWF	   secretion,	   and	   probably	   contribute	   to	   DVT	   by	   activating	   the	  endothelium	  to	  release	  WPBs.	  We	  further	  show	  in	  in-­‐vitro	  studies	  that	  mast	  cell	  releasate	  was	  able	  to	  stimulate	  expression	  of	  ICAM-­‐1	  on	  HUVECS.	  ICAM-­‐1	  is	  an	  adhesion	  receptor	  for	  leukocytes.	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Mast	   cells	  are	   therefore	  able	   to	   support	  DVT	  by	  up	   regulating	  endothelial	   cells	  and	  causing	  WBPs	  to	  secrete	  WVF	  and	  P-­‐selectin.	  	  Plasma	  soluble	  P-­‐selectin	  is	  known	  to	  be	  a	  biomarker	  of	  DVT	  as	  it	  promotes	  DVT	  in	  mice	   (Antonopoulos	  et	  al	  2014;	  Ramacciotti	  et	  al	  2011).	  We	  show	  that	  mast	  cells	  are	  able	  to	  regulate	  sP-­‐selectin	  in	  the	  plasma,	  as	  while	  IVC	  stenosis	  caused	  an	   increased	   in	   plasma	   sP-­‐selectin	   levels	   in	   WT	   mice,	   this	   increase	   was	   not	  observed	  in	  KitW-­‐sh	  mice	  lacking	  mast	  cells.	  The	  increase	  in	  plasma	  sP-­‐selectin	  	  in	  WT	  mice	   following	   stenosis	   supports	   the	   similarities	   of	  DVT	   in	  humans	   and	  the	   animal	  model.	   The	   elevated	   plasma	   sP-­‐selectin	   could	   originate	   from	   either	  platelets	  or	  the	  endothelium,	  but	  regardless	  of	  the	  origin,	  this	  result	  shows	  it	  is	  also	  regulated	  by	  mast	  cells.	  	  In	  conclusion,	  throughout	  this	  chapter	  we	  have	  provided	  evidence	  that	  mast	  cells	  are	   important	   regulators	   of	   DVT.	   And	   blocking	   mast	   cells	   can	   be	   protective	  against	  venous	  thrombosis.	  The	  pro-­‐thrombotic	  effect	  mediated	  by	  mast	  cells	  is	  most	  likely	  to	  be	  through	  release	  of	  histamine,	  although	  we	  cannot	  rule	  out	  other	  mast	  cell	  granule	  components.	  Because	  temporarily	  blocking	  mast	  cell	  is	  unlikely	  to	   have	   any	   bleeding	   side	   effects,	   as	   KitW-­‐sh	  mice	   show	   normal	   bleeding	   times,	  mast	  cells	  are	  potentially	  a	  good	  target	  for	  preventing	  DVT	  in	  humans.	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5.1	  Introduction	  	  It	   is	  now	  commonly	  known	  that	  during	  the	   formation	  of	  deep	  vein	  thrombosis,	  inflammatory	  cells	  accumulate	   in	   the	  vessel	  wall	  and	   in	   the	  thrombus,	  and	   it	   is	  not	  only	  platelets	  and	  RBCs	  that	  are	  important	  in	  this	  thrombus	  formation	  (Diaz	  2011).	  Inflammation	  and	  thrombosis	  are	  now	  considered	  to	  be	  intimately	  linked;	  in	   fact	   DVT	   can	   be	   considered	   as	   an	   immunothrombotic	   disease	   (Saha	   et	   al	  2011).	  Many	   treatments	   for	   DVT	   are	   concerned	  with	   preventing	   thrombus	   growth	   or	  extension	   such	   as	   anticoagulants,	   but	   few	   have	   an	   effect	   on	   existing	   thrombi	  which	  are	  able	  to	  resolve	  naturally,	  a	  process	  in	  which	  immune	  cells	  are	  believed	  to	  play	  a	  critical	  role	  (Mondarai	  et	  al	  2005).	  Treatments	   that	   speed	   up	   the	   thrombus	   resolution	   process,	   for	   example	  mechanical	  removal	  or	  thrombolysis,	  are	  associated	  with	  bleeding	  complications	  and	   increased	   risk	   of	  mortality.	   Treatment	   options,	  which	   could	   accelerate	   the	  natural	  thrombus	  resolution	  process,	  would	  be	  very	  attractive,	  as	  these	  would	  be	  associated	  with	  less	  complicated	  side	  effects	  (Patterson	  et	  al	  2010).	  	  	  A	   number	   of	   immune	   cells	   are	   implicated	   in	   inflammatory	   diseases,	   and	   some	  have	  been	  shown	  to	  play	  important	  roles	  in	  diseases	  such	  as	  atherosclerosis	  and	  DVT.	  One	  such	  important	  immune	  cell	  is	  the	  T-­‐lymphocyte,	  or	  T-­‐cell.	  	  T-­‐cells	   are	   a	   type	   of	   white	   blood	   cells	   that	   play	   a	   critical	   role	   in	   the	   immune	  response.	  There	  are	  different	   subsets	  of	  T-­‐cells;	  helper,	   regulatory	  or	   cytotoxic	  cells.	  Cytotoxic	  T-­‐cells	  or	  ‘killer’	  cells	  are	  activated	  by	  various	  cytokines	  and	  bind	  to,	  and	  destroy	  infected	  cells.	  T-­‐helper	  cells	  secrete	  cytokines,	  and	  these	  chemical	  messengers	   stimulate	   B-­‐cells	   to	   differentiate	   into	   antibody	   producing	   plasma	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cells.	  Regulatory	  T-­‐cells	   (Tregs)	  play	  a	   critical	   role	   in	   suppressing	  an	  excessive	  immune	  response	  and	  maintaining	  self-­‐tolerance.	  A	  deficiency	  in	  T-­‐reg	  cells	  can	  cause	   a	   number	   of	   allergies	   or	   autoimmune	   diseases.	   There	   are	   different	  subpopulations	   of	   Treg	   cells	   including	   natural	   Tregs,	   which	   are	   most	   well	  studied	   and	   express	   the	   surface	  markers	   CD4,	   CD25	   and	   Foxp3.	   These	   natural	  Treg	   cells	   develop	   in	   the	   thymus	   and	   have	   a	   predetermined	   function	   to	   be	  specialist	   suppressive	   cells.	   Other	   types	   such	   as	   inducible	   Tregs	   are	   more	  adaptive,	   and	   acquire	   their	   function	   after	   coming	   into	   contact	   with	   specific	  antigens	  (Xu	  et	  al	  2013).	  There	  have	  been	  reports	  that	  Tregs	  play	  a	  protective	  role	  in	  a	  number	  of	  diseases	  including	   myocardial	   infarction,	   atherosclerosis	   and	   in	   ischemia/reperfusion	  injury	  in	  liver	  and	  kidney.	  This	  protective	  role	  has	  been	  attributed	  to	  the	  ability	  of	  Tregs	  to	  relieve	  an	  excessive	  inflammatory	  response	  (Xu	  et	  al	  2013).	  	  A	  number	  of	  studies	  have	  shown	  T-­‐cells	  to	  be	  implicated	  in	  arterial	  diseases.	  For	  example	  atherosclerosis	  (Mor	  et	  al	  2007),	  however	  there	  is	  still	  controversy	  over	  whether	  T-­‐cells	  play	  a	  protective	  or	  deleterious	  role.	  Because	   atherosclerosis	   is	   considered	   to	   be	   an	   inflammatory	   disease,	   T-­‐cells	  appeared	  to	  be	  good	  candidates	  for	  potentially	  regulating	  this	  inflammation.	  This	  is	  because	  they	  influence	  plaque	  development	  by	  secreting	  mediators,	  and	  they	  are	  regulated	  by	  both	  soluble	  and	  membrane	  bound	  molecules	  from	  many	  cells	  at	  the	  disease	  site	  (Robertson	  et	  al	  2006).	  It	  was	  shown	  by	  Robertson	  et	  al	  (2006)	  that	  the	  predominant	  T	  cell	  subset	  found	  in	   atherosclerotic	   lesions	   in	   apoE-­‐/-­‐	   and	   LDLR-­‐/-­‐	   mice	   were	   CD4+	   T-­‐cells.	   In	  these	  mice	  it	  was	  shown	  that	  a	  deficiency	  in	  adaptive	  immunity	  led	  to	  a	  decrease	  atherosclerosis.	   If	   immune	   deficient	   scid/scid	   mice	   were	   reconstituted	   with	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CD4+	   cells,	   this	   accelerated	   atherosclerosis,	   demonstrating	   the	   important	   role	  they	  play	  in	  the	  disease.	  Further	  work	  supported	  this	  theory,	  using	  anti-­‐CD4	  antibodies	  to	  deplete	  these	  cells	  in	  C57BL6	  mice;	  this	  reduced	  fatty	  streak	  development,	  with	  the	  mice	  on	  an	  atherogenic	   diet	   (Huber	   et	   al	   2001).	   Authors	   suggest	   that	   T-­‐cell	   activation	   is	  important	   for	   the	   early	  progression	  of	   the	  disease,	   but	  not	   for	   its	   initiation.	  T-­‐cells	  play	  a	  vital	  role	  in	  the	  balancing	  act	  between	  if	  an	  atherosclerotic	  lesion	  will	  develop	   into	  a	  stable	  plaque,	  or	   if	  an	   immune	  reaction	  could	   lead	  to	  rupture	  of	  the	  plaque	  and	  eventually	  end	  in	  stroke.	  	  It	  has	  been	  shown	  that	  T-­‐regulatory	  cells	  (Tregs)	  may	  have	  a	  role	  in	  changing	  the	  functional	  status	  of	  the	  endothelium.	  The	  role	  that	  they	  play	  in	  ischemic	  stroke	  is	  still	  very	  controversial.	  Two	  theories	  have	  been	  put	  forward,	  one	  that	  they	  have	  a	   protective	   role	   against	   ischemic	   injury	   by	   modulating	   the	   inflammatory	  response.	  And	  conversely,	  that	  they	  could	  potentially	  be	  exacerbating	  the	  insult	  by	  causing	  micro	  vascular	  dysfunction	  (Xu	  et	  al	  2013).	  	  Liesz	   et	   al	   have	   shown	   that	   Tregs	  might	   have	   a	   protective	   role	   in	   post-­‐stroke	  injury	   by	   preventing	   secondary	   infarct	   growth.	   They	   used	   2	   different	   mouse	  model	  approaches	   to	  show	  this.	  The	  model	  of	  middle	  cerebral	  artery	  occlusion	  (MCAO)	  was	  used	   in	  mice	   that	  had	  been	  administered	  anti-­‐CD25	  antibody	   two	  days	   previously,	   which	   specifically	   depletes	   Tregs.	   Mice	   deficient	   in	   Tregs	  showed	   significantly	   enlarged	   infarct	   size,	   and	   significantly	   worse	   neuronal	  function.	  They	  further	  verified	  this	   finding	  by	  performing	  adoptive	  cell	   transfer	  of	  Tregs	   into	  Rag2-­‐/-­‐	  mice	  that	   lack	   lymphocytes.	  Mice	  that	  received	  Tregs	  had	  significantly	  smaller	  infarcts	  following	  MCAO	  than	  those	  mice	  that	  only	  received	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CD4+	  T-­‐cells,	  demonstrating	  that	  lack	  of	  Tregs	  is	  probably	  associated	  with	  worse	  outcome.	  	  Furthermore	  other	  studies	  have	  supported	  this	  protective	  role,	  Li	  et	  al	  (2012)	   showed	   that	   post	   stroke,	   adoptive	   transfer	   on	  Tregs	  within	   24	   h	   could	  dramatically	   reduce	   ischemic	   stroke	   volume,	   and	   showed	   prolonged	   beneficial	  effects.	  In	  contrast	  to	  these	  findings,	  Kleinschnitz	  et	  al	  (2013)	  show	  that	  Tregs	  may	  have	  a	  negative	   role,	   and	   could	   in	   fact	   exacerbate	   ischemic-­‐reperfusion	  damage	  24h	  after	   stoke.	   They	   used	   DEREG	   mice,	   which	   had	   depleted	   Tregs	   to	   show	   that	  following	  60	  mins	  MCAO,	  there	  was	  in	  fact	  a	  decrease	  in	   infarct	  volume	  and	  an	  improvement	   in	   neurological	   function.	   Similarly	   to	   Liez	   et	   al	   (2009),	   they	   also	  performed	  adoptive	  transfer	  studies	  into	  Rag2-­‐/-­‐	  mice.	  However	  Kleinschnitz	  et	  al	   report	   that	   mice	   that	   received	   adoptively	   transferred	   Tregs,	   had	   increased	  infarct	  size.	  	  While	  the	  controversy	  remains	  over	  if	  Tregs	  have	  a	  positive	  or	  negative	  impact	  on	  post-­‐stroke	  outcome,	  some	  studies	  have	  contradicted	  both	  and	  have	  actually	  found	  them	  to	  have	  neither	  effect	  (Stubbe	  et	  al	  2013).	  Ren	  et	  al	  (2011)	  also	  used	  the	   DEREG	   mouse	   model,	   and	   following	   60	   min	   MCAO	   showed	   no	   significant	  difference	  in	  infarct	  size	  between	  mice	  with	  or	  without	  Tregs.	  	  	  Tregs	  adhere	  to	  the	  vascular	  endothelium	  and	  it	  is	  therefore	  possible	  that	  they	  activate	   or	   down	   regulate	   it,	   as	   well	   the	   role	   of	   T-­‐cells	   in	   arterial	   thrombotic	  disorders,	   others	   have	   previously	   reported	   that	   T-­‐cells	   may	   play	   a	   role	   in	  regulating	  post-­‐thrombotic	  vein	  wall	   inflammation,	  and	  resolution	  of	  deep	  vein	  thrombosis	  in	  vivo	  (Luther	  2016).	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Siefert	  et	  al	  (2014)	  studied	  the	  role	  of	  T-­‐cells	   in	  DVT	  resolution.	  They	  used	  the	  stasis	  model	  to	  replicate	  DVT	  in	  T	  cell	  depleted	  mice,	  achieved	  using	  an	  anti-­‐CD3	  antibody.	  Thrombus	  resolution	  in	  both	  control	  and	  T-­‐cell	  depleted	  animals	  was	  measured	  by	  thrombus	  and	  vein	  wall	  weight.	  	  Mice	  that	  were	  depleted	  of	  T-­‐cells	  during	   thrombus	   resolution	   (day	   0-­‐12)	   resulted	   in	   a	   35%	   increase	   in	   thrombi	  size	  by	  day	  12	  compared	  to	  controls.	  This	  highlights	  that	  T-­‐cell	  depletion	  impairs	  thrombus	  resolution.	  Thrombi	  were	  also	  analyzed,	  and	  those	  from	  mice	  in	  which	  T-­‐cells	   had	   been	   depleted,	   showed	   decreased	   levels	   of	   several	   important	  mediators	   of	   thrombus	   resolution	   such	   as	   plasminogen	   activator	   inhibitor-­‐1	  (PAI-­‐1)	  and	  urokinase	  plasminogen	  activator	  (uPA).	  	  Their	  results	  suggest	  that	  T-­‐cells	   are	   important	   in	   regulating	   the	   expression	   of	   these	   mediators	   upon	  recruitment	  to	  the	  resolving	  thrombus	  and	  that	  T-­‐cells	  are	  important	  players	  in	  the	  process	  of	  resolution.	  	  Others	  have	  also	  reported	  this	  role	  in	  thrombus	  resolution.	  It	  is	  known	  that	  both	  CD4+	  and	  CD8+	  T-­‐cells	  infiltrate	  the	  thrombus	  and	  vein	  wall	  upon	  DVT	  initiation,	  Luther	   et	   al	   (2016)	   suggest	   that	   in	   the	   vein	  wall	   the	   cells	  most	   predominantly	  recruited	  are	  effector-­‐memory	  T-­‐cells.	  And	  these	  cells	  are	  important	  in	  thrombus	  resolution	  by	  also	  recruiting	  neutrophils	  and	  monocytes	  to	  the	  thrombus.	  They	  show	  that	  depletion	  of	  effector-­‐memory	  T-­‐cells	  delayed	  thrombus	  resolution.	  	  While	  previous	  studies	  have	  shown	  that	  T-­‐cells	  play	  a	  role	  in	  the	  pathogenesis	  of	  many	   arterial	   thrombotic	   disorders,	   and	   that	   they	   are	   also	   important	   in	   the	  resolution	  of	  DVT,	  we	  wanted	  to	   further	   investigate	   if	   they	  played	  a	  role	   in	   the	  initiation	  of	  DVT.	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T	   cells	   are	   not	   the	   only	   immune	   cells	   suggested	   to	   have	   a	   role	   in	   vascular	  diseases.	   B-­‐cells	   have	   also	   been	   shown	   to	   play	   a	   role	   for	   example	   in	  atherosclerosis.	  B	  cells	  can	  be	  divided	   into	   two	  subsets;	  B1	  and	  B2	  cells.	   It	  has	  been	  suggested	  that	  B1	  cells	  are	  atheroprotective,	  and	  they	  exert	  this	  protection	  via	  the	  production	  of	  natural	   IgM	  antibodies	  (Tsiantoulas	  et	  al	  2015).	  Whilst	   in	  contrast	  it	  is	  suggested	  that	  B2	  cells	  are	  proatherogenic.	  For	  certain	  autoimmune	  disorders	   such	   as	   rheumatoid	   arthritis,	   depletion	   of	   B	   cells	   has	   become	   a	  valuable	  treatment	  option.	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
	  	   128	  
5.2	  Results	  	  5.2.1	  –	  Nude	  mice	  appear	  to	  have	  a	  prothrombotic	  phenotype	  in	  DVT	  In	   order	   to	   investigate	   if	   T-­‐cells	   play	   a	   role	   in	  deep	   vein	   thrombosis,	  we	   again	  used	   the	   IVC	   stenosis	   model	   as	   previously	   described	   in	   methods	   (2.7.3)	   on	  Foxn1nu,	   or	   ‘nude’	  mice.	   Nude	  mice	   have	   a	  mutation	   in	   the	   FOXN1	   gene,	   and	  subsequently	   have	   an	   absent	   thymus,	   and	   therefore	   are	   unable	   to	   produce	   T-­‐lymphocytes.	  	  IVC	  stenosis	  was	  performed	  for	  two	  different	  time	  points,	  for	  48	  h	  and	  for	  6	  h.	  48	  h	  after	  stenosis,	  70%	  of	  nude	  mice	  (with	  absent	  T-­‐cells)	  produced	  a	   thrombus,	  and	  60%	  of	  nude	  mice	  produced	  a	   thrombus	  after	  6	  hours	   (figure	  5.1).	  However	  only	  40%	  of	  WT	  mice	  produced	  a	  thrombus	  after	  48	  h,	  and	  only	  10%	  of	  WT	  mice	  after	  6	  h.	  Thrombosis	  prevalence	  in	  the	  WT	  mice	  were	  however	  lower	  than	  would	  be	  expected,	  and	  lower	  than	  described	  in	  the	  literature	  (Brill	  et	  al	  2011).	  This	  discrepancy	  could	  be	  attributed	  to	  different	  sources	  of	  WT	  mice	  (Jackson	  Lab	  Vs.	  Taconic	  of	  Charles	  River),	  or	  differences	  in	  their	  diet.	  	  Although	  a	  preliminary	  result,	   there	  seemed	  to	  be	  an	  obvious	  phenotype	  in	  the	  nude	  mice	  (figure	  5.1),	  with	  thrombosis	  prevalence	  being	  significantly	  higher	  in	  those	   mice	   without	   T-­‐cells,	   compared	   to	  WTs	   at	   both	   time	   points.	   This	   could	  suggest	  that	  T-­‐cells	  offer	  a	  protective	  role	  in	  DVT	  development.	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  5.2.2-­‐	  T-­‐regulatory	  cells	  do	  not	  appear	  to	  be	  protective	  in	  DVT	  	  	  As	  nude	  mice	  have	  an	  absent	  thymus,	  they	  are	  depleted	  of	  all	  T-­‐cells.	  We	  decided	  to	  do	  further	  studies	  but	  investigating	  the	  role	  more	  specifically	  of	  one	  subset	  of	  T-­‐cells;	  the	  T-­‐regulatory	  cells	  (Tregs).	  Tregs	  have	  already	  been	  reported	  to	  play	  a	  role	  in	  a	  number	  of	  diseases	  including	  atherosclerosis	  and	  ischemia	  reperfusion	  injury	   in	   liver	   and	   kidney	   (Xu	   et	   al	   2013).	   As	   previously	   stated	   this	   protective	  role	  was	  attributed	   to	   the	  ability	  of	  Tregs	   to	  relieve	  an	  excessive	   inflammatory	  response.	  As	  DVT	  has	  inflammatory	  components,	  we	  investigated	  the	  role	  these	  T-­‐regulatory	  cells	  may	  play.	  	  C57BL6	  mice	  were	   injected	  with	   an	   anti-­‐CD25	   antibody	   48	   hours	   prior	   to	   IVC	  stenosis.	   T-­‐regulatory	   cells	   constitutively	   express	   IL-­‐2R	   alpha	   chain	   (CD25)	   on	  their	   surface	   therefore	   the	   anti-­‐CD25	   antibody	   depletes	   the	   T-­‐reg	   population	  (Noris	  et	  al	  2007).	  The	  control	  group	  was	  injected	  with	  an	  IgG	  control	  antibody.	  Thrombi	  were	  then	  removed	  and	  measured	  6h	  post	  stenosis.	  In	  contrast	  to	  the	  nude	  mice,	   those	  mice	  that	  received	  an	  anti-­‐CD25	  Ab	  did	  not	  have	   a	   pro-­‐thrombotic	   phenotype.	   40%	   of	   mice	   that	   received	   the	   anti-­‐CD25	  antibody	  produced	  a	  thrombus,	  compared	  to	  20%	  of	   the	  IgG	  control	  mice.	  This	  was	   not	   significantly	   different	   (0.32),	   and	   suggests	   that	   Tregs	   do	   not	   play	   a	  protective	  role	  in	  DVT.	  However	  thrombosis	  prevalence	  was	  measured	  after	  6	  h,	  compared	  to	  in	  the	  nude	  mice	  that	  were	  measured	  after	  48	  h	  stenosis.	  Also	  only	  20%	  of	  control	  mice	  produced	  a	  thrombus,	  which	  as	  previously	  stated	   is	   lower	  than	  we	  would	  expect,	  possibly	  due	  to	  differences	  in	  the	  source	  of	  mice.	  Another	  consideration	  is	  that	  we	  did	  not	  achieve	  100%	  depletion	  of	  Tregs	  with	  the	  anti-­‐CD25	  Antibody	  depletion.	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Figure	  5.2	  –	  No	  phenotype	  was	  observed	  after	  injection	  of	  C57BL6	  mice	  
with	  anti-­‐CD25	  Ab.	  	  
	  C57BL6	  mice	  received	  an	  injection	  of	  either	  IgG	  control	  or	  anti-­‐CD25	  antibody	  48	  hours	   prior	   to	   IVC	   stenosis.	   Thrombosis	   prevalence	   and	   thrombi	   weight	   are	  shown	  above	  6	  h	  after	  stenosis.	  Each	  dot	  represents	  one	  mouse,	  for	  both	  groups	  n=10.	  ii)	  Shows	  Thrombosis	  prevalence	  was	  20%	  in	  the	  IgG	  control,	  and	  40%	  in	  anti-­‐CD25	   group.	   There	  was	   no	   significant	   difference	   in	   deep	   vein	   thrombosis	  prevalence	  between	  those	  mice	  that	  had	  T-­‐regulatory	  cells	  and	  those	  that	  did	  not	  (p=0.32).	  Statistical	  analysis	  was	  performed	  using	  a	  contingency	  table,	  followed	  The	  Fisher’s	  exact	  test.	  (Performed	  in	  collaboration	  with	  A.Brill)	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Figure	  5.3	  -­‐	  Rag1-­‐/-­‐	  mice	  (no	  mature	  B	  or	  T	  lymphocytes)	  are	  not	  
prothrombotic	  	  Both	   Rag1-­‐/-­‐	   and	  WT	  mice	   underwent	   stenosis	   of	   the	   IVC	   and	   after	   48	   hours	  thrombus	  prevalence	  and	  weight	  was	  measured.	  30%	  of	  Rag1-­‐/-­‐	  mice	  produced	  a	  thrombus,	  compared	  to	  50%	  of	  WT	  mice;	  this	  was	  not	  a	  significant	  difference	  (p=0.37).	  Each	  dot	  represents	  one	  mouse	  (Rag1-­‐/-­‐	  mice	  n=	  13,	  WT	  mice	  n=	  8).	  Statistical	   analysis	   was	   performed	   using	   a	   contingency	   table,	   followed	   by	   the	  Fisher’s	  exact	  test.	  (Performed	  in	  collaboration	  with	  A.Brill)	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  5.2.4	  T-­‐cells	  are	  present	  in	  DVT	  thrombi	  of	  C57BL6	  mice	  partially	  co-­‐localized	  with	  neutrophils	  
	  As	  we	  hypothesized	  that	  T-­‐cells	  may	  be	  protective	  in	  deep	  vein	  thrombosis,	  or	  at	  least	  play	  some	  role,	  we	   looked	  at	   if	  where	   they	  are	   localized	   in	   the	   thrombus.	  Figure	  5.4	  shows	  staining	  of	  a	  cross	  section	  of	  thrombi	  from	  a	  WT	  mouse	  after	  48	  h	   IVC	   stenosis.	   CD3	   is	   a	   T-­‐cell	  marker	   and	   these	   are	   shown	   in	   green,	   Gr1	   is	   a	  neutrophil	  marker	  and	   these	  are	   shown	  as	   red	   in	   figure	  5.4.	   It	   appears	   that	  T-­‐cells	   may	   partially	   co-­‐localize	   with	   neutrophils.	   It	   has	   been	   suggested	   that	  neutrophils	   may	   bind	   to	   the	   activated	   endothelium	   prior	   to	   platelets	   during	  thrombus	   formation,	   at	   least	   in	   the	   artery,	   and	   this	   may	   be	   a	   critical	   step	  (Darbousset	  et	  al	  2012).	   It	   is	  also	  known	  that	  neutrophils	  are	   important	   in	   the	  clotting	  cascade	  as	  they	  release	  extracellular	  traps	  (NETs)	  and	  bind	  to	  factor	  XIII.	  It	  is	  possible	  that	  NETs	  may	  also	  recruit	  T-­‐cells	  in	  the	  same	  way	  as	  they	  recruit	  platelets	  and	  RBCs	  (Fuchs	  et	  al	  2010).	  And	  it	  is	  unknown	  whether	  the	  interaction	  of	  T-­‐cells	  with	  neutrophils	  could	  affect	  NETosis.	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Figure	  5.4-­‐	  T-­‐cells	  are	  present	  in	  DVT	  thrombi	  and	  partially	  co-­‐localize	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5.3-­‐	  Discussion	  	  Studies	  have	  previously	   shown	   that	   inflammatory	   cells	   accumulate	   in	   both	   the	  vein	   wall	   and	   in	   the	   thrombus	   during	   the	   progression	   of	   venous	   thrombotic	  disorders	   (Saha	  et	  al	  2011).	  Further	   research	  has	  confirmed	   that	   inflammation	  and	  thrombus	  are	  intimately	  linked,	  this	  is	  now	  well	  known.	  However	  the	  exact	  contribution	  of	  each	  immune	  cell	  to	  venous	  thrombosis	  is	  still	  controversial,	  and	  the	  mechanisms	  are	  not	  fully	  understood.	  We	  know	  that	  activation	  of	  the	  endothelium	  is	  a	  crucial	  step	  in	  the	  formation	  of	  DVT;	  this	  activation	  leads	  to	  up-­‐regulation	  of	  tissue	  factor	  (TF),	  which	  is	  critical	  in	   thrombogenesis	   (Chu	   2011).	   The	   activation	   of	   the	   endothelium	   by	   immune	  cells	   is	   therefore	   probably	   an	   important	   inflammatory	   process	   resulting	   in	  thrombosis.	  	  As	   previously	   discussed,	   T-­‐cells,	   specifically	   T-­‐regulatory	   cells,	   have	   been	  suggested	   to	   play	   a	   role	   in	   a	   number	   of	   cardiovascular	   disorders	   such	   as	  myocardial	   infarction	   and	   atherosclerosis.	   This	   protective	   role	   has	   been	  attributed	  to	  the	  ability	  of	  Tregs	  to	  relieve	  an	  excessive	  inflammatory	  response.	  There	   is	   still	   some	   controversy	   however	   over	   whether	   these	   cells	   play	   a	  protective	  or	  deleterious	  role	  in	  the	  disease	  pathogenesis.	  	  We	  therefore	  wanted	  to	  investigate,	  using	  a	  number	  of	  mouse	  models,	   if	  T-­‐cells	  may	  play	  a	  role	  in	  deep	  vein	  thrombosis,	  which	  has	  an	  inflammatory	  component.	  We	   showed	   that	   Foxn1nu	   ‘nude	  mice’,	   which	   have	   and	   absent	   thymus	   and	   an	  inability	   to	   produce	   T-­‐lymphocytes,	   have	   a	   prothrombotic	   phenotype	   in	   DVT	  (results,	  figure	  5.1).	  We	  performed	  IVC	  stenosis	  for	  two	  time	  point’s	  6h	  and	  48h	  in	   both	   nude	   and	   WT	   mice.	   	   There	   was	   a	   significant	   difference	   between	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thrombosis	   prevalence	   in	   nude	   and	   WT	   mice	   after	   6	   h	   IVC	   stenosis	   (60%	  thrombosis	  prevalence),	  but	  although	  there	  was	  a	  trend	  this	  was	  not	  significantly	  different	  after	  48h	  (70%	  thrombosis	  prevalence).	   	  Although	   this	   is	  preliminary	  data,	  it	  does	  suggest	  that	  T-­‐cells	  may	  offer	  a	  protective	  role	  in	  DVT,	  and	  lack	  of	  T-­‐cells	   is	   detrimental.	   This	   could	   be	   due	   to	   their	   ability	   to	   reduce	   an	   excessive	  inflammatory	   response,	   and	   therefore	   reduce	   the	   number	   of	   platelets	   and	  further	   inflammatory	   mediators	   to	   the	   site.	   However	   in	   this	   experiment,	  thrombosis	  prevalence	  in	  WT	  mice	  was	  much	  lower	  than	  would	  be	  expected,	  and	  lower	   than	   is	   reported	   in	   the	   literature.	  We	   show	  WTs	   to	   have	   40%	  and	   10%	  thrombosis	   prevalence	   after	   48	   h	   and	   6	   h	   respectively,	   and	  we	  would	   usually	  expect	   to	   see	   ~60%.	   This	   difference	   could	   however	   be	   attributed	   to	   different	  sources	  of	  WT	  mice,	   or	  differences	   in	   their	  diet.	   Further	   studies	   are	  needed	   to	  confirm	   this	  phenotype,	   and	   these	   studies	   should	  use	   a	   greater	  number	  of	  WT	  mice,	  and	  they	  should	  be	  littermate	  controls.	  	  	  As	  nude	  mice	  have	  an	  absent	  thymus	  they	  do	  not	  have	  the	  ability	  to	  produce	  any	  T-­‐cells	   at	   all.	  We	  wanted	   to	   investigate	   further	  which	   specific	   subset	   of	  T-­‐cells	  were	   responsible	   for	   the	   phenotype	   seen	   in	   the	   nude	   mice,	   and	   therefore	  deceiver	   which	   T-­‐cells	   may	   be	   protective	   in	   DVT.	   T-­‐regulatory	   cells	   were	  considered	  to	  be	  a	  good	  candidate	  as	  they	  have	  already	  been	  shown	  to	  play	  a	  role	  in	  a	  number	  of	  cardiovascular	  diseases	  that	  have	  an	  inflammatory	  component.	  	  To	  do	  this	  we	  used	  an	  anti-­‐CD25	  antibody	  that	  specifically	  depletes	  T-­‐regulatory	  cells	   (Tregs),	   as	   they	   constitutively	   express	   IL-­‐2R	   alpha	   chain	   (D25)	   on	   their	  surface.	   C57BL6	  mice	   received	   an	   injection	   of	   the	   antibody	   48	   h	   prior	   to	   IVC	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stenosis.	   In	   contrast	   to	  nude	  mice,	  only	  40%	  of	  mice	   lacking	  Tregs	  produced	  a	  thrombus,	  and	  20%	  of	  WT	  mice	  (Results,	  figure	  5.2).	  	  Again,	  as	  previously	  stated,	  for	   unknown	   reasons	   thrombosis	   prevalence	   in	   the	  WT	  mice	  was	  much	   lower	  than	  would	  usually	  be	  expected.	  Also	  we	  measured	   thrombosis	  prevalence	  and	  thrombus	  weight	  6	  h	   after	   IVC	   stenosis,	   but	  not	   after	  48	  h.	   In	  order	   to	   further	  study	   if	   Tregs	   may	   have	   a	   role	   in	   DVT,	   we	   would	   repeat	   the	   experiment	   and	  perform	  IVC	  stenosis	   for	   two	   time	  points,	  both	  6	  h	  and	  48	  hrs.	   	  Another	   factor	  that	   we	   cannot	   rule	   out	   is	   that	   the	   anti-­‐CD25	   antibody	   did	   not	   achieve	   100%	  depletion	   of	   Tregs.	   The	   other	   possibility	   is	   that	   T-­‐regulatory	   cells	   are	   not	   the	  subset	  of	  cells	  that	  offer	  the	  protection	  seen	  in	  the	  nude	  mice.	  	  	  We	  next	  decided	  to	  use	  Rag1-­‐/-­‐	  mice	  to	  see	  if	  these	  have	  a	  phenotype	  similar	  to	  that	  of	  the	  nude	  mice.	  Rag1-­‐/-­‐	  mice	  have	  no	  T-­‐cells	  or	  B-­‐cells,	  as	  they	  are	  not	  able	  to	   perform	   VDJ	   recombination,	   the	   process	   where	   T	   and	   B-­‐cells	   randomly	  assemble	   different	   gene	   segments	   in	   order	   to	   generate	   their	   unique	   antigen	  receptors.	   B-­‐cells	   have	   also	   previously	   been	   implicated	   in	   a	   number	   of	  inflammatory	   diseases,	   specifically	   in	   atherosclerosis,	   but	   whether	   they	   are	  atheroprotective	  or	  proatherogenic	   is	  still	  under	  debate.	  We	  suspected	  that	  the	  absence	   of	   both	   B	   and	   T-­‐	   cells	   in	   combination	   may	   give	   a	   prothrombotic	  phenotype.	  As	  can	  been	  in	  results,	  figure	  5.3,	  this	  was	  not	  the	  case.	  Only	  30%	  of	  Rag1-­‐/-­‐	   mice	   produced	   a	   thrombus,	   compared	   to	   50%	   of	   the	   WT	   mice.	  Thrombosis	   prevalence	   in	   the	  WT	  mice	  was	   around	  what	  we	  would	   normally	  expect.	  This	  result	  suggested	  that	  T-­‐cells	  and	  B-­‐cells,	  or	  at	   least	   in	  combination	  do	  not	  exert	  a	  protective	  role	  in	  DVT,	  as	  mice	  lacking	  both	  of	  these	  immune	  cells	  still	  show	  lower	  levels	  of	  thrombosis	  than	  in	  controls.	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If	   T-­‐cells	   are	   implicated	   in	   DVT,	   as	   the	   data	   from	   the	   nude	  mice	   suggests,	   we	  wanted	  to	  know	  whereabouts,	  if	  at	  all,	  they	  are	  located	  in	  the	  thrombi	  following	  IVC	  stenosis,	  and	  if	  they	  possibly	  interact	  with	  any	  other	  immune	  cells.	  	  Because	  recent	  findings	  suggest	  neutrophils	  may	  also	  be	  important	  in	  promoting	  DVT	  through	  their	  release	  of	  their	  extracellular	  chromatin,	  forming	  NETs	  (Brill	  et	  al	   2012).	  We	   hypothesized	   that	   these	  NETs	  may	   be	   important	   in	   recruiting	   or	  capturing	  T-­‐cells	   in	  the	  same	  way	  they	  recruit	  platelets	  and	  RBCs.	  Figure	  5.4	  C,	  revealed	   that	   when	   staining	   for	   CD3	   (a	   T-­‐cell	   marker)	   and	   Gr1	   (a	   neutrophil	  marker)	   that	   these	  cells	  did	   in	   fact	   co-­‐localize	  within	   the	   thrombus.	  This	   could	  suggest	  because	  of	  their	  close	  proximity,	  that	  they	  do	  interact	  in	  some	  way.	  And	  potentially	  this	  may	  not	  be	  so	  T-­‐cells	  promote	  DVT,	  but	  they	  could	  be	  involved	  in	  thrombus	  resolution.	  	  As	  our	  results	  are	  very	  preliminary,	  and	  it	  is	  still	  not	  clear	  if	  T-­‐cells	  may	  exert	  a	  protective	  role	  in	  deep	  vein	  thrombosis,	  further	  work	  is	  needed	  to	  repeat	  these	  experiments	  and	  increase	  the	  number	  of	  mice	  used	  in	  all	  groups.	  We	  would	  also	  aim	  to	  get	  around	  60%	  thrombosis	  prevalence	  in	  WT	  mice	  as	  is	  suggested	  in	  the	  literature,	  and	  use	  littermate	  controls	  for	  all	  studies.	  	  	  	  	  	  	  	  	  	  
	  	   140	  
	  	  	  	  	  	  	  	  
	  
Chapter	  6	  	  
	  



































	  	   141	  
6.1	  –	  Introduction	  	  Neutrophils	   are	   considered	   primarily	   to	   be	   an	   innate	   immune	   cell,	   with	   a	  primary	   function	   to	   act	   as	   a	   phagocytic	   cell	   against	   foreign	   bacteria.	   More	  recently	   however,	   their	   function	   has	   been	   shown	   to	   be	  multifaceted,	   playing	   a	  role	  in	  coagulation	  and	  many	  other	  processes	  (Kimball	  2016).	  It	   was	   first	   shown	   by	   Brinkman	   et	   al	   (2004)	   that	   in	   response	   to	  lipopolysaccharide	   (LPS),	   neutrophils	   release	   their	   granule	   chromatin	   and	  proteins;	  these	  extracellular	  fibers	  are	  able	  to	  bind	  both	  gram-­‐positive	  and	  gram-­‐negative	   bacteria.	   These	   extracellular	   chromatin	   fibers,	   bound	   to	   histones	   and	  granular	   antimicrobial	   proteins,	   are	   termed	   neutrophil	   extracellular	   traps	  (NETs),	  and	  the	  process	  by	  which	  this	  occurs	  is	  NETosis.	  Whilst	   it	   is	   known	   that	  NETs	  play	   a	   key	   role	   in	   the	   form	  of	   an	   innate	   immune	  response,	   by	   capturing	   and	   killing	   bacteria,	   ensuring	   they	   cannot	   spread	   and	  providing	   a	   high	   local	   concentration	   of	   antimicrobial	   agents,	   they	   have	   also	  recently	   been	   suggested	   to	   potentiate	   thrombosis.	   During	   thrombus	  development,	   neutrophils	   contribute	   to	   the	   formation	   of	   an	   intravascular	  scaffold,	  where	  its	  function	  is	  likely	  to	  be	  both	  to	  support	  thrombus	  growth	  and	  to	  capture	  and	  destroy	  pathogens	  (Engelmann	  et	  al	  2013).	  	  NETs	  have	  not	  only	  been	  implicated	  in	  venous	  thrombosis,	  but	  also	  have	  a	  role	  in	  sepsis,	   trauma	   and	   cancer-­‐related	   thrombosis	   (Kimball	   et	   al	   2016).	   Although	  they	   have	   a	   role	   in	   a	   variety	   of	   diseases,	   it	   was	   reported	   that	   NETs	   have	   a	  common	   role	   in	   all	   of	   them,	   that	   they	   increased	   ischemia	   and	   the	   chance	   of	  further	  injury	  through	  micro	  or	  macrovascular	  thrombosis.	  Whilst	   the	  exact	  mechanisms	  of	  NETosis	  are	   still	   largely	  unknown,	   it	   is	  known	  that	  it	  is	  a	  distinct	  form	  of	  cell	  death,	  different	  to	  necrosis	  and	  apoptosis.	  The	  cell	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death	   pathway	   that	   leads	   to	   NET	   production	   is	   dependent	   on	   ROS	   production	  (see	   fig	   1	   chapter	   1.1).	   ROS	   causes	   break	  down	  of	   the	   nuclear	  membrane,	   and	  delobulation	   of	   the	   nucleus.	   The	   chromatin	   is	   then	   able	   to	   mix	   with	   granular	  proteins	  before	  eventually	  the	  plasma	  membrane	  ruptures	  and	  the	  contents	  are	  released.	   ROS	   production	   also	   promotes	   peptidylarginine	   Deminase	   (PAD4)	   to	  citrillinate	  histones.	  	  Neutrophils	   express	   high	   levels	   of	   the	   enzyme	   PAD4,	   and	   this	   is	   used	   as	   a	  marker	   of	   NET	   formation.	   It	   is	   this	   enzyme	   that	   allows	   citrullination,	   the	  replacement	  of	  positively	  charged	  arginine	   for	  uncharged	  citrulline.	  Wang	  et	  al	  (2009)	   show	   that	   it	   is	   hypercitrullination	   of	   histones	   by	   PAD4	   that	   mediates	  chromatin	   decondensation	   and	   further	   NET	   formation.	   They	   also	   show	   that	  inhibition	  of	  PAD4	  decreased	  NET	  formation.	  One	   of	   the	   earliest	   studies	   that	   showed	   NETs	   have	   an	   important	   role	   in	  thrombosis	  was	  conducted	  by	  Fuchs	  et	  al	  (2010).	  He	  showed	  that	  NETs	  caused	  platelet	  adhesion,	  activation	  and	  aggregation,	  whilst	   treatment	  with	  DNAase	  or	  the	   anticoagulant	   heparin,	   prevented	   thrombosis	   by	   dismantling	   this	   NET	  scaffold.	   They	   showed	   NETs	   not	   only	   recruited	   red	   blood	   cells,	   they	   also	  promoted	  fibrin	  deposition.	  Further	  work	  by	  Brill	  et	  al	  (2012)	  showed	  that	  NETs	  may	  actually	  promote	  deep	  vein	  thrombosis	  (DVT)	  and	  NETs	  form	  an	  important	  structural	  part	  of	  a	  venous	  thrombus.	  The	  IVC	  stenosis	  mouse	  model	  was	  used	  in	  these	  experiments,	  and	  the	  authors	   demonstrated	   that	   following	   IVC	   stenosis,	   mice	   had	   increased	   plasma	  levels	  of	  extracellular	  DNA.	  Also	  thrombi	  that	   formed	  in	  these	  mice	  were	  taken	  for	   immunohistochemical	   staining,	  which	  revealed	   that	  neutrophils	   (which	  had	  Gr-­‐1	  positive	  staining)	  were	  found	  in	  both	  the	  red	  part	  and	  the	  white	  part	  of	  the	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thrombus.	  Furthermore,	  citrullinated	  histone	  H3	  (CitH3),	  a	  marker	  of	  NETs,	  was	  found	  in	  the	  red	  part	  of	  the	  thrombus,	  associated	  with	  Gr-­‐1	  staining.	  	  If	  mice	  were	  administered	  DNAase,	   this	  was	  protective	  after	  both	  6	  h	  and	  48	  h	  stenosis.	   In	   contrast	   if	   mice	   received	   an	   infusion	   of	   calf	   thymus	   histones,	   this	  increased	   DVT	   following	   stenosis,	   likely	   due	   to	   the	   increased	   levels	   of	   plasma	  VWF	   this	   induced.	   They	   were	   therefore	   able	   to	   show	   that	   this	   extracellular	  chromatin,	  probably	  originating	   from	  neutrophils,	  was	  a	   crucial	   structural	  part	  of	  the	  thrombus	  and	  both	  this	  scaffold,	  and	  histones	  appear	  to	  contribute	  to	  DVT.	  	  Recent	  studies	  have	  shown	  that	  NETs	  may	  collaborate	  with	  platelets	  to	  promote	  intravascular	   coagulation	   in	   mouse	   models	   of	   sepsis	   (McDonald	   et	   al	   2017).	  During	   sepsis	   NETs	   are	   released,	   and	   as	   well	   as	   having	   a	   positive	   effect	   in	  contributing	  to	  host	  defense,	  they	  may	  also	  contribute	  to	  tissue	  damage	  and	  are	  believed	   to	   contribute	   to	   coagulation.	  McDonald	   et	   al	   showed	   that	   NETs	  were	  actually	  critical	  in	  the	  development	  of	  sepsis-­‐	  induced	  intravascular	  coagulation,	  regardless	  of	  the	  type	  of	  bacterial	  infection	  (gram	  positive	  or	  negative).	  If	  NETs	  were	   inhibited	   during	   sepsis,	   this	   reduced	   organ	   damage,	   increased	  microvascular	   perfusion	   and	   reduced	   intravascular	   coagulation.	   They	   also	  performed	   in-­‐vivo	   imaging	   of	  mouse	  models	   of	   sepsis,	   and	   demonstrated	   that	  within	   the	  NETs,	   there	  was	   increased	  platelet	  aggregation,	   thrombin	  activation	  and	  fibrin	  clot	  formation.	  Many	  studies	  have	  recently	  shown	  that	  NETs	  could	  also	  have	  an	  important	  role	  in	  non-­‐infectious	  sterile	   inflammation.	  Following	  NETosis	   intracellular	  proteins	  are	   exposed	   to	   the	   extracellular	   space,	   this	   could	   potentially	   lead	   to	   the	  presentation	  of	  auto-­‐antigens	  to	  the	  host	  immune	  system	  (Jorch	  &	  Kubes	  2017).	  
	  	   144	  
They	  have	  been	  shown	  to	  play	  a	  role	  in	  several	  non-­‐infectious	  autoimmune,	  and	  autoinflammatory	   diseases	   such	   as	   systemic	   lupus	   erythematosus	   (SLE),	  rheumatoid	   arthritis	   (RA)	   and	   Psoriasis.	   Rheumatoid	   arthritis	   (RA)	   is	   an	  autoimmune	  disease,	  which	  is	  characterized	  by	  chronic	  synovial	  inflammation	  at	  the	  joints,	  which	  can	  result	  in	  both	  bone	  and	  cartilage	  injury.	  RA	  patients	  have	  an	  increased	   level	   of	   NET	   producing	   neutrophils	   in	   the	   synovial	   fluid	   of	   their	  synovial	   cavities;	   circulating	   neutrophils	   of	   these	   patients	   are	   also	  more	   easily	  simulated	   to	   undergo	   NETosis	   in	   comparison	   to	   healthy	   individuals,	   and	   have	  increased	  amounts	  of	  ROS	  (Delgado-­‐Rizo	  et	  al	  2017).	  It	  is	  thought	  that	  NETs	  act	  as	   a	   source	   of	   autoantigens	   in	   these	   patients,	   when	   neutrophils	   release	   NETs	  along	  with	   their	   granular	   contents,	   cytoplasmic	   self-­‐antigens	   are	   also	   released	  into	  the	  joints	  (Khandpur	  et	  al	  2013).	  	  Similarly,	  people	  with	  systemic	  lupus	  erythematosus	  (SLE)	  have	  increased	  levels	  of	   anti-­‐ribonucleo-­‐protein	   and	   anti-­‐DNA	   antibodies	   in	   their	   serum,	   and	   the	  increased	   in	   these	   antibodies	   is	   believed	   to	   be	   due	   to	   NETs.	   In	   patients	   with	  Lupus,	  not	  only	  do	  their	  NETs	  contain	  higher	   levels	  of	  pathogenic	  autoantigens	  compared	  to	  healthy	  controls,	  leading	  to	  increased	  tissue	  damage,	  they	  also	  have	  impaired	  NET	  degradation	  so	  they	  are	  more	  persistent	  (Jorch	  &	  Kubes	  2017).	  	  	  The	  exact	  mechanisms	  of	  NET	  formation	  are	  still	  largely	  not	  understood,	  or	  what	  causes	   NETs	   to	   form	   in	   thrombosis.	   We	   already	   know	   thrombin	   is	   critical	   in	  thrombosis,	   and	   it	   has	   also	   previously	   been	   shown	   to	   stimulate	   chemotaxis	   of	  neutrophils.	   Jenkins	   et	   al	   (1995)	   showed	   that	   thrombin	   triggered	   directional	  movement	  of	  neutrophils	  at	   low	  concentrations,	  while	  at	  higher	  concentrations	  cell	  movement	  was	  inhibited.	  Treatment	  of	  neutrophils	  with	  thrombin	  receptor	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activating	  peptide	   (TRAP),	   failed	   to	   stimulate	   actin	  polymerization,	   believed	   to	  be	  required	  for	  neutrophil	  movement	  in	  chemotaxis.	  This	  indicated	  that	  another	  receptor,	  not	  PAR1	  probably	  exists	  for	  thrombin	  induced	  neutrophil	  chemotaxis.	  It	   was	   then	   later	   shown	   by	   another	   group	   that	   neutrophils	   stimulated	   with	  thrombin	   appear	   to	   have	   a	   dramatic	   reduction	   in	   the	   number	   of	   cytoplasmic	  granules,	  as	  well	  as	  numerous	  empty	  vesicles	   in	   their	   cytoplasm	  (Stuardo	  et	  al	  2004).	   These	   studies	   therefore	   showed	   that	   thrombin	   is	   having	   an	   effect	   on	  neutrophils,	   but	   through	  what	  mechanisms	   is	   not	   known,	   it	  may	   be	   through	   a	  PAR	  independent	  mechanism.	  We	  then	  wanted	  to	  ask	  the	  question,	   if	   thrombin	  could	  induce	  NET	  formation	  in	  thrombosis.	  	  As	   well	   as	   understanding	   the	   cause	   of	   NETosis	   in	   thrombosis,	   we	   wanted	   to	  further	   investigate	   the	   exact	   mechanism	   behind	   this.	   Previous	   studies	   have	  shown	  that	  the	  cytoskeleton	  may	  be	  important	  in	  NET	  release	  (Neeli	  et	  al	  2009).	  	  Usually	  any	  large	  changes	  in	  cell	  morphology	  involve	  the	  cytoskeleton.	  The	  actin	  cytoskeleton	  is	  already	  known	  to	  be	  involved	  in	  several	  functions	  of	  neutrophils	  such	  as	  phagocytosis,	  cell	  attachment	  and	  migration,	  whilst	  microtubules	  play	  an	  important	   role	   in	   transporting	   granules.	   As	   NETosis	   involves	   a	   change	   in	   cell	  morphology	  and	  release	  of	  granule	  contents,	  it	  seemed	  reasonable	  to	  predict	  that	  both	  the	  actin	  and	  tubulin	  networks	  may	  play	  a	  role	  in	  this,	  but	  at	  which	  stage	  is	  unclear.	  	  Neeli	   et	   al	   tested	   this	   hypothesis	   by	   incubating	   neutrophils	   with	   either	  nocodazole,	  a	  drug	  that	  interferes	  with	  tubulin	  polymerization,	  or	  cytochalasin	  D,	  which	  interferes	  with	  actin	  filament	  polymerization,	  prior	  to	  treatment	  with	  LPS.	  They	   measured	   both	   levels	   of	   NET	   release,	   and	   of	   histone	   H3	   deimination.	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Around	   30%	   of	   neutrophils	   treated	   with	   just	   LPS	   produced	   NETs.	   However,	  following	   treatment	   with	   nocodozole	   prior	   to	   LPS,	   most	   neutrophils	   had	   a	  similar	   appearance	   to	   control	   cells,	   with	   only	   5%	   of	   the	   cells	   showing	   NET	  release.	   These	   cells	   also	   showed	   a	   reduced	   level	   of	   histone	   H3	   deminination.	  Similarly,	   treatment	  of	  neutrophils	  with	  cytochalasin	  D	  also	  resulted	   in	  most	  of	  the	   neutrophils	   maintaining	   their	   naïve	   morphology,	   and	   only	   9%	   of	   them	  produced	  NETs.	  Although	   the	   results	   are	   striking,	   it	   is	   not	   clear	   exactly	   how	   the	   cytoskeleton	  plays	  a	  role	  in	  this	  NET	  release.	  One	  suggestion	  is	  the	  actin	  filaments	  may	  play	  a	  role	   in	  allowing	  the	  rupture	  of	  the	  plasma	  membrane	  and	  deployment	  of	  NETs.	  Actin	  filaments	  could	  act	  to	  push	  the	  chromatin	  through	  a	  breach	  in	  the	  plasma	  membrane.	  This	  hypothesis	  seems	  plausible	  since	  those	  neutrophils	  treated	  with	  cytochalasin	   D	   (which	   disrupts	   actin	   polymerization)	   prior	   to	   LPS,	   showed	  chromatin	   was	   able	   to	   mix	   with	   the	   cytoplasmic	   contents	   following	   nuclear	  envelope	  breakdown,	  but	  the	  plasma	  membrane	  still	  remained	  a	  barrier	  to	  NET	  release.	  	  In	  this	  chapter	  I	  aimed	  to	  uncover	  the	  signaling	  pathways	  that	  may	  lead	  to	  NET	  formation,	  based	  on	  what	  is	  already	  known,	  we	  decided	  to	  target	  specific	  stages	  in	  the	  NETosis	  pathway	  with	  inhibitors	  to	  see	  if	  these	  played	  an	  important	  role,	  and	  if	  we	  could	  inhibit	  NETosis	  happening.	  Figure	  1	  below	  shows	  at	  which	  points	  in	  the	  pathway	  we	  were	  trying	  to	  inhibit	  NETosis.	  We	  also	  wanted	  to	  investigate	  what	   causes	   NETosis	   during	   thrombosis,	   specifically	   in	   DVT,	   a	   sterile	  inflammatory	  environment.	  	  	  
	  	   147	  
	  


























	  	   148	  
A	   B	  
C	   D	  
6.2	  Results	  	  	  6.2.1	  NET	  formation	  by	  murine	  neutrophils	  	  Neutrophils	   were	   isolated	   from	   the	   bone	   marrow	   of	   mice	   as	   described	   in	  methods	   2.5	   by	   using	   a	   percoll	   gradient.	   We	   wanted	   to	   make	   sure	   we	   could	  replicate	   the	   well-­‐known	   protocol	   for	   neutrophil	   activation,	   and	   we	   tested	   a	  range	  of	  common	  activators	  to	  see	  if	  they	  produced	  NETs	  in	  murine	  neutrophils	  in	  our	  hands.	  A	  24	  well	  cell	  culture	  plate	  was	  prepared	  by	  putting	  a	  13mm	  round	  glass	  cover	  slip	   into	  each	  well,	  2	  X	  105	  neutrophils	  were	   then	  seeded	   into	  each	  well	   in	   500μl	   RPMI,	   and	   incubated	   at	   37oC	   for	   1h.	   After	   this	   time,	   neutrophils	  were	  activated	  with	  100nM	  PMA,	  100μg/ml	  LPS	  or	  20μM	  Ionomycin	  for	  3h.	  Cells	  were	  then	  fixed	  and	  stained	  with	  DAPI,	  the	  DNA	  dye	  so	  NETS	  can	  be	  visualized.	  As	  can	  be	  seen	  below	  in	  figure	  6.1,	  NETs	  were	  produced	  by	  murine	  neutrophils	  using	  all	  of	  the	  activators.	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Figure	  6.2	  –	  Murine	  neutrophils	  activated	  to	  produce	  NETs	  
	  Neutrophils	  were	  stimulated	  with	  various	  activators	  for	  3h,	  and	  stained	  with	  the	  DNA	  dye	  DAPI	  to	  visualize	  NET	  formation.	  2	  X	  105	  neutrophils	  were	  seeded	  per	  well.	  A)	  Control	  un-­‐stimulated	  neutrophils,	  B)	  Neutrophils	  activated	  with	  100nm	  PMA,	  C)	  Neutrophils	  activated	  with	  100	  μg/ml	  LPS	  D)	  Neutrophils	  activated	  with	  20	  μM	  Ionomycin	  	  6.2.2	  Immunostaining	  for	  citrullinated	  histone	  H3	  in	  murine	  neutrophils	  	  Citrullination	  of	  histone	  H3,	  the	  process	  whereby	  positively	  charged	  arginine	  is	  replaced	   for	   uncharged	   citrulline	   is	   a	   marker	   of	   NET	   formation.	   The	   enzyme	  PAD4	  is	  responsible	  for	  this	  process,	  and	  it	  is	  known	  that	  hypercitrullination	  by	  PAD4	   mediates	   chromatin	   decondensation	   and	   NET	   formation.	   As	   Cit-­‐H3	  staining	  is	  now	  commonly	  used	  as	  a	  method	  to	  detect	  NETs,	  we	  performed	  this	  immunostaining	  using	  an	  anti-­‐Histone	  H3	  antibody.	  Figure	  6.3	  below	  shows	   in	  the	   control	   untreated	   neutrophils	   (A&B),	   no	   NETs	   were	   produced,	   clear	  lobulated	  neutrophils	  can	  be	  seen	  (purple),	  and	  Phalloidin	  (green)	  staining	  also	  shows	   the	   actin	   cytoskeleton	   is	   evenly	  distributed.	  Whilst	   In	   those	  neutrophils	  activated	  with	  20μm	  Ionomycin	  (Figure	  6.3	  C	  &	  D),	  NETs	  can	  be	  clearly	  seen	  by	  the	  Cit-­‐H3	  and	  DNA	  staining,	  interestingly	  figure	  D	  shows	  the	  distribution	  of	  the	  actin	   cytoskeleton	   (green)	   to	   the	   edge	   of	   the	   cell,	   possibly	   before	   it	   is	   used	   to	  deploy	  the	  NETs.	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Figure	  6.3-­‐	  Immunostaining	  for	  citrullinated	  histone	  H3	  in	  murine	  
neutrophils	  	  	  A	   &	   B)	   un-­‐stimulated	   neutrophils.	   C	   &	   D)	   neutrophils	   stimulated	   with	   20μM	  Ionomycin.	   Immunostaining	   was	   performed	   using	   DAPI	   (DNA	   stain),	   anti-­‐Histone	   H3	   antibody	   (pink)	   and	   Phalloidin	   (green)	   to	   stain	   the	   actin	  cytoskeleton.	  	  	  	  	  	  	  	  	  	  
A	  	   B	  	  
C	  	   D	  	  
	  	  	  
=	  Citrullinated	  histone	  H3 =	  DNA =	  Polymerized	  actin	  cytoskeleton 
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  6.2.3	  Activating	  human	  neutrophils	  to	  produce	  NETs	  	  We	   found	   that	   working	   with	   murine	   neutrophils	   was	   inconsistent	   and	   with	  neutrophils	  in	  the	  control	  group	  often	  being	  activated,	  probably	  as	  a	  result	  of	  the	  isolation	  process.	  We	  therefore	  decided	  to	  isolate	  and	  stimulate	  neutrophils	  from	  human	   whole	   blood,	   as	   this	   is	   common	   practice	   with	   a	   more	   standardized	  protocol.	  Neutrophils	  were	  isolated	  as	  described	  in	  methods	  2.6.	  They	  were	  then	  activated	  with	  5μm	   Ionomycin,	  10μg/ml	  LPS	  or	  100nm	  PMA.	  The	  extracellular	  chromatin	  was	  stained	  using	  DAPI	  dye.	  As	  can	  be	  seen	  in	  figure	  6.4	  below,	  NETs	  formed	  in	  human	  neutrophils	  using	  all	  of	  the	  activators.	  Unexpectedly	  however,	  few	  NETs	   could	   also	   be	   seen	   in	   the	   control	   (figure	   A	   below),	   neutrophils	  may	  have	   been	   activated	   during	   the	   isolation	   procedure.	   However	   following	  quantification,	   NETs	   were	   produced	   to	   a	   much	   greater	   extent	   if	   treated	   with	  activators,	   the	   greatest	   NET	   production	   being	   seen	   following	   addition	   of	   5μM	  Ionomycin	  (figure	  D).	  Quantification	  was	  performed	  by	   taking	  4	  representative	  images	   per	   treatment	   condition;	   the	   percentage	   of	   NET	   coverage	   per	   area	   of	  view	  field	  was	  then	  calculated.	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Figure	  6.4	  –	  Activation	  of	  human	  neutrophils	  
	  Neutrophils	  were	  stimulated	  with	  various	  activators	  for	  3h,	  and	  stained	  with	  the	  DNA	  dye	  DAPI	  to	  visualize	  NET	  formation.	  2	  X	  105	  neutrophils	  were	  seeded	  per	  well.	  A)	  Control	  un-­‐stimulated	  neutrophils.	  B)	  Neutrophils	  activated	  with	  100nM	  PMA.	  C)	  Neutrophils	  activated	  with	  10μg/ml.	  LPS	  D)	  Neutrophils	  activated	  with	  5μM	  Ionomycin.	  	  	  6.2.4	  Targeting	  different	  stages	  of	  the	  NETosis	  pathway	  to	  prevent	  NET	  formation	  As	   NETs	   have	   been	   found	   to	   be	   implicated	   in	   a	   number	   of	   diseases,	   including	  thrombosis,	   we	   wanted	   to	   investigate	   the	   signaling	   pathways	   which	   leads	   to	  their	   formation,	   and	   to	   see	   if	  we	   could	   target	   specific	   parts	   of	   the	   pathway	   to	  inhibit	   NETosis.	   We	   used	   either	   PMA	   (100nM)	   or	   Ionomycin	   (2μM)	   as	   the	  activators	   for	  NETs,	   as	   I	   had	   previously	   seen	   high	   levels	   of	   NETosis	   in	   human	  neutrophils	   at	   these	   concentrations.	   In	   addition	   to	   these	   activator’s,	   1h	   later	  
A	   B	  
C	  
D	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neutrophils	   were	   incubated	   with	   one	   of	   the	   following	   inhibitors:	  Wortmannin	  (10μM),	   Cytochalasin	   D	   (10μM)	   or	   SB203580	   (10μm).	   Figure	   6.1	   above	  demonstrates	   at	   which	   stages	   in	   the	   NETosis	   pathway	   these	   inhibitors	   were	  targeting.	   As	   it	   has	   been	   previously	   suggested	   that	   the	   actin	   cytoskeleton	  may	  play	  a	  role	  in	  the	  deployment	  of	  NETs	  (Neeli	  et	  al	  2009),	  we	  wanted	  to	  see	  if	  we	  could	  replicate	  this,	  using	  cytochalasin	  D	  the	  actin	  polymerization	  inhibitor.	  This	  may	  work	   to	   prevent	   rupture	   of	   the	  plasma	  membrane,	   and	   therefore	  prevent	  NET	  release.	  We	  also	  chose	  to	  test	  Wortmannin,	  which	  is	  a	  PI3K	  inhibitor.	  One	  of	  the	  possible	  routes,	   which	  may	   lead	   to	   NET	   release,	   is	   autophagy,	   a	   regulated	   form	   of	   cell	  death.	  Wortmannin	   inhibits	  PI3K,	  and	   therefore	   interrupts	   the	  PI3K-­‐Akt-­‐mTOR	  pathway	   that	   culminates	   in	   autophagy.	   The	   other	   pathway	   we	   wanted	   to	  investigate	   was	   the	   raf-­‐MEK-­‐ERK	   pathway,	   it	   has	   been	   suggested	   that	   it	   is	  important	  for	  generation	  of	  ROS,	  and	  that	  this	  pathway	  induces	  the	  expression	  of	  antiapoptotic	  proteins,	  which	  inhibit	  apoptosis	  to	  allow	  for	  NETosis	  (Hakkim	  et	  al	   2011).	  We	   therefore	   used	   the	   P38	  MAPKinase	   inhibitor	   (or	   ERK	   inhibitor),	  SB203580	  to	  see	  if	  inhibiting	  MAPKinase	  had	  an	  impact	  on	  NET	  release.	  	  Figure	  6.5	  below	  shows	  representative	  images	  of	  all	  conditions,	  both	  activators	  with	  and	  without	  the	  3	  inhibitors.	  We	  saw	  no	  obvious	  difference	  in	  the	  amount	  of	  NETs	   produced	   between	   any	   of	   the	   neutrophils	   that	   received	   an	   inhibitor,	   or	  those	  which	  received	  an	  activator	  only.	  We	  therefore	  concluded	  that	  it	  was	  very	  unlikely	   that	   these	  parts	  of	   the	  pathway	  would	  be	  good	   therapeutic	   targets	   for	  preventing	   NETosis	   in	   thrombosis,	   and	   that	   other	   signaling	   pathways	   may	   be	  more	  important.	  We	  therefore	  need	  to	  do	  further	  work	  to	  establish	  at	  what	  stage	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we	  could	  inhibit	  NETosis,	  one	  future	  question	  would	  be	  to	  investigate	  the	  role	  of	  Src	  an	  Syk	  Kinases,	  which	  are	  found	  upstream	  of	  PKC.	  	  
	  	  
Figure	  6.5	  NET	  formation	  using	  a	  range	  of	  inhibitors	  
Ionomycin	  (2μm)	  	   PMA	  (100nM)	  
+	  Wortmannin	  
+	  Cytochalasin	  D	  
+	  SB203580	  
A	   B	  
C	   D	  
E	   F	  
G	   H	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2	  X	  105	  neutrophils	  were	  seeded	  per	  well	  and	  activated	  with	  either	   Ionomycin	  (2μM)	  or	  PMA	  (100nM).	  Various	  inhibitors	  were	  added	  to	  each	  group	  to	  try	  and	  prevent	   NETosis;	   wortmannin	   (10μM),	   cytochalasin	   D	   (10μM)	   or	   SB203580	  (10μM).	  No	  difference	  in	  NETosis	  was	  found	  between	  the	  inhibitors	  and	  controls.	  	  6.2.5	  The	  role	  of	  thrombin	  in	  NETosis	  We	   know	   that	   NETs	   have	   been	   reported	   to	   play	   a	   role	   in	   thrombosis.	   It	   was	  shown	  by	  Brill	  et	  al	  (2012)	  using	  the	  mouse	  IVC	  stenosis	  model,	  that	  NETs	  may	  actually	  promote	  deep	  vein	   thrombosis,	   and	   they	   form	  an	   important	   structural	  part	  of	  the	  thrombus.	  We	  wanted	  to	  investigate	  what	  promotes	  this	  NET	  release	  in	   DVT,	   a	   sterile	   inflammatory	   environment.	   The	   obvious	   target	   to	   investigate	  was	   thrombin,	  as	  we	  already	  know	  this	   is	  critical	   in	   thrombosis.	  Thrombin	  has	  also	   previously	   been	   shown	   to	   trigger	   directional	   movement	   of	   neutrophils	  (Jenkins	   1995),	   although	   the	   receptor	   through	  which	   thrombin	  works	  was	   not	  identified.	  It	  has	  also	  been	  shown	  to	  lead	  to	  a	  dramatic	  reduction	  in	  the	  number	  of	   cytoplasmic	   granules	   in	   neutrophils	   (Studardo	   et	   al	   2004).	   We	   wanted	   to	  investigate	  if	  thrombin	  is	  the	  candidate	  for	  inducing	  NETs	  in	  DVT.	  	  Neutrophils	  were	   seeded	   into	   a	   24	  well	   plate,	  with	   3	  wells	   for	   each	   treatment	  condition.	  3	  wells	  contained	  un-­‐stimulated	  neutrophils,	  then	  3	  contained	  of	  each	  of	   the	   activators;	   PMA	   (100nM)	   or	   Ionomycin	   (2μM)	   to	   act	   as	   the	   controls.	   3	  different	   concentrations	   of	   thrombin	  were	   then	   tested;	   0.1	   units/ml	   thrombin	  1unit/ml	  and	  5units/ml.	  This	  experiment	  was	  repeated	  5	  times,	  with	  the	  average	  area	   of	  NETs	  per	   view	   field,	   per	   condition	  being	   calculated.	   Figure	  6.6A	  below	  shows	   representative	   images	   of	   neutrophils	   treated	   with	   each	   of	   the	  concentrations	   of	   thrombin,	   compared	   to	   the	   control	   untreated	   neutrophils.	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Figure	   6.6B	   shows	   the	   results	   of	   all	   5	   experiments	   combined,	   and	   the	   graph	  represents	  the	  %	  area	  of	  view	  field	  covered	  by	  NETs.	  A	  significant	  difference	  was	  found	  between	  both	  0.1	  unit/ml	  and	  1unit/ml	  thrombin	  and	  the	  control	  using	  an	  ANOVA,	   followed	   by	   Dunnetts	   multiple	   comparisons	   test,	   but	   no	   significant	  difference	   was	   found	   between	   5units/ml	   thrombin	   and	   the	   control.	   Although	  preliminary	  data,	  these	  results	  could	  suggest	  that	  thrombin	  could	  be	  responsible	  for	  the	  induction	  of	  NET	  formation	  during	  thrombosis.	  	  
	  
	  
Figure	  6.6A	   -­‐	  Representative	   images	  of	  neutrophils	   treated	  with	  different	  
concentrations	  of	  thrombin.	  
	  A)	   Control–	   untreated	   neutrophils,	   B)	   neutrophils	   treated	   with	   0.1	   units/ml	  thrombin,	  C)	  neutrophils	  treated	  with	  1unit/ml	  thrombin,	  D)	  neutrophils	  treated	  with	  5	  units/ml	  thrombin	  	  
A	   B	  
C	   D	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Figure	  6.6	  B	  –	  The	  average	  %	  area	  of	  view	  field	  covered	  by	  NETs	  following	  
addition	  of	  different	  concentrations	  of	  thrombin	  to	  neutrophils	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6.3	  Discussion	  Studies	  have	  recently	  shown	  that	  neutrophils	  play	  multifaceted	  roles	  in	  a	  variety	  of	   illnesses,	  and	  are	  no	   longer	  considered	  to	   just	  be	  phagocytic	  cells,	   important	  for	  protecting	  the	  host	  against	  bacterial	  infections	  (Kimball	  2016).	  We	  know	  that	  neutrophils	   produce	   NETs,	   and	   these	   have	   a	   variety	   of	   roles,	   not	   only	   during	  infectious	  diseases	  to	  trap	  bacteria,	  but	  also	  in	  sterile	  inflammatory	  settings	  such	  as	  that	  found	  in	  thrombosis.	  	  Work	   by	   Fuchs	   et	   al	   showed	   that	   NETs	   were	   capable	   of	   promoting	   platelet	  adhesion,	   aggregation	   and	   activation,	   whilst	   it	   was	   later	   shown	   that	   they	   are	  involved	   in	   deep	   vein	   thrombosis,	   forming	   an	   important	   structural	   part	   of	   the	  thrombus	  (Brill	  et	  al	  2012).	  We	  therefore	  wanted	  to	  further	  explore	  the	  role	  of	  NETs	   in	   thrombosis,	   and	   to	   understand	   the	   mechanisms	   of	   NETosis	   in	   a	  thrombotic	  environment.	  	  	  	  We	   investigated	   various	   stages	   of	   the	  NETosis	   pathway	   to	   try	   and	   find	   a	   good	  target	   for	   preventing	  NET	   formation.	  We	  were	   unable	   to	   see	   any	   difference	   in	  NET	  formation	  using	  Wortmannin,	  Cytochalasin	  D	  or	  SB203580	  as	  inhibitors.	  	  It	  is	   unlikely	   that	   autophagy	   is	   the	   main	   cause	   of	   NET	   release,	   as	   wortmannin	  inhibits	   PI3K,	   which	   in	   turn	   would	   prevent	   the	   PI3K-­‐Akt-­‐mTOR	   pathway	  culminating	  in	  autophagy.	  It	  is	  more	  likely	  that	  an	  alternative	  form	  of	  cell	  death	  is	   responsible	   for	   NET	   release.	  We	   also	   found	   no	   inhibition	   of	   NET	   formation	  using	  SB203580,	  a	  MAPKinase	  inhibitor.	  We	  hypothesized	  that	  this	  inhibitor	  may	  lead	  to	  decreased	  ROS	  production,	  and	  subsequently	  decreased	  NET	  release,	  as	  we	   know	   ROS	   is	   important	   for	   activating	   PAD4,	   and	   for	   disintegration	   of	   the	  granular	  membrane.	  However	  this	  was	  not	  the	  case,	  if	  we	  were	  to	  continue	  this	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study	  further	  we	  would	  look	  at	  the	  role	  of	  kinases	  upstream	  of	  PKC,	  for	  example	  investigating	  if	  Src	  and	  Syk	  play	  a	  role	  in	  NET	  release.	  We	  also	  wanted	  to	  investigate	  the	  effects	  of	  cytochalasin	  D	  on	  NET	  release;	  this	  interferes	  the	  actin	  polymerization	  and	  had	  previously	  been	  reported	  to	  inhibit	  NET	  formation	  after	  activation	  with	  LPS	  in	  a	  study	  by	  Neeli	  et	  al	  (2009).	  We	  were	  not	  however	  able	  to	  see	  this	  same	  inhibition,	  and	  NET	  release	  was	  similar	  in	  the	  control	   and	   cytochalasin	   D	   treated	   neutrophils.	  We	   did	   however	   use	   different	  activators	   to	   the	  ones	  used	   in	   this	  study,	  PMA	  and	  Ionomycin.	   In	   the	   future	  we	  would	  repeat	  this	  study	  testing	  all	  of	  the	  activators	  prior	  to	   inhibition,	  and	  at	  a	  range	  of	   concentrations.	  Although	   the	  actin	   cytoskeleton	  may	  be	   important	   for	  NET	  release,	  and	  aid	  in	  the	  deployment	  of	  the	  extracellular	  chromatin,	  it	  may	  not	  be	   the	   primary	   cause	   of	   NET	   release	   and	   other	   pathways	   may	   be	   more	  important.	  	  The	  next	  question	  we	  wanted	   to	   investigate	  was	  what	   causes	  NET	  release	   in	  a	  thrombotic	   environment,	   specifically	   in	   DVT.	   NETs	   have	   been	   found	   in	   the	  thrombi	   formed	   in	   the	   deep	   veins,	   and	   we	   know	   that	   this	   is	   a	   sterile	  inflammatory	  environment;	  therefore	  the	  cause	  of	  this	  NET	  release	  was	  not	  due	  to	   bacteria	   or	   other	   infectious	   agents.	   The	   obvious	   candidate	   was	   thrombin.	  Thrombin	   has	   a	   diverse	   range	   of	   biological	   roles,	   and	   acts	   as	   both	   a	   pro-­‐coagulant	   and	   a	   pro-­‐inflammatory	   mediator	   (Hongbao	   et	   al	   2008).	   It	   plays	   a	  crucial	  in	  thrombosis,	  and	  it	  also	  plays	  a	  role	  during	  inflammation	  in	  acting	  as	  a	  neutrophil	   chemoattractant	   (Esmon	   2000).	   	   Thrombin	   induces	   neutrophils	   to	  move	  towards	  its	  chemical	  gradient	  (the	  site	  of	  injury	  for	  example)	  to	  carry	  out	  their	   function.	   It	   is	   possible	   that	   thrombin	   also	   activates	   the	   neutrophils	   to	  produce	  NETs.	  We	  tested	  a	  range	  of	  concentrations	  of	  thrombin;	  0.1	  units/ml,	  1	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unit/ml	  and	  5	  units/ml.	  We	  found	  that	  thrombin	  did	   induce	  NET	  production	  at	  all	  concentrations,	  at	  levels	  comparable	  to	  that	  of	  PMA	  and	  Ionomycin,	  or	  in	  the	  case	   of	   1	   unit/ml	   thrombin,	   an	   even	   higher	   level	   of	   NET	   production	   was	  measured	  compared	  to	  the	  other	  activators	  (see	  figure	  6.6B).	  When	  compared	  to	  the	  control	  group,	  a	  significant	  difference	  was	  found	  using	  and	  ANOVA	  between	  the	   treatment	   conditions	   and	   0.1	   and	   1	   unit/ml	   thrombin.	   There	   was	   an	  insignificant	   difference	   however	   between	   5units/ml	   thrombin	   and	   the	   control.	  	  These	   results	   are	   promising,	   and	   suggest	   that	   thrombin	  may	   be	   the	   candidate	  that	   induces	  NETosis	   in	   a	   thrombotic	   environment.	   Further	  work	   is	   needed	   to	  confirm	  this	  finding.	  	  If	  we	  were	  to	  continue	  with	  these	  experiments	  further,	  we	  would	  aim	  to	  increase	  the	  N	  numbers,	  these	  results	  show	  the	  average	  of	  4	  experiments,	  and	  we	  would	  want	   to	   try	   and	   take	   the	   average	   of	   at	   least	   10	   experiments.	   Quantification	   of	  NETs	   can	   be	   problematic;	   applicability	   of	   measuring	   fluorescent	   intensity	   is	  questionable	   because	   the	   intensity	   of	   NETs	   and	   intact	   nuclei	   is	   insufficiently	  different	   to	   ensure	   reliable	   discrimination.	   Therefore,	   we	   developed	  quantification	   based	   on	  manual	   delineation	   of	  NETs	   and	   currently	   express	   the	  area	   covered	   by	  NETs	   as	   a	   percentage	   of	   the	   total	   area	   of	   each	   view	   field.	  We	  were	   able	   to	   do	   this	   by	   randomly	   selecting	   3	   different	   areas	   per	   well,	   per	  treatment	   condition.	   The	   random	   nature	   of	   our	   selection	   process	   may	   mean	  quantification	   is	   not	   entirely	   accurate	   and	   the	   only	  way	   to	   overcome	   this	   is	   to	  increase	  the	  N	  numbers.	  	  Another	  problem	  we	  encountered	  was	  getting	  a	   low	  level	  of	  NET	  production	  in	  the	  control,	  which	  is	  unusual;	  this	  could	  explain	  the	  non-­‐significant	  result	  when	  comparing	   PMA	   and	   ionomycin	   against	   the	   control,	   which	   are	   usually	   used	   as	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standards.	   This	   low	   level	   of	   NET	   production	  was	   probably	   due	   to	   neutrophils	  being	   activated	   during	   the	   isolation	   process.	   	  We	  would	   need	   to	   optimize	   the	  neutrophil	   isolation	   protocol	   in	   order	   to	   get	   better	   quality	   isolation,	   with	   less	  contamination	   of	   RBC’s	   and	   other	   factors,	   which	   could	   potentially	   activate	  neutrophils.	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  



























	  	   163	  
7.1	  Summary	  of	  Results	  	  	  Platelets	   play	   a	   critical	   role	   in	   thrombosis,	   and	   many	   of	   the	   major	   platelet	  receptors	   that	   play	   important	   roles	   in	   arterial	   thrombosis	   have	   already	   been	  studied,	  but	   less	  so	   in	  venous	  thrombosis.	  The	  overall	  aim	  of	   this	   thesis	  was	  to	  identify	   new	   targets	   to	   prevent	   deep	   vein	   thrombosis,	   which	   will	   not	   lead	   to	  bleeding	  complications	  as	  a	  side	  effect.	  	  In	   this	   thesis	   I	  wanted	  to	  (i)	   investigate	   the	  role	  of	  CLEC-­‐2	  and	  GPVI	   in	  venous	  thrombosis	   and	   compare	   this	   to	   their	   roles	   in	   arterial	   thrombosis.	   (ii)	   To	  investigate	  if	  other	  immune	  cells,	  namely	  mast	  cells	  and	  T-­‐cells	  play	  a	  role	  in	  DVT	  (iii)	  to	  study	  the	  signaling	  pathways	  leading	  to	  NETosis,	  and	  the	  cause	  of	  NETosis	  in	  thrombosis.	  	  7.1.1	  The	  role	  of	  GPVI	  and	  CLEC-­‐2	  in	  DVT	  I	  have	  assessed	  the	  role	  of	  both	  GPVI	  and	  CLEC-­‐2	   in	  DVT	  using	   in	  vivo	  models,	  the	  well-­‐established	   IVC	   stenosis	  model	   to	   replicate	   DVT,	   and	   the	   laser	   injury	  model.	   Whilst	   I	   found	   GPVI	   deficiency	   resulted	   in	   only	   an	   insignificant	   trend	  towards	   decreased	   DVT	   prevalence	   in	   the	   stenosis	   model,	   CLEC-­‐2	   deficiency	  resulted	   in	  protection	   against	  DVT.	   I	   also	   show	   that	  podoplanin,	   the	   ligand	   for	  CLEC-­‐2	   is	   constitutively	   expressed	   in	   the	   IVC	   wall,	   and	   this	   expression	   is	   up	  regulated	   following	   IVC	   stenosis.	   This	   podoplanin	   expression	  was	   then	   further	  increased	  if	  IVC	  stenosis	  resulted	  in	  thrombus	  formation.	  Further	  experiments	  to	  investigate	   the	   relationship	   between	   podoplanin	   expression	   in	   the	   vessel	   wall	  and	  DVT	  were	  performed.	  	  I	  then	  showed	  in	  the	  in-­‐vivo	  IVC	  stenosis	  model,	  that	  mice	  administered	  with	  an	  anti-­‐podoplanin	  antibody,	  still	  formed	  thrombi	  with	  a	  prevalence	  similar	  to	  that	  found	   in	   control	  mice,	   however	   thrombus	   size	  was	   decreased	   in	  mice	  without	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podoplanin.	   This	   implied	   that	   podoplanin	   is	  most	   likely	   involved	   in	   thrombus	  propagation,	   rather	   than	   thrombus	   initiation.	   Although	   both	   CLEC-­‐2	   and	  podoplanin	   appear	   to	   be	   important	   in	   DVT,	  we	   cannot	   categorically	   state	   that	  they	  work	  together	  as	  a	  receptor-­‐ligand	  couple.	  Further	  investigation	  is	  needed	  to	  ascertain	  the	  exact	  source	  of	  podoplanin	  in	  the	  IVC.	  I	  did	  however	  rule	  out	  a	  few	  potential	  sources	  of	  podoplanin	  in	  the	  IVC.	  I	  show	  it	  is	  unlikely	  to	  be	  from	  endothelial	  or	  hematopoietic	  cells,	  as	  mice	  with	  podoplanin	  knocked	  out	  on	  these	  cells	  maintained	  podoplanin	  expression	  in	  the	  IVC.	  I	  was	  also	  able	  to	  demonstrate	  that	  the	  dramatic	  phenotype	  seen	  in	  the	  CLEC-­‐2	  knock	   out	   mice	   using	   the	   IVC	   stenosis	   model,	   was	   not	   due	   impaired	   platelet-­‐platelet	   interactions,	   because	   thrombus	   formation	   was	   normal	   in	   these	   mice	  using	  the	  laser	  injury	  model.	  GPVI	  deficient	  mice	  however	  showed	  an	  interesting	  phenotype	   in	   the	   laser	   injury	  model,	   thrombi	   in	   these	  mice	  started	  to	   form	  but	  embolized,	   not	   allowing	   for	   thrombus	   propagation,	   this	   result	   conflicts	   with	  those	  published	  by	  Dubois	  et	  al	  2006.	  However	  mice	  used	  by	  Dubois	  et	  al	  in	  their	  experiment	  were	  FcRγ-­‐deficient	  mice,	  not	  GPVI	  knock-­‐out	  mice,	   this	  could	  be	  a	  reason	  for	  the	  discrepancy	  shown.	  Although	  further	  studies	  are	  required	  to	   investigate	   if	  podoplanin	  mediates	  the	  prothrombotic	  effect	  CLEC-­‐2,	  and	  if	  so	  where	  the	  source	  of	  this	  podoplanin	  is,	  we	  can	   conclude	   that	   complete	   deficiency	   of	   CLEC-­‐2	   protects	  mice	   from	  DVT,	   and	  therefore	  is	  an	  attractive	  therapeutic	  target	  considering	  these	  mice	  have	  minimal	  impairments	  in	  hemostasis.	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7.1.2	  The	  role	  of	  mast	  cells	  in	  DVT	  	  Mechanisms	  of	  DVT	  involve	  not	  only	  blood	  coagulation,	  but	  also	  aspects	  of	  sterile	  inflammation.	   We	   know	   recruitment	   of	   both	   immune	   cells	   and	   platelets	   are	  important	   for	  DVT	  and	  we	  wanted	   to	   investigate	   the	   role	  mast	   cells	  may	  have.	  Interestingly	   mast	   cells	   contain	   both	   pro-­‐inflammatory	   mediators	   in	   their	  granules	  e.g.	  Histamine,	  as	  well	  as	  inhibitors	  of	  coagulation	  such	  as	  heparin.	  	  In	   this	   thesis	   we	   report	   a	   novel	   role	   of	   mast	   cells	   in	   DVT,	   we	   show	   that	   two	  strains	  of	  mast	  cell	  deficient	  mice	  were	  completely	  protected	  against	  DVT	  in	  the	  IVC	  stenosis	  model.	  This	  suggested	  to	  us	  that	  mast	  cells	  contain	  a	  pro-­‐thrombotic	  component,	   which	   overrides	   the	   anti-­‐thrombotic	   abilities	   of	   other	   mast	   cell	  constituents.	  	  We	   then	   performed	   further	   experiments	   to	   confirm	   that	   it	   was	   indeed	   lack	   of	  mast	   cells	   causing	   this	   anti-­‐thrombotic	   phenotype,	   and	   not	   from	   other	   defects	  that	  may	  be	  caused	  by	  the	  c-­‐KIT	  mutation	  in	  KITW-­‐sh	  mice.	  We	  demonstrate	  that	  adoptive	   transfer	   of	   in	   vitro	   differentiated	   mast	   cells	   into	   mast	   cell	   deficient	  KITW-­‐sh	  mice	  restored	  thrombosis	  following	  IVC	  stenosis.	  	  To	   support	   our	   results	   further	   we	   performed	   more	   experiments	   instead	  targeting	   mast	   cells	   pharmacologically.	   Compound	   48-­‐80	   exhausted	   the	  intracellular	   pool	   of	   mediators	   of	   mast	   cells,	   and	   Sodium	   cromoglycate	   and	  ketotifen	  are	  mast	  cell	  membrane	  stabilizers,	  which	  prevent	  the	  liberation	  of	  the	  granule	  contents.	  Both	  of	  these	  approaches	  protected	  mice	  from	  DVT,	  supporting	  the	   assumption	   the	  mast	   cell	   contents	   play	   a	   role	   in	  DVT.	  As	  we	  hypothesized	  that	  histamine	  might	  be	  the	  likely	  candidate	  responsible	  for	  this	  phenotype,	  we	  performed	  In-­‐Vivo	  experiments	  using	  topical	  application	  of	  histamine	  to	  the	  IVC.	  This	  was	   able	   to	   induced	  DVT	   in	  mast	   cell	   deficient	  mice.	   Together	  my	   results	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show	   that	   mast	   cells	   (probably	   working	   through	   histamine,	   although	   other	  constituents	   may	   be	   involved)	   may	   be	   a	   good	   therapeutic	   target	   for	   DVT	  prevention	  in	  humans.	  	  	  7.1.3	  Other	  immune	  cells	  in	  DVT:	  T-­‐cells	  and	  neutrophils	  	  We	  know	  that	  DVT	  is	  now	  considered	  to	  be	  an	  immunothrombotic	  disorder,	  and	  that	  various	  inflammatory	  cells	  accumulate	  in	  the	  thrombus	  and	  the	  vessel	  wall	  during	  DVT.	   In	   this	   thesis	  we	  explored	   further	   the	  novel	  role	  of	  T-­‐cells	  and	  the	  more	  commonly	  studied	  role	  of	  NETs	  in	  DVT.	  	  I	   show	   using	   the	   in	   vivo	   IVC	   stenosis	  model	   that	   nude	  mice	   lacking	   all	   T-­‐cells	  have	   a	   prothrombotic	   phenotype	   in	   DVT.	   Suggesting	   that	   T-­‐cells	   may	   offer	   a	  protective	   role	   in	  DVT	  and	   that	   lack	  of	  T-­‐cells	   is	  detrimental.	  We	  hypothesized	  that	   this	   results	   was	   probably	   due	   to	   T-­‐cells	   ability	   to	   reduce	   and	   excessive	  inflammatory	   response,	   and	   therefore	   reducing	   the	   number	   of	   platelets	   and	  other	  inflammatory	  mediators	  recruited	  to	  the	  site.	  	  Because	  nude	  mice	  have	  no	  T	  lymphocytes	  at	  all,	  we	  wanted	  to	  perform	  further	  studies	   to	   investigate	  which	   specific	   subset	   of	   T-­‐cells	  were	   responsible	   for	   the	  protective	   role	   observed.	  We	   used	   anti-­‐CD25	   to	   deplete	   T-­‐regulatory	   cells	   and	  performed	   IVC	   stenosis	   to	   these	   mice.	   We	   show	   that	   T-­‐regulatory	   cells	   are	  probably	  not	  the	  subset	  of	  cells	  responsible	  for	  protection	  from	  DVT	  since	  a	  non-­‐significant	  prothrombotic	  phenotype	  was	  observed	  in	  these	  mice.	  We	  also	  show	  that	  Rag1-­‐/-­‐	  mice	  that	  lack	  both	  B	  and	  T-­‐cells	  are	  not	  protected	  against	  DVT	  and	  we	  did	  not	  see	  the	  same	  phenotype	  we	  observed	  in	  the	  nude	  mice.	  	  Overall	   whilst	   we	   suggest	   that	   nude	   mice	   are	   prothrombotic,	   and	   that	   T-­‐cells	  may	   exert	   a	   protective	   role	   in	   DVT,	   further	   work	   is	   needed	   to	   confirm	   these	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findings.	  Especially	  as	  thrombosis	  prevalence	  in	  our	  controls	  for	  this	  experiment	  were	  not	  at	  the	  usual	  levels	  we	  would	  expect.	  	  	  I	  also	  wanted	   to	   investigate	  where	   in	   the	   thrombus	  T-­‐cells	  may	  be	   located	  and	  we	   hypothesized	   that	   NETs	   which	   are	   responsible	   for	   capturing	   platelets	   and	  RBCs	  in	  the	  thrombus,	  may	  also	  be	  responsible	  for	  capturing	  T-­‐cells.	  	  I	   show	   in	   this	   study	   that	   neutrophils	   and	   T-­‐cells	   do	   in	   fact	   co-­‐localize	   in	   the	  thrombus.	  Although	  this	  is	  preliminary	  data,	  it	  may	  suggest	  that	  NETs	  and	  T-­‐cells	  could	  interact	  in	  DVT,	  and	  this	  could	  be	  to	  play	  a	  role	  in	  thrombus	  resolution.	  	  	  Previous	  studies	  had	  already	  reported	  a	   role	  of	  NETs	   in	   thrombosis	   (Brill	   et	  al	  2012).	  	  They	  had	  already	  shown	  that	  NETs	  form	  an	  important	  structural	  part	  of	  the	   thrombus	   in	   DVT,	   I	   wanted	   to	   investigate	   what	   is	   the	   cause	   of	   this	   NET	  release	   in	   thrombosis,	   a	   sterile	   inflammatory	   environment.	   The	   obvious	  candidate	   for	   us	   to	   investigate	   was	   thrombin,	   after	   addition	   of	   a	   range	   of	  concentrations	  of	  thrombin,	  we	  show	  that	  it	  can	  induce	  NET	  release	  and	  both	  0.1	  and	   1	   unit/ml	   thrombin	   resulted	   in	   a	   significant	   increase	   in	   NET	   coverage	  compared	   to	   control	   untreated	   NETs.	   Although	   these	   are	   very	   preliminary	  experiments,	  we	  show	  promising	  signs	  that	  thrombin	  can	  induce	  NET	  formation	  and	  therefore	  may	  be	  a	  likely	  candidate	  for	  the	  cause	  of	  NETosis	  during	  DVT.	  	  I	   also	   wanted	   to	   investigate	   which	   stages	   of	   the	   NETosis	   pathway	   could	  potentially	  be	  targeted	  in	  order	  to	  prevent	  NET	  formation.	   I	  performed	  various	  in	   vitro	   experiments	   using	   a	   range	   of	   inhibitors;	   Wortmannin,	   which	   inhibits	  PI3K,	  cytochalasin	  D	  that	  inhibits	  actin	  polymerization	  and	  SB203580	  which	  is	  a	  MAP	  kinase	  inhibitor.	  I	  did	  not	  observe	  a	  decrease	  in	  NET	  formation	  comparing	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any	  or	  the	  inhibitors	  to	  the	  control,	  I	  therefore	  concluded	  from	  this	  experiment	  that	  other	  stages	  of	  the	  pathway	  were	  probably	  more	  important	  for	  NET	  release	  and	  further	  work	  is	  needed	  to	  both	  optimize	  the	  study	  to	  ensure	  control	  samples	  have	  minimal	  neutrophil	  activation,	  and	  to	  identify	  other	  potential	  stages	  in	  the	  pathway	  to	  target.	  	  7.2	  Future	  directions	  Throughout	  this	  thesis	  I	  have	  identified	  new	  targets,	  including	  both	  CLEC-­‐2	  and	  mast	  cells,	  which	  we	  show	  to	  be	  involved	  in	  DVT.	  	  In	  murine	  models,	  mice	  lacking	  either	  CLEC-­‐2	  or	  mast	  cells	  are	  protected	  against	  DVT	  and	  therefore	  we	  suggest	  these	   are	   prothrombotic.	  We	   have	   also	   demonstrated	   that	   T-­‐cells	   may	   have	   a	  protective	  role	  in	  DVT.	  However	  all	  of	  these	  results	  are	  only	  the	  beginning	  on	  a	  long	  chain	  of	   studies	   that	  now	  need	   to	  be	  performed.	  Target	  Validation	  should	  now	   take	  place	   to	   see	   if	   these	   identified	   targets	   produce	   the	   same	   results	   in	   a	  clinically	  relevant	  setting	  in	  humans.	  	  Although	  our	  results	  appear	  to	  be	  striking	  in	  mice,	  translational	  studies	  need	  be	  performed	   in	  humans;	   this	  should	  begin	  with	  clinical	   trials.	  These	   trials	  should	  be	  randomized	  double-­‐blind	  trials,	   for	  example	  to	  test	   if	  drugs	  preventing	  mast	  cell	   degranulation	   correlate	   with	   a	   positive	   outcome	   in	   DVT,	   patients	   should	  randomly	   be	   assigned	   either	   a	   placebo	   or	  mast	   cell	  membrane	   stabilizer,	  with	  both	  the	  patient	  and	  clinician	  not	  knowing	  which	  they	  are	  receiving.	  	  Other	   factors	   need	   to	   be	   considered	   in	   these	   translational	   studies	   such	   as	   the	  stage	  of	  the	  disease.	  The	  outcomes	  of	  our	  studies	  in	  mice	  are	  all	  at	  the	  first	  stage	  of	   DVT	   onset,	   studies	   need	   to	   be	   performed	   in	   humans	   to	   see	   if	   these	  targets/cells	   still	   have	   the	   same	   effect	   in	   patients	   who	   are	   experiencing	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reoccurrence	  of	  the	  disease,	  or	  in	  patients	  who	  also	  have	  pulmonary	  embolisms	  for	  example,	  the	  biggest	  major	  complication	  with	  DVT.	  Other	  parameters	  should	  also	   be	   measured	   in	   the	   same	   way	   we	   measured	   in	   mice,	   for	   example	  investigating	  if	  plasma	  levels	  of	  histamine	  are	  increased	  in	  patients	  with	  DVT.	  There	   are	   some	   inherent	   limitations	   of	   our	   studies,	   for	   example	   in	   all	  experiments	  we	  perform	  IVC	  stenosis	  using	  young,	  healthy	  8-­‐10	  week	  old	  mice.	  Seeing	   as	   the	   prevalence	   of	   DVT	   is	   highest	   among	   an	   ageing	   population,	   who	  potentially	   also	   have	  many	   other	   diseases	  which	  may	   be	   contributing	   to	   their	  outcome,	  there	  is	  an	  argument	  that	  our	  model	  is	  not	  representative	  of	  the	  biggest	  target	   population.	   We	   therefore	   need	   to	   question	   if	   this	   surgery	   could	   be	  performed	  on	  aged	  mice,	  which	  questionably	  would	  be	  more	   representative	  of	  the	  population	  in	  which	  DVT	  occurs	  most	  frequently.	  A	  strength	  of	  out	  study	  in	  comparison	   to	   others	   however	   is	   that	  we	   did	   use	   both	  male	   and	   female	  mice,	  whereas	  most	   other	   studies	  use	  mainly	  male	  mice,	  we	   can	   therefore	   infer	   that	  our	  observations	  are	  the	  same	  across	  both	  genders.	  	  Another	  limitation	  of	  this	  study	  could	  be	  the	  IVC	  stenosis	  model	  itself.	  Whilst	  it	  is	  widely	  used	  and	  accepted,	  stenosis	  only	  mimics	  blood	  flow	  distortion,	  which	  we	  do	   know	   is	   important	   in	   venous	   thrombosis,	   however	   other	   factors	  may	   be	   at	  play	  in	  humans	  which	  this	  mouse	  model	  cannot	  replicate.	  	  	  7.3	  Final	  conclusions	  	  The	   overall	   findings	   of	   this	   thesis	   show	   I	   have	   identified	   a	   novel	   role	   of	   both	  CLEC-­‐2	  and	  mast	  cells	  in	  DVT.	  I	  show	  that	  CLEC-­‐2	  deficiency	  is	  protective	  in	  DVT,	  and	  that	  CLEC-­‐2	  may	  interact	  with	  its	  ligand	  podoplanin	  found	  in	  the	  IVC	  wall	  to	  exert	   its	   prothrombotic	   phenotype.	   I	   have	   shown	   a	   novel	   role	   of	  mast	   cells	   in	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DVT,	  with	  mast	  cell	  deficiency	  being	  protective.	  I	  also	  suggest	  that	  the	  mast	  cell	  constituent	  responsible	  for	  the	  prothrombotic	  phenotype	  in	  DVT	  is	  most	  likely	  to	  be	  histamine.	  Whilst	  only	  preliminary	  results,	  I	  also	  show	  that	  T-­‐cells	  may	  have	  a	  protective	   role	   in	  DVT	   and	   that	   thrombin	  may	   be	   important	   for	   the	   release	   of	  NETs	  by	  neutrophils	  in	  the	  thrombus.	  These	   are	   all	   potentially	   very	   good	   targets	   for	   preventing	   or	   treating	   DVT	   in	  humans	  seeing	  as	  they	  all	  have	  limited	  bleeding	  complications	  as	  a	  side	  effect.	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